As filed with the Securities and Exchange Commission on July 27, 2018

Registration No. 333-225742

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Amendment No. 4

to

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

CUSHMAN & WAKEFIELD plc

(Exact name of Registrant as specified in its charter)

 

England and Wales

  6500   98-1193584

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

  (I.R.S. Employer Identification No.)

 

 

125 Old Broad Street

London, United Kingdom, EC2N 1AR

Telephone: +44 20 3296 3000

(Address including zip code, telephone number, including area code, of Registrant’s Principal Executive Offices)

 

 

Brett Soloway

Cushman & Wakefield

225 West Wacker Drive

Chicago, Illinois 60606

Telephone: (312) 470-1800

(Name, address including zip code, telephone number, including area code, of agent for service)

 

 

Copies To:

 

Jeffrey D. Karpf

Helena K. Grannis

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, New York 10006

(212) 225-2000

 

Brett Soloway

Cushman & Wakefield

225 West Wacker Drive

Chicago, Illinois 60606

(312) 470-1800

 

Patrick O’Brien

Thomas J. Fraser

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, Massachusetts 02199

(617) 951-7000

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date hereof.

 

 

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. ☐

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large accelerated filer  ☐   Accelerated filer  ☐   Non-accelerated filer  ☒   Smaller reporting company   ☐   Emerging growth company  ☐
    (Do not check if a smaller reporting company)    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

 

Amount to be

Registered (1)(2)

 

Proposed

Maximum

Offering Price

Per Share (3)

  Proposed Maximum
Aggregate
Offering Price (1)
  Amount of
Registration
Fee (2)(4)

Ordinary shares, $0.10 nominal value per share

 

51,750,000

 

$18.00

  $931,500,000   $115,971.75

 

 

(1) Includes 6,750,000 shares that the underwriters have an option to purchase from the registrant.
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) promulgated under the Securities Act of 1933, as amended.
(3) Anticipated to be between $16.00 and $18.00.
(4) Includes $115,971.75 the registrant previously paid in connection with previous filings of this registration statement.

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 


Explanatory Note

Cushman & Wakefield plc (alternately, “Cushman & Wakefield,” “the Company,” “we,” “ours,” “us” and other similar terms) is filing this Amendment No. 4 (the “Amendment”) to its Registration Statement on Form S-1 (File No. 333-225742) as an exhibits only filing to file Exhibits 1.1, 4.2, 4.3, 10.22, 10.45 and 10.46. Accordingly, this Amendment consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature pages to the Registration Statement and the filed exhibits. The prospectus is unchanged and has been omitted.


PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

Estimated expenses (except for the SEC registration fee, FINRA filing fee and stock exchange listing fee) payable in connection with the sale of the ordinary shares in this offering are as follows:

 

 SEC registration fee

   $ 115,972              

 FINRA filing fee

     140,225              

 NYSE listing fee

     25,000              

 Printing and engraving expenses

     750,000              

 Legal fees and expenses

     2,000,000              

 Accounting fees and expenses

     543,500              

 Transfer agent and registrar fees and expenses

     500,000              

 Miscellaneous

     3,425,303              
  

 

 

 

 Total

   $ 7,500,000              
  

 

 

 

We will bear all of the expenses shown above.

Item 14. Indemnification of Directors and Officers.

Our articles of association provide that, subject to the U.K. Companies Act 2006, we shall indemnify, out of our assets, any director of the Company or any associated company against all losses, liabilities and expenditures which he or she may sustain or incur in the execution of the duties of his or her office or otherwise in relation thereto.

The relevant provisions under the U.K. Companies Act 2006 are Sections 205, 206, 232, 233, 234, 235, 236, 237, 238 and 1157.

Section 205 provides that a company can provide a director with the funds to meet expenditures incurred or to be incurred in defending any criminal or civil proceedings or in connection with any application under sections 661(3) and 661(4) (acquisition of shares by innocent nominee) or section 1157 (described below). Such financial assistance must be repaid if the director is convicted, judgment is found against such director or the court refuses to grant the relief on the application.

Section 206 provides that a company can provide a director with the funds to meet expenditures incurred or to be incurred by him or her in defending in an investigation by a regulatory authority, or against action proposed to be taken by a regulatory authority, in connection with any alleged negligence, default, breach of duty or breach of trust by him or her in relation to the company or an associated company.

Section 232 provides that any provision to exempt to any extent a director from liability from negligence, default, breach of duty or trust by him or her in relation to the company is void. Any provision by which a company directly or indirectly provides (to any extent) an indemnity for a director of the company or an associated company against any such liability is also void unless it is a qualifying third party indemnity provision.

 

II-1


Section 233 permits liability insurance, commonly known as directors’ and officers’ liability insurance, purchased and maintained by a company against liability for negligence, default, breach of duty or breach of trust in relation to the company.

Pursuant to Section 234, an indemnity is a qualifying third party indemnity as long as it does not provide: (i) any indemnity against any liability incurred by the director to the company or to any associated company; (ii) any indemnity against any liability incurred by the director to pay a fine imposed in criminal proceedings or a sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature; and (iii) any indemnity against any liability incurred by the director in defending criminal proceedings in which he or she is convicted, civil proceedings brought by the company or an associated company in which judgment is given against such director or where the court refuses to grant such director relief under an application under sections 661(3) and 661(4) (acquisition of shares by innocent nominee) or its power under section 1157 (described below).

Section 235 allows a company to provide an indemnity to a director if the company is a trustee of an occupational pension scheme, with such indemnity to protect against liability incurred in connection with the company’s activities as trustee of the scheme.

Any indemnity provided under Section 234 or Section 235 in force for the benefit of one or more directors of the company or an associated company must be disclosed in the directors’ annual report in accordance with Section 236 and copies of such indemnification provisions made available for inspection in accordance with Section 237 (and every shareholder has a right to inspect and request such copies under Section 238).

Section 1157 provides that in proceedings against an officer of a company for negligence, default, breach of duty or breach of trust, the court may relieve such officer from liability if it appears to the court that such officer may be liable but acted honestly and reasonably and that having regard to all the circumstances of the case, such officer ought fairly to be excused. Further, an officer who has reason to apprehend that a claim of negligence, default, breach of duty or breach of trust will or might be made against him or her, such officer may apply to the court for relief, and the court will have the same power to relieve such officer as it would if the proceedings had actually been brought.

A court has wide discretion in granting relief, and may authorize civil proceedings to be brought in the name of the company by a shareholder on terms that the court directs. Except in these limited circumstances, English law does not generally permit class action lawsuits by shareholders on behalf of the company or on behalf of other shareholders.

In connection with this offering, we will enter into deeds of indemnification with each of our directors and executive officers. Pursuant to these agreements, we agree to indemnify these individuals to the fullest extent permissible under English law against liabilities arising out of, or in connection with, the actual or purported exercise of, or failure to exercise, any of his or her powers, duties or responsibilities as a director or officer, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We also agree to use all reasonable endeavors to provide and maintain appropriate directors’ and officers’ liability insurance (including ensuring that premiums are properly paid) for their benefit for so long as any claims may lawfully be brought against them.

We have obtained and expect to continue to maintain insurance policies under which our directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities that might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not we would have the power to indemnify such person against such liability under the provisions of English law.

 

II-2


In the underwriting agreement, the underwriters will agree to indemnify, under certain conditions, us, members of our board of directors, members of management and persons who control us within the meaning of the Securities Act, against certain liabilities.

Item 15. Recent Sales of Unregistered Securities.

In the three years preceding the filing of this registration statement, we have issued, or will issue, the following securities that were not registered, or will not be registered, under the Securities Act. No underwriters were used in any of the transactions described below. In this section, unless noted, all references to ordinary shares, options, restricted share units and corresponding exercise prices and all per ordinary share amounts reflect the Company’s figures prior to undertaking the Share Consolidation and have not been adjusted to give effect to the Share Consolidation.

Restructuring Matters

In connection with its formation on June 13, 2018, Cushman & Wakefield Limited issued one fully paid up ordinary share (the “subscriber share”) to DTZ Investment Holdings GenPar LLP (“DTZ GenPar”), as the general partner of Holdings LP. The issuance of the subscriber share was not registered under the Securities Act, because the subscriber share was offered and sold in a transaction by the issuer not involving any public offering exempt from registration under Section 4(a)(2) of the Securities Act.

In connection with the Share Exchange on July 6, 2018, Cushman & Wakefield Limited issued 1,532,092,920 ordinary shares to GTU Ops Inc., as nominee for Computershare Trust Company N.A. (the “Depositary Nominee”), in exchange for 153,081,863.85 and 1,379,011,057 ordinary shares of DTZ Jersey Holdings Limited, previously held by FTL Nominees 1 Limited and FTL Nominees 2 Limited, respectively, on bare trust for certain members of the Company’s management and Holdings LP, respectively. Holdings LP is an English limited partnership whose partners consist of the Principal Shareholders. Upon receipt of the ordinary shares of Cushman & Wakefield Limited, the Depositary Nominee issued 153,081,864 and 1,379,011,056 depositary receipts in respect of such shares to each of FTL Nominees 1 Limited and FTL Nominees 2 Limited respectively, who hold such depositary receipts on bare trust for certain members of the Company’s management and Holdings LP, respectively. Such ordinary shares were issued in reliance on the exemption contained in Section 4(a)(2) of the Securities Act, as transactions by issuers not involving a public offering. On July 6, 2018, a stock transfer form for the transfer of the subscriber share was executed in favor of the Depositary Nominee.

On July 11, 2018, Cushman & Wakefield Limited issued 50,000 redeemable preference shares, with a nominal value of £1.00 each, and fully paid up, to DTZ GenPar in exchange for an undertaking to pay the nominal value. The preference shares were issued in reliance on the exemption contained in Section 4(a)(2) of the Securities Act, as transactions by issuers not involving a public offering.

Options and Restricted Units

From January 1, 2018 through June 30, 2018, DTZ Jersey Holdings Limited granted options to purchase an aggregate of 2,735,295 ordinary shares at a weighted average price of $1.70 per share and issued 706,095 ordinary shares upon exercise of vested options for aggregate consideration of $707,579.

In 2017 and 2016, DTZ Jersey Holdings Limited granted options to purchase an aggregate of 2,241,178 and 17,754,902 ordinary shares, respectively, at a weighted average price of $1.70 and $1.23 per share, respectively, and issued 9,526 and zero ordinary shares, respectively, upon exercise of vested options for aggregate consideration of $11,431 and $0, respectively.

From April 1, 2015 through December 31, 2015, DTZ Jersey Holdings Limited granted options to purchase an aggregate of 40,067,583 ordinary shares at a weighted average price of $1.00 per share and did not issue any ordinary shares upon exercise of vested options.

From January 1, 2018 through June 30, 2018, DTZ Jersey Holdings Limited granted 8,723,235 RSUs to be settled in ordinary shares and issued 1,213,047 ordinary shares upon settlement of RSUs.

 

II-3


In 2017 and 2016, DTZ Jersey Holdings Limited granted 5,420,007 and 71,373,407 RSUs, respectively, to be settled in ordinary shares and issued 6,580,280 and 4,765,028 ordinary shares, respectively, upon settlement of RSUs.

From April 1, 2015 through December 31, 2015, DTZ Jersey Holdings Limited granted 42,625,201 RSUs to be settled in ordinary shares and issued 0 ordinary shares upon exercise of settlement of RSUs.

DTZ Jersey Holdings Limited deemed the grants of stock options and RSUs and the issuances of ordinary shares upon the exercise of stock options and settlement of RSUs described above as exempt from registration pursuant to Section 4(a)(2) of the Securities Act or in reliance on Rule 701 of the Securities Act as offers and sales of securities under compensatory benefit plans and contracts relating to compensation in compliance with Rule 701. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to information about us.

Issuances to Management Holders

From January 1, 2018 through June 30, 2018, DTZ Jersey Holdings Limited issued an aggregate of 5,118,215 ordinary shares at a weighted average price of $1.70 per share for aggregate consideration of $8,700,966.

In 2017 and 2016, DTZ Jersey Holdings Limited issued an aggregate of 13,352,095 ordinary shares and 23,507,031 ordinary shares, respectively, at a weighted average price of $1.70 and $1.23 per share for aggregate consideration of $22,562,562 and $33,165,424, respectively.

From April 1, 2015 through December 31, 2015, DTZ Jersey Holdings Limited issued an aggregate of 7,414,860 ordinary shares at a weighted average price of $1.00 per share for aggregate consideration of $7,414,860.

No underwriters were used in the foregoing transactions. DTZ Jersey Holdings Limited deemed the issuances of ordinary shares described immediately above as exempt from registration pursuant to Section 4(a)(2) of the Securities Act, as transactions not involving a public offering.

Acquisitions

On July 27, 2018, a subsidiary of the Company acquired 100% of the interests in Inc Re Australia Pty Ltd. for cash and equity consideration consisting of (i) an upfront cash payment of AUD $10 million, (ii) a deferred cash payment of AUD $9 million payable in installments over a five-year period and (iii) AUD $1 million of the Company’s ordinary shares, to be calculated based on the initial public offering price of the ordinary shares sold in this offering. At an assumed initial public offering price of $17.00 per ordinary share, the midpoint of the price range set forth on the cover of this prospectus, and the AUD/USD currency exchange rate as of July 27, 2018, and after taking into effect the Share Consolidation, the Company will issue an aggregate of approximately 43,500 ordinary shares in connection with the acquisition.

On March 2, 2017, DTZ Jersey Holdings Limited acquired 100% of the interests in Ashlar Urban for total cash consideration of CAD $9,800,000. In connection with the acquisition, DTZ Jersey Holdings Limited issued an aggregate of 588,235 ordinary shares to certain management shareholders.

On November 15, 2016, DTZ Jersey Holdings Limited acquired 50% percent of the partnership interests in DTZ Zadelhoff V.O.F. for total cash consideration of €27,000,000. In connection with the acquisition, DTZ Jersey Holdings Limited issued an aggregate of 5,555,000 ordinary shares to certain management shareholders

On August 9, 2016, DTZ Jersey Holdings Limited acquired 100% of the assets of Taylor & Mathis of Florida for total cash consideration of $28,750,000. In connection with the acquisition, DTZ Jersey Holdings Limited issued an aggregate of 1,764,705 ordinary shares to certain management shareholders.

 

II-4


On May 31, 2016, DTZ Jersey Holdings Limited acquired 100% of the assets of Multi-Family Advisors “MHA” for total cash consideration of $31,386,000. In connection with the acquisition, DTZ Jersey Holdings Limited issued an aggregate of 294,118 ordinary shares to certain management shareholders.

No underwriters were used in the foregoing transactions. DTZ Jersey Holdings Limited deemed the issuances of ordinary shares described immediately above as exempt from registration pursuant to Section 4(a)(2) of the Securities Act, as transactions not involving a public offering.

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits: The list of exhibits is set forth beginning on page II-3 of this Registration Statement and is incorporated herein by reference.

(b) Financial Statement Schedules: Schedule II – Valuation & Qualifying Accounts is included in the financial statements and incorporated herein by reference.

Item 17. Undertakings.

* (f) The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

* (h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

*(i) The undersigned registrant hereby undertakes that:

 

    For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the undersigned registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

    For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  * Paragraph references correspond to those of Regulation S-K, Item 512.

 

II-5


EXHIBIT INDEX

 

Exhibit Number

  

 Description of Exhibits

  1.1    

    Form of Underwriting Agreement

  3.1**

    Articles of Association of the Registrant

  4.1**

    Form of Ordinary Shares Certificate

  4.2    

  

Form of Registration Rights Agreement by and among Cushman & Wakefield plc and certain shareholders

  4.3    

  

Form of Joinder Agreement to Registration Rights Agreement by and between Cushman & Wakefield plc and Vanke Service (HongKong) Co., Limited

  5.1*  

    Opinion of Cleary Gottlieb Steen & Hamilton LLP

  8.1*  

    Tax Opinion of Cleary Gottlieb Steen & Hamilton LLP

10.1**

  

Syndicated Facility Agreement (First Lien), dated as of November 4, 2014, among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, UBS AG, Stamford Branch, as Administrative Agent and Collateral Agent, and the lenders party thereto

10.2**

  

Amendment No. 1 to the First Lien Credit Agreement, dated as of August 13, 2015, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, UBS AG, the Lenders party thereto, the L/C Issuers party thereto and UBS AG, Stamford Branch, as Administrative Agent and Swing Line Lender

10.3**

  

First Lien Amendment No. 2, dated as of September 1, 2015, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the 2015-1 Additional Term Lenders party thereto, the 2015-1 Converting Term Lenders party thereto, the 2015-1 Incremental Term Lenders party thereto, the Consenting Revolving Lenders party thereto, the 2015-1 Incremental Revolving Credit Lenders party thereto, each L/C Issuer party thereto, UBS AG, Stamford Branch, as Administrative Agent and Swing Line Lender and, for purposes of Sections 5, 8, 9 and 11 through 15 thereof only, each of the other Loan Parties party as of the date thereof

10.4**

  

First Lien Amendment No. 3, dated as of December 22, 2015, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, UBS AG, Stamford Branch, as the Incremental Term Lender and Administrative Agent and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

10.5**

  

Amendment No. 4 to the First Lien Credit Agreement, dated as of April 28, 2016, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the Lenders party thereto, the L/C Issuers party thereto, and UBS AG, Stamford Branch, as Administrative Agent and Swing Line Lender

10.6**

  

First Lien Amendment No. 5, dated as of June 14, 2016, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, UBS AG, Stamford Branch, as the Incremental Term Lender and Administrative Agent and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

10.7**

  

First Lien Amendment No. 6, dated as of November 14, 2016, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, UBS AG, Stamford Branch, as the Incremental Term Lender and Administrative Agent and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

 

II-6


Exhibit Number

  

 Description of Exhibits

10.8**

  

Amendment No. 7 to the First Lien Credit Agreement, dated as of November 14, 2016, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the Lenders party thereto and UBS AG, Stamford Branch, as Administrative Agent

10.9**

  

First Lien Amendment No. 8, dated as of September 15, 2017, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the 2022 Revolving Credit Lenders party thereto, the L/C Issuers party thereto, UBS AG, Stamford Branch, as Administrative Agent and Swing Line Lender and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

10.10**

  

Amendment No. 9 to the First Lien Credit Agreement, dated as of September 15, 2017, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the Lenders party thereto and UBS AG, Stamford Branch, as Administrative Agent

10.11**

  

First Lien Amendment No. 10, dated as of March 15, 2018, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, UBS AG, Stamford Branch, as the Incremental Term Lender, Administrative Agent and Swing Line Lender, Barclays Bank Plc, Fifth Third Bank and Morgan Stanley Bank, N.A. as the Incremental Revolving Credit Lenders, each L/C Issuer party thereto and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

10.12**

  

Amendment No. 11 to the First Lien Credit Agreement, dated as of March 15, 2018, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the Lenders party thereto and UBS AG, Stamford Branch, as Administrative Agent

10.13**

  

Syndicated Facility Agreement (Second Lien), dated as of November 4, 2014, among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, Bank of America, N.A., as Administrative Agent and Collateral Agent, and the lenders party thereto

10.14**

  

Amendment No. 1 to the Second Lien Credit Agreement, dated as of August 13, 2015, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the Lenders party thereto and Bank of America, N.A., as Administrative Agent

10.15**

  

Second Lien Amendment No. 2, dated as of September 1, 2015, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the 2015-2 Incremental Lenders party thereto, Bank of America, N.A., as Administrative Agent and, for purposes of Sections 6 and 9 through 15 thereof only, each of the other Loan Parties as of the date thereof

10.16**

  

Second Lien Amendment No. 3, dated as of December 22, 2015, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, Bank of America, N.A., as the Incremental Lender and Administrative Agent and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

 

II-7


Exhibit Number

  

 Description of Exhibits

    10.17**

  

Amendment No. 4 to the Second Lien Credit Agreement, dated as of April 28, 2016, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, the Lenders party thereto and Bank of America, N.A., as Administrative Agent

    10.18**

  

Second Lien Amendment No. 5, dated as of May 19, 2017, by and among DTZ UK Guarantor Limited, DTZ U.S. Borrower, LLC, DTZ Aus Holdco Pty Limited, Owl Rock Capital Corporation and Owl Rock Capital Corporation II, as the Incremental Lenders and Bank of America, N.A., as Administrative Agent and, for purposes of Sections 4, 8, 9, 10, 11, 12 and 13 thereof only, each of the other Loan Parties party as of the date thereof

    10.19**

  

Form of Deed of Indemnity for Directors

    10.20**

  

Form of Deed of Indemnity for Officers

    10.21**

  

Form of Non-executive Director Appointment Letter

    10.22

  

Form of Shareholders Agreement by and among Cushman & Wakefield plc and the shareholders party therto

    10.23**

  

Agreement for the Provision of Depositary Services and Custody Services, dated as of July 6, 2018, in respect of Cushman & Wakefield Limited Depositary Receipts among Computershare Trust Company, N.A., Cushman & Wakefield Limited, FTL Nominees 1 Limited, FTL Nominees 2 Limited and other Holders of Depositary Receipts

    10.24**

  

Cushman & Wakefield plc 2018 Omnibus Management Share and Cash Incentive Plan, effective as of June 19, 2018

    10.25**

  

Cushman & Wakefield plc 2018 Omnibus Non-Employee Director Share and Cash Incentive Plan, effective as of June 19, 2018

    10.26**

  

DTZ Jersey Holdings Limited Management Equity Incentive Plan, amended and restated effective as of January 7, 2016

    10.27**

  

Form of 2018 Stock Option Award Agreement under the DTZ Jersey Holdings Limited Management Equity Incentive Plan

    10.28**

  

Form of Pre-2018 Stock Option Award Agreement under the DTZ Jersey Holdings Limited Management Equity Incentive Plan

    10.29**

  

Form of Offer to Amend Certain Outstanding Stock Options in connection with the DTZ Jersey Holdings Limited Management Equity Incentive Plan

    10.30**

  

Form of DTZ Jersey Holdings Limited Restricted Stock Unit Grant Agreement

    10.31**

  

Form of Bonus Deferral and Co-Investment Restricted Stock Unit Grant Letter Agreement

    10.32**

  

Form of DTZ Jersey Holdings Limited Management Stockholders’ Agreement

    10.33**

  

Form of Trust Over Shares and Nominee Shareholder Agreement

    10.34**

  

Cushman & Wakefield, Inc. Executive Employee Severance Plan, effective June 14, 2018

    10.35**

  

Amended and Restated Employment Agreement between Brett White, Cushman & Wakefield Global, Inc. and DTZ Jersey Holdings Limited, dated June 8, 2018

 

II-8


Exhibit Number

  

 Description of Exhibits

    10.36**

  

Option Grant Agreement between Brett White and DTZ Jersey Holdings Limited, dated May 8, 2015

    10.37**

  

Restricted Stock Unit Grant Agreement between Brett White and DTZ Jersey Holdings Limited, dated May 8, 2015

    10.38**

  

Restricted Stock Unit Grant Agreement between Brett White and DTZ Jersey Holdings Limited, dated May 8, 2015

    10.39**

  

Restricted Stock Unit Grant Agreement between Brett White and DTZ Jersey Holdings Limited, dated October 5, 2015

    10.40**

  

Form of Restricted Stock Unit Grant Agreement for grants in 2018, 2019 and 2020 between Brett White and DTZ Jersey Holdings Limited

    10.41**

  

Side Letter between Brett White and Cushman & Wakefield Global, Inc., dated June 8, 2018

    10.42**

  

Employment Agreement between Duncan Palmer and DTZ US NewCo, Inc., dated March 16, 2015

    10.43**

  

Executive Service Agreement between Matthew Bouw and Cushman & Wakefield PTY LTD, dated April 19, 2018

    10.44**

  

Relocation and Repatriation Benefits Letter Agreement addressed to Matthew Bouw, dated December 11, 2017

    10.45

  

Purchase Agreement by and among Cushman & Wakefield plc and Vanke Service (HongKong) Co., Limited, dated as of July 24, 2018

    10.46

  

Form of Shareholder Agreement by and among Cushman & Wakefield plc and Vanke Service (HongKong) Co., Limited

    21.1**

    List of subsidiaries upon completion of this offering

    23.1**

     Consent of KPMG US LLP, Independent Registered Public Accounting Firm

    23.2**

    Consent of Ernst & Young LLP, Independent Auditors

    23.3*

    Consent of Cleary Gottlieb Steen & Hamilton LLP (included in Exhibit 5.1)

    24.1**

    Powers of Attorney (included on signature page)

 

* To be filed by amendment.
** Previously filed.

 

II-9


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Chicago, Illinois on July 27, 2018.

 

CUSHMAN & WAKEFIELD PLC

    / S / B RETT W HITE
By:   Brett White
Title:   Director, Executive Chairman and Chief Executive Officer

* * * *

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

 

Name

  

Title

 

Date

/ S / B RETT W HITE

Brett White

   Director, Executive Chairman and Chief Executive Officer (Principal Executive Officer and Authorized Representative in the United States)   July 27, 2018

/ S / D UNCAN P ALMER

Duncan Palmer

   Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)   July 27, 2018

*

Rajeev Ruparelia

   Director   July 27, 2018

*

Qi Chen

   Director   July 27, 2018

*

Lincoln Pan

   Director   July 27, 2018

*

Timothy Dattels

   Director   July 27, 2018

*

Jonathan Coslet

   Director   July 27, 2018

*

Billie Williamson

   Director   July 27, 2018

 

By   / S / D UNCAN P ALMER
 

Duncan Palmer

Attorney-in-fact

 

II-10

Exhibit 1.1

         Shares

 

CUSHMAN & WAKEFIELD PLC

ORDINARY SHARES, NOMINAL VALUE $0.10 PER SHARE

 

 

 

UNDERWRITING AGREEMENT

 

        , 2018

 


        , 2018

 

Morgan Stanley & Co. LLC

J.P. Morgan Securities LLC

Goldman Sachs & Co. LLC

UBS Securities LLC

As Representatives of the several Underwriters

named in Schedule I hereto

 

c/o    Morgan Stanley & Co. LLC
   1585 Broadway
   New York, New York 10036
c/o    J.P. Morgan Securities LLC
   383 Madison Avenue
   New York, New York 10179
c/o    Goldman Sachs & Co. LLC
   200 West Street
   New York, New York 10282
c/o    UBS Securities LLC
   1285 Avenue of the Americas
   New York, New York 10019

Ladies and Gentlemen:

Cushman & Wakefield plc, a public limited company organized under the laws of England and Wales (the “ Company ”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “ Underwriters ”) for whom Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and UBS Securities LLC are acting as representatives (the “ Representatives ”),          of its ordinary shares, nominal value $0.10 per share (the “ Firm Shares ”). The Company also proposes to issue and sell to the several Underwriters not more than an additional          shares of its ordinary shares, nominal value $0.10 per share (the “ Additional Shares ”) if and to the extent that the Representatives shall have determined to exercise, on behalf of the Underwriters, the right to purchase such ordinary shares granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “ Shares. ” The ordinary shares, nominal value $0.10 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “ Ordinary Shares.


The Company has filed with the Securities and Exchange Commission (the “ Commission ”) a registration statement, including a prospectus, relating to the Shares. The registration statement as amended at the time it becomes effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A under the Securities Act of 1933, as amended (the “ Securities Act ”), is hereinafter referred to as the “ Registration Statement .” The prospectus in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the “ Prospectus. ” If the Company has filed an abbreviated registration statement to register the sale of additional Ordinary Shares pursuant to Rule 462(b) under the Securities Act (a “ Rule  462 Registration Statement ”), then any reference herein to the term “ Registration Statement ” shall be deemed to include such Rule 462 Registration Statement.

For purposes of this Agreement, “ free writing prospectus ” has the meaning set forth in Rule 405 under the Securities Act, “ Time of Sale Prospectus ” means the preliminary prospectus together with the documents and pricing information set forth in Schedule II hereto, and “ broadly available road show ” means a “bona fide electronic road show” as defined in Rule 433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms “Registration Statement,” “preliminary prospectus,” “Time of Sale Prospectus” and “Prospectus” shall include the documents, if any, incorporated by reference therein as of the date hereof.

1. Representations and Warranties . The Company represents and warrants to and agrees with each of the Underwriters that:

(a)     The Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission.

(b)     (i) The Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iii) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section 4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iv) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit

 

2


to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (v) as of its date and the Closing Date, the Prospectus does not contain and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein.

(c)     The Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to each of the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of each of the Representatives, prepare, use or refer to, any free writing prospectus.

(d)     The Company has been duly organized, is validly existing as a company in good standing under the laws of the jurisdiction of its organization, has the corporate power and authority to own its properties and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.

(e)     Each of the Company’s subsidiaries has been duly incorporated, organized or formed, is validly existing as a corporation or otherwise in good standing under the laws of the jurisdiction of its incorporation or organization or formation (to the extent the concept of good standing is applicable in such jurisdiction), has the requisite power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification (to the extent the concept of good standing is applicable in such

 

3


jurisdiction), except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. All of the issued share capital of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable (to the extent such concepts are applicable under relevant law) and are owned directly by the Company or a subsidiary of the Company, free and clear of all liens, encumbrances, equities or claims, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. As used in this Agreement with respect to the Company, “subsidiaries” shall mean direct and indirect subsidiaries of the Company.

(f)     This Agreement has been duly authorized, executed and delivered by the Company.

(g)     The authorized share capital of the Company conforms as to legal matters to the description thereof contained in each of the Time of Sale Prospectus and the Prospectus.

(h)     The Ordinary Shares outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and non-assessable.

(i)     The Shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights.

(j)     The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement, including the issuance and sale of the Shares, will not (i) contravene any provision of applicable law, (ii) contravene any provision of the memorandum or articles of association of the Company, (iii) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or (iv) contravene any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except that, in the case of clauses (i) and (iii) as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power and ability of the Company to perform its obligations under this Agreement. No consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may have already been obtained or made or be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares.

 

4


(k)     There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business, or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus.

(l)     There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i) other than proceedings accurately described in all material respects in the Time of Sale Prospectus and proceedings that would not, individually or in the aggregate, reasonably be expected to, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time of Sale Prospectus or (ii) that are required to be described in the Registration Statement or the Prospectus and are not so described in all material respects. There are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are not described or filed as required.

(m)     Each preliminary prospectus filed as part of the registration statement as originally filed or as part of any amendment thereto, or filed pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder.

(n)     The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Prospectus will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended.

(o)     The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“ Environmental Laws ”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not,

 

5


individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.

(p)     There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.

(q)     Except with respect to the registration rights agreement in connection with the consummation of the offering, as disclosed in the Time of Sale Prospectus and the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement.

(r)     Other than DTZ U.S. Borrower, LLC, neither the Company nor any of its subsidiaries has any securities rated by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”).

(s)     None of the Company or its subsidiaries or affiliates, or any director or officer thereof, or, to the Company’s knowledge, any employee, agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) (“ Government Official ”) in order to influence official action, or to any person in violation of any applicable anti-corruption laws. The Company and its subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein. Neither the Company nor its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws.

 

6


(t)     The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “ Anti-Money Laundering Laws ”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

(u)     (i) None of the Company, any of its subsidiaries, or any director or officer thereof, or, to the Company’s knowledge, any employee, agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (“ Person ”) that is, or is owned or controlled by one or more Persons that are:

(A)     the subject of any sanctions administered or enforced by the U.S. Department of the Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “ Sanctions ”), or

(B)     located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria).

(ii)     The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any direct or indirect subsidiary, joint venture partner or other Person:

(A)     to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or

(B)     in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).

(iii)     Since November 1, 2014, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any

 

7


Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

(v)     Subsequent to the respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i) the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii) the Company has not purchased any of its outstanding share capital (other than from its employees or other service providers in connection with the termination of their service pursuant to plans or agreements described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively), nor declared, paid or otherwise made any dividend or distribution of any kind on its share capital other than ordinary and customary dividends; and (iii) there has not been any material change in the share capital (other than the exercise or forfeiture of equity awards outstanding as of such respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, in each case granted pursuant to the equity compensation plans described in the Time of Sale Prospectus), short-term debt or long-term debt of the Company and its subsidiaries (other than borrowings, if any, under the First Lien Credit Agreement or the Second Lien Credit Agreement, each as defined in the Registration Statement and described in the Registration Statement, the Time of Sale Prospectus and the Prospectus), except in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively.

(w)     The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property, whether tangible or intangible, owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries. Any real property and buildings held under lease by the Company and its subsidiaries are held by the Company or its subsidiaries, as applicable, under valid, subsisting and, to the Company’s knowledge, enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the Time of Sale Prospectus.

(x)     Except as would not, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries taken as a whole, and except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i) to the knowledge of the Company, the Company and its subsidiaries own or have valid, binding and enforceable rights under all patents, patent applications, patent rights, licenses, inventions, copyrights, trade secrets

 

8


(including any unpatented and/or unpatentable proprietary or confidential information, systems or procedures included therein), trademarks, service marks, trade names, domain names and other intellectual property (collectively, the “ Intellectual Property ”) used in or necessary for the conduct of their respective businesses as currently conducted, except as enforceability of any licenses may be limited by bankruptcy and other similar laws affecting the rights of creditors generally and general principles of equity; (ii) neither the Company nor any of its subsidiaries has sent or received any written notice of any claim of infringement, dilution or misappropriation with respect to any Intellectual Property; (iii) no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the validity or enforceability of any Intellectual Property owned by the Company or its subsidiaries; (iv) to the knowledge of the Company, no third party is infringing, diluting, misappropriating or conflicting with or has infringed, diluted or misappropriated any Intellectual Property owned by the Company or its subsidiaries; and (v) to the knowledge of the Company, the conduct of the Company’s and its subsidiaries’ respective businesses as currently conducted does not infringe, dilute or misappropriate any third party’s Intellectual Property.

(y)     Except as would not, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries taken as a whole, and except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, to the knowledge of the Company, (i) there has been no security breach or other security compromise of or relating to any of the Company’s or its subsidiaries’ information technology and computer systems, networks, hardware, software, data, trade secrets, or equipment; and (ii) the Company and its subsidiaries are presently in compliance with all applicable laws, regulations, contractual obligations and internal policies relating to data privacy and security or personally identifiable information.

(z)     No material labor dispute with the employees of the Company or any of its subsidiaries exists, except as described in the Time of Sale Prospectus, or, to the knowledge of the Company, is imminent. The Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would be reasonably likely to have a material adverse effect on the Company and its subsidiaries, taken as a whole.

(aa)     Except (i) as described in the Time of Sale Prospectus or (ii) as would not, individually or in the aggregate, have, or reasonably be expected to have, a material adverse effect on the Company and its subsidiaries, taken as a whole, (A) each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ ERISA ”), whether or not subject to ERISA that the Company or any member of its “Controlled Group” (defined as any organization which is under common control or treated as a single employer with the Company under ERISA or Section 414 of the Internal Revenue Code of 1986, as amended (the “ Code ”)) sponsors,

 

9


maintains or contributed to, or otherwise has liability (contingent or otherwise) in respect of (each, a “ Plan ”), has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (B) no non-exempt prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan; (C) no Plan is subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA; (D) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA in respect of any Plan; (E) there is no pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan; and (F) none of the following events has occurred or is reasonably likely to occur: (x) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its subsidiaries in the current fiscal year of the Company and its subsidiaries compared to the amount of such contributions made in the Company and its subsidiaries’ most recently completed fiscal year; or (y) a material increase in the Company and its subsidiaries’ “accumulated post-retirement benefit obligations” (within the meaning of Statement of Financial Accounting Standards 106) compared to the amount of such obligations in the Company and its subsidiaries’ most recently completed fiscal year.

(bb)     The Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are, in the reasonable judgment of the Company, prudent and customary in the businesses in which they are engaged. Neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for, except to the extent that such refusal would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. Neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus.

(cc)     The Company and its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to obtain such certificates, authorizations or permits, individually or in the aggregate, would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a

 

10


material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus.

(dd)     (i) KPMG LLP, who has certified certain financial statements of the Company and its subsidiaries included in the Registration Statement, is an independent public accountant as required by the Securities Act and the rules and regulations of the Commission thereunder and the rules and regulations of the Public Company Accounting Oversight Board (United States) and (ii) Ernst & Young LLP, who has certified certain financial statements of C&W Group, Inc. and its subsidiaries included in the Registration Statement, is an independent public accountant as required by the Securities Act and the rules and regulations of the Commission thereunder and the rules and regulations of the Public Company Accounting Oversight Board (United States).

(ee)     The consolidated financial statements of the Company included in the Registration Statement, the Time of Sale Prospectus and the Prospectus, together with the related notes, present fairly in all material respects the financial position of the Company and its consolidated subsidiaries at the dates indicated and, in the case of the statements of operations, shareholders’ equity and cash flows of the Company and its consolidated subsidiaries, for the periods specified. The consolidated financial statements of C&W Group, Inc. included in the Registration Statement, the Time of Sale Prospectus and the Prospectus, together with the related notes, present fairly in all material respects the financial position of C&W Group, Inc. and its consolidated subsidiaries at the dates indicated and, in the case of the statements of operations, shareholders’ equity and cash flows of C&W Group, Inc. and its consolidated subsidiaries, for the periods specified. Each of the consolidated financial statements of the Company and the consolidated financial statements of C&W Group, Inc. included in the Registration Statement, the Time of Sale Prospectus and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and have been prepared in conformity with U.S. generally accepted accounting principles (“ GAAP ”) applied on a consistent basis throughout the periods involved except (i) the unaudited, interim financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission and (ii) as otherwise disclosed therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus or the Prospectus under the Securities Act and the rules and regulations of the Commission thereunder. To the extent included in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the pro forma financial information and the related notes thereto included therein have been prepared in accordance with the applicable requirements of the Securities Act and comply with Regulation G of the Exchange Act, and Item 10 of Regulation S-K of the Securities Act, to the extent applicable, and the assumptions underlying such pro forma financial information are reasonable and are set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus in all material respects. All other information

 

11


regarding the financial condition or results of operations of the Company or its subsidiaries included in the Registration Statement, the Time of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby.

(ff)     The Company and its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance (it being understood that this subsection shall not require the Company to comply with Section 404 of the Sarbanes Oxley Act of 2002, as amended, as of an earlier date than it would otherwise be required to so comply under applicable law) that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Time of Sale Prospectus, since the end of the Company’s most recent audited fiscal year, there has been (i) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

(gg)     The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act. Such disclosure controls and procedures have been designed to ensure that material information relating to the Company is made known to the Company’s principal executive officer and principal financial officer by others within the Company.

(hh)     Except as described in the Time of Sale Prospectus, the Company has not sold, issued or distributed any Ordinary Shares during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulations D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.

(ii)     Except to the extent it would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, (i) each of the Company and its subsidiaries has filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or has requested extensions thereof, (ii) all such filed returns are true and accurate in all material respects, and (iii) each of the Company and its subsidiaries has paid all taxes required to be paid, whether or not shown on such returns (except as currently being contested in good faith and for which reserves required by GAAP

 

12


have been created in the financial statements of the Company). No tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect on the Company and its subsidiaries, taken as a whole.

(jj)     Under the current laws of England and Wales, all dividends and other distributions declared and payable on the Shares in cash may be freely remitted out of England and Wales and may be paid in, or freely converted into, United States dollars, in each case without there being required any consent, approval, authorization or order of, or qualification with, any court or governmental agency or body in England and Wales; and except as disclosed in the Time of Sale Prospectus, all such dividends and other distributions paid by the Company will not be subject to withholding under the laws and regulations of England and Wales.

(kk)     No stamp, documentary, issuance, registration, transfer or other similar taxes or duties are payable by or on behalf of the Underwriters, the Company or any of its subsidiaries or the purchasers procured by the Underwriters, in the United Kingdom or to any taxing authority thereof or therein in connection with (i) the execution, delivery or consummation of this Agreement, (ii) the creation of the Shares, and the issue and allotment and delivery of the Shares by the Company to Cede & Co. as nominee for the Depositary Trust Company (“ DTC ”), to be credited by way of book entry interests to the respective DTC participant accounts of the several Underwriters, or (iii) the resale by the Underwriters of the book entry interests in the Shares to purchasers procured by the Underwriters within the DTC clearance system and in respect of which no written instrument of transfer is entered into.

(ll)     The Company believes that it was not a “passive foreign investment company” (“ PFIC ”) for U.S. federal income tax purposes for its most recent taxable year and it does not expect to be a PFIC for its current taxable year or in the foreseeable future.

(mm)     It is not necessary under the laws of England and Wales (i) to enable the Underwriters to enforce their rights under this Agreement, to enable any holder of Shares to enforce their respective rights thereunder, provided that they are not otherwise engaged in business in the United Kingdom, or (ii) solely by reason of the execution, delivery or consummation of this Agreement, for any of the Underwriters or any holder of Shares of the Company to be qualified or entitled to carry out business in the United Kingdom.

(nn)     Upon execution and delivery, this Agreement will be in proper form under the laws of England and Wales for the enforcement thereof against the

 

13


Company, and to ensure the legality, validity, enforceability or admissibility into evidence in England and Wales of this Agreement.

(oo)     Except as described in the Time of Sale Prospectus, the courts of the United Kingdom would recognize as a valid judgment any final monetary judgment obtained against the Company in the courts of the State of New York.

(pp)     Neither the Company nor any of its subsidiaries nor any of its or their properties or assets has any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) under the laws of England and Wales. The irrevocable and unconditional waiver and agreement of the Company contained in Section 16(a) not to plead or claim any such immunity in any legal action, suit or proceeding based on this Agreement is valid and binding under the laws of England and Wales.

(qq)     The choice of law of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of England and Wales and will be honored by the courts of England and Wales. The Company has the power to submit, and pursuant to Section 16(a) has, to the extent permitted by law, legally, validly, effectively and irrevocably submitted, to the jurisdiction of the Specified Courts (as defined in Section 16(a)), and has the power to designate, appoint and empower, and pursuant to Section 16(b), has legally, validly and effectively designated, appointed and empowered an agent for service of process in any suit or proceeding based on or arising under this Agreement in any of the Specified Courts.

2.     Agreements to Sell and Purchase. The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of Firm Shares set forth in Schedule I hereto opposite its name at $         a share (the “ Purchase Price ”).

On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly, up to          Additional Shares at the Purchase Price to be delivered in the manner set out in Section 4, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not payable on such Additional Shares. The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after the written notice is given and may not be earlier than the closing date for the Firm Shares

 

14


nor later than ten business days after the date of such notice. Additional Shares may be purchased as provided in Section 4 hereof solely for the purpose of covering over-allotments made in connection with the offering of the Firm Shares. On each day, if any, that Additional Shares are to be purchased (an “ Option Closing Date ”), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm Shares.

3.     Terms of Public Offering . The Company is advised by the Representatives that the Underwriters propose to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in the Representatives’ judgment is advisable. The Company is further advised by the Representatives that the Shares are to be offered to the public initially at $         a share (the “ Public Offering Price ”) and to certain dealers selected by the Representatives at a price that represents a concession not in excess of $         a share under the Public Offering Price, and that any Underwriter may allow, and such dealers may reallow, a concession, not in excess of $         a share, to any Underwriter or to certain other dealers.

4.     Payment and Delivery. Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on         , 2018 or at such other time on the same or such other date, not later than          1 , 2018, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the “ Closing Date .”

Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section 2 or at such other time on the same or on such other date, in any event not later than          2 , 2018, as shall be designated in writing by the Representatives.

The Firm Shares and Additional Shares shall be delivered to such DTC accounts of the Underwriters, and in such denominations, as the Representatives shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares and Additional Shares shall be delivered to the Representatives on the Closing Date or an Option Closing Date, as the case may be, for the respective DTC accounts notified by the Underwriters in accordance

 

  1  

To be five business days after the scheduled closing date.

  2  

To be ten business days after the expiration of the greenshoe option.

 

15


with this Section 4, with any amounts in respect of any transfer taxes payable by the Underwriters in connection with such delivery, if any, duly deducted from the Purchase Price payable to the Company by the Underwriters.

5.     Conditions to the Underwriters Obligations . The obligations of the Company to sell the Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition that the Registration Statement shall have become effective not later than          [a.m.] [p.m.], New York City time, on the date hereof.

The several obligations of the Underwriters are subject to the following further conditions:

(a)     Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:

(i)     there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of DTZ U.S. Borrower, LLC by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act; and

(ii)     there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus that, in the Representatives’ judgment, is material and adverse and that makes it, in Representatives’ judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.

(b)     The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.

The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.

(c)     The Underwriters shall have received on the Closing Date one or more opinions and a negative assurance letter of Cleary Gottlieb Steen & Hamilton LLP, outside counsel for the Company, dated the Closing Date, in form and substance satisfactory to the Underwriters.

 

16


(d)     The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Ropes & Gray LLP, counsel for the Underwriters, dated the Closing Date, in form and substance satisfactory to the Underwriters.

With respect to Sections 5(c) and 5(d) above, Cleary Gottlieb Steen & Hamilton LLP and Ropes & Gray LLP, respectively, may state that their opinions and beliefs are based upon their participation in the preparation of the Registration Statement, the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification, except as specified.

The opinion or opinions of Cleary Gottlieb Steen & Hamilton LLP described in Section 5(c) above shall be rendered to the Underwriters at the request of the Company and shall so state therein.

(e)     The Underwriters shall have received, on each of the date hereof and the Closing Date, letters dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, from each of KPMG LLP and Ernst & Young LLP, independent public accountants, containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; provided that any letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date hereof.

(f)     The lock-up agreements, each substantially in the form of Exhibit A hereto, among the Representatives and the shareholders, officers and directors of the Company, listed on Schedule III relating to sales and certain other dispositions of Ordinary Shares or certain other securities, delivered to the Representatives on or before the date hereof (the “ Lock-Up Agreements ”), shall be in full force and effect on the Closing Date.

(g)     The Underwriters shall have received, on each of the date hereof and the Closing Date, a certificate of the chief financial officer of the Company certifying as to the accuracy of certain financial information included in the Registration Statement, the Time of Sale Prospectus and the Prospectus, in form and substance satisfactory to the Underwriters.

(h)     The several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to the Representatives on the applicable Option Closing Date of the following:

(i)     a certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered on the Closing Date pursuant to Section 5(b) hereof remains true and correct as of such Option Closing Date;

 

17


(ii)     one or more opinions of Cleary Gottlieb Steen & Hamilton LLP, outside counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion or opinions required by Section 5(c) hereof;

(iii)     an opinion of Ropes & Gray LLP, counsel for the Underwriters, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 5(d) hereof;

(iv)     a letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from each of KPMG LLP and Ernst & Young LLP, independent public accountants, substantially in the same form and substance as the letter furnished by each to the Underwriters pursuant to Section 5(e) hereof; provided that any letter delivered on the Option Closing Date shall use a “cut-off date” not earlier than three business days prior to such Option Closing Date;

(v)     a certificate dated the Option Closing Date and signed by the chief financial officer of the Company certifying as to the accuracy of certain financial information contained in the Prospectus as of such Option Closing Date; and

(vi)     such other documents as the Representatives may reasonably request with respect to the good standing of the Company, the due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares.

6.     Covenants of the Company . The Company covenants with each Underwriter as follows:

(a)     To furnish to the Representatives, without charge, twelve conformed copies of the Registration Statement (including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to the Representatives in New York City, without charge, prior to 10:00 a.m. New York City time on the second business day succeeding the date of this Agreement and during the period mentioned in Section 6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as the Representatives may reasonably request.

(b)     Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the Representatives reasonably

 

18


object, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such rule.

(c)     To furnish to the Representatives a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives reasonably object.

(d)     Not to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder.

(e)     If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.

(f)     If, during such period after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses the Representatives will furnish to the Company) to which Shares may have been sold by the Representatives on behalf

 

19


of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.

(g)     To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request; provided that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.

(h)     To make generally available to the Company’s security holders and to the Representatives as soon as practicable an earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder, provided that the Company will be deemed to have complied with such requirement by filing such earnings statement on the Commission’s Electronic Data Gathering, Analysis, and Retrieval system (or any successor system) (“ EDGAR ”).

(i)     Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel and the Company’s accountants in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii) all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii) the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as provided in Section 6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum; provided that such fees and expenses payable by the Company pursuant to this subsection (iii) are not to exceed $10,000 exclusive of any

 

20


applicable VAT, (iv) all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry Regulatory Authority, (v) all fees and expenses in connection with the preparation and filing of the registration statement on Form 8-A relating to the Ordinary Shares and all costs and expenses incident to listing the Shares on the Exchange, (vi) the cost of printing certificates representing the Shares, (vii) the costs and charges of any transfer agent, registrar or depositary, (viii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and fifty percent (50%) of the cost of any aircraft chartered in connection with the road show (the remaining 50% of the costs of such aircraft to be paid by the Underwriters), (ix) the document production charges and expenses associated with printing this Agreement and (x) all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that the provisions of this Section 6(i) will exclude, and that the Underwriters will pay: (a) all net income taxes payable by the Underwriters in respect of underwriting commissions payable under, or in connection with, this Agreement or the matters contemplated hereunder; and (b) except as provided in this Section, Section 8 entitled “Indemnity and Contribution” and the last paragraph of Section 10 below, all costs and expenses of the Underwriters, including fees and disbursements of their counsel.

(j)     The Company shall pay, and shall indemnify and hold the Underwriters harmless against, any stamp, documentary, issuance, registration, transfer or other similar taxes or duties (including interest or penalties thereon, except to the extent such interest or penalties arise as a result of the unreasonable default or delay of the Underwriters) imposed under the laws of any jurisdiction or any political sub-division or taxing authority thereof or therein that is payable in connection with (i) the execution, delivery, consummation or enforcement of this Agreement, (ii) the creation of the Shares, and the issue and allotment of the Shares by the Company to Cede & Co. as nominee for DTC to be credited by way of book entry interests to the respective DTC participant accounts of the several Underwriters, (iii) the resale by the Underwriters of the book entry interests in the Shares to purchasers procured by the Underwriters within the DTC clearance system, as contemplated under this Agreement or (iv) stabilization transactions in respect of the Shares described under the section titled “Underwriters” in the Prospectus or the Time of Sale Prospectus, where such transactions are to be settled by transfers of book entry interests in DTC. Any amount payable by the Company to the Underwriters pursuant to this Section 6(j) may be deducted by

 

21


the Underwriters from any payment to be made by the Underwriters to the Company in connection with this Agreement.

(k)     The Company has caused to be delivered to you prior to the date of this Agreement a Lock-Up Agreement from each individual or entity listed on Schedule III hereto. The Company shall not take any steps to enable the breach of (i) any Lock-Up Agreement, (ii) the lock-up provision contained in Section 3(a) of any of the Company’s Management Stockholders’ Agreements (each, a “ Management Stockholders’ Agreement ”) and (iii) the lock-up provisions contained in Section 3(a) of either of the two respective Company’s Stockholders’ Agreements dated January 8, 2016 (the “ Stockholders’ Agreements ”). The Company will not, without the prior written consent of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC, consent to, grant any waiver to or exception from or otherwise release any such holder from the restrictions contained in Section 3(a) of the Management Stockholders’ Agreement or Section 3(a) of the Stockholders’ Agreements. Additionally, the Company will use commercially reasonable efforts to issue stop transfer instructions to its transfer agent and registrar for the Ordinary Shares with respect to any transaction or contemplated transaction that would constitute a breach of or default under the applicable Lock-Up Agreement, Management Stockholders’ Agreement or Stockholders’ Agreements.

(l)     The Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers (the “ Certification ”), together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification of the Certification.

The Company also covenants with each Underwriter that, without the prior written consent of each of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC on behalf of the Underwriters, it will not, during the period ending 180 days after the date of the Prospectus (the “ Restricted Period ”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Ordinary Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Ordinary Shares or such other securities, in cash or otherwise or (3) file any registration statement or make a confidential submission with the Commission relating to the offering of any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares.

The restrictions contained in the preceding paragraph shall not apply to (a) the Shares to be sold hereunder, (b) the issuance by the Company of Ordinary Shares upon

 

22


the exercise of an option or warrant or the conversion of a security outstanding on the date hereof of which the Underwriters have been advised in writing, (c) the grant of restricted stock, options or other equity awards pursuant to employee benefit plans of the Company in effect on the date hereof and referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus, provided that the recipients thereof execute and deliver to the Representatives a “lock-up” agreement substantially in the form of Exhibit A hereto for the remainder of the Restricted Period or, in the case of options, such options do not become exercisable during Restricted Period, (d) the filing by the Company of a registration statement with the Commission on Form S-8 relating to the offering of securities granted or to be granted in accordance with the terms of an equity incentive plan, employee benefit plan, employment agreement or similar arrangement in effect on the date hereof and described in the Time of Sale Prospectus and the Prospectus (provided that any Ordinary Shares registered pursuant to such registration statement shall be subject to restrictions described in the preceding paragraph for the remainder of the Restricted Period), (e) the sale or issuance of or entry into an agreement to sell or issue Ordinary Shares or any securities convertible into or exercisable or exchangeable for such Ordinary Shares in connection with bona fide mergers, acquisitions or joint ventures, provided that the aggregate number of Ordinary Shares or securities convertible into or exercisable for Ordinary Shares (on an as-converted or as-exercised basis, as the case may be) that the Company may sell or issue or agree to sell or issue pursuant to this clause (e) shall not exceed 10% of the total number of Ordinary Shares issued and outstanding immediately following the completion of the transactions contemplated by this Agreement, and provided, further , that in the case of this clause (e), any recipient of such securities shall execute and deliver to the Representatives a “lock-up” agreement substantially in the form of Exhibit A hereto covering the remainder of the Restricted Period, (f) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Ordinary Shares, provided that (i) such plan does not provide for the transfer of Ordinary Shares during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Ordinary Shares may be made under such plan during the Restricted Period, (g) the sale or issuance of Ordinary Shares to one or more employees of the Company as required pursuant to an agreement in effect on the date hereof, provided that (a) any such Ordinary Shares shall be subject to the lock-up provisions of an existing Stockholders Agreement and (b) the aggregate number of Ordinary Shares that the Company may sell or issue or agree to sell or issue pursuant to this clause (g) shall not exceed 0.3% of the total number of Ordinary Shares issued and outstanding immediately following the completion of the transactions contemplated by this Agreement or (h) the sale of Ordinary Shares (i) to the Specified Holder (as defined below) pursuant to one or more private placement transactions closing no later than August 31, 2018 and (ii) to the Specified Holder following any exercise of an over-allotment option by the Underwriters pursuant to this Agreement in order to enable the Specified Holders to maintain the same proportion of Ordinary Shares held to the total number of Ordinary Shares issued and outstanding immediately prior to the exercise of such over-allotment option, provided that (A) the total number of Ordinary Shares transferred pursuant to this clause (h) shall not exceed 4.9% of the then-

 

23


outstanding Ordinary Shares of the Company and (B) in the case of any transfer pursuant to this clause (h), the Specified Holder shall sign and deliver to the Representatives a lock-up letter substantially in the form of the letter attached hereto as Exhibit A. “Specified Holder” means Vanke Service (Hong Kong) Co., Limited.

If Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC, in their sole discretion, agree to release or waive the restrictions set forth in a Lock-Up Agreement described in Section 5(f) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B hereto through a major news service at least two business days before the effective date of the release or waiver.

7.     Covenants of the Underwriters . Each Underwriter severally covenants with the Company not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.

8.     Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any reasonably incurred and documented legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, any road show as defined in Rule 433(h) under the Securities Act (a “road show”), or the Prospectus or any amendment or supplement thereto, caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein.

(b)     Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information relating to such

 

24


Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or any amendment or supplement thereto.

(c)     In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the “ indemnified party ”) shall promptly notify the person against whom such indemnity may be sought (the “ indemnifying party ”) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred and documented fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the reasonably incurred and documented fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel; (ii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party; (iii) the indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party; or (iv) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonably incurred and documented fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such reasonably incurred and documented fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representatives, in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonably incurred and documented fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request, and (ii) such indemnifying party shall not have reimbursed the

 

25


indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement (i) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and (ii) does not include a statement admitting fault, culpability or a failure to act, by or on behalf of any indemnified party.

(d)     To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Underwriters’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective number of Shares they have purchased hereunder, and not joint.

(e)     The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the limitations set forth

 

26


above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Shares underwritten by it and distributed to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity.

(f)     The indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment for any of the Shares.

9.     Termination . The Underwriters may terminate this Agreement by notice given by the Representatives to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on, or by, as the case may be, the New York Stock Exchange or the Nasdaq Global Market, (ii) trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in securities settlement, payment or clearance services in the United States or England and Wales shall have occurred, (iv) any moratorium on commercial banking activities shall have been declared by Federal or New York State or relevant foreign country authorities or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets, or any calamity or crisis that, in the Representatives’ judgment, is material and adverse and which, individually or together with any other event specified in this clause (v), makes it, in the Representatives’ judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus.

10.     Effectiveness; Defaulting Underwriters . This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is

 

27


not more than one-tenth of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as the Representatives may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of one-ninth of such number of Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter or the Company. In any such case either the Representatives or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Additional Shares to be purchased on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i) terminate their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii) purchase not less than the number of Additional Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.

If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.

11.     Entire Agreement . (a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares.

 

28


(b)     The Company acknowledges that in connection with the offering of the Shares: (i) the Underwriters have acted at arm’s length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, (iii) the Underwriters may have interests that differ from those of the Company and (iv) the Underwriters are not advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares.

12.     Counterparts . This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

13.     Applicable Law . This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.

14.     Headings . The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement.

15.     Notices . All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed or sent to each of the Representatives at c/o Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department, c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attention: Equity Syndicate Desk, c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attention: Registration Department, c/o UBS Securities LLC, 1285 Avenue of the Americas, New York, New York 10019, Attention: Syndicate, and in each case, with a copy (which copy shall not constitute notice) to Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, Massachusetts 02199, Attention: Patrick O’Brien, and if to the Company shall be delivered, mailed or sent to Cushman & Wakefield plc, 225 West Wacker Drive, Suite 3000, Chicago, Illinois 60606, Attention: Harry Hsing, with a copy (which copy shall not constitute notice) to Cleary Gottlieb Steen & Hamilton LLP, New York, New York 10006, Attention: Jeffrey Karpf.

16.     Submission to Jurisdiction; Appointment of Agents for Service . (a) The Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York (the “ Specified Courts ”) over any suit, action or proceeding arising out of or relating to this Agreement, the Prospectus, the Registration Statement or the offering of the Shares (each, a “ Related Proceeding ”). The Company irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any Related Proceeding brought in such a court and any claim that any such Related Proceeding brought in such a court has been brought in an inconvenient forum. To the extent that the

 

29


Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to itself or its property, the Company irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any such suit, action or proceeding.

(b)     The Company hereby irrevocably appoints         , with offices at          as its agent for service of process in any Related Proceeding and agrees that service of process in any such Related Proceeding may be made upon it at the office of such agent. The Company waives, to the fullest extent permitted by law, any other requirements of or objections to personal jurisdiction with respect thereto. The Company represents and warrants that such agent has agreed to act as the Company’s agent for service of process, and the Company agrees to take any and all action, including the filing of any and all documents and instruments, that may be necessary to continue such appointment in full force and effect.

17.     Judgment Currency . If for the purposes of obtaining judgment in any court it is necessary to convert a sum due hereunder into any currency other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Underwriters could purchase United States dollars with such other currency in The City of New York on the business day preceding that on which final judgment is given. The obligation of the Company with respect to any sum due from it to any Underwriter or any person controlling any Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day following receipt by such Underwriter or controlling person of any sum in such other currency, and only to the extent that such Underwriter or controlling person may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such Underwriter or controlling person hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter or controlling person against such loss. If the United States dollars so purchased are greater than the sum originally due to such Underwriter or controlling person hereunder, such Underwriter or controlling person agrees to pay to the Company an amount equal to the excess of the dollars so purchased over the sum originally due to such Underwriter or controlling person hereunder.

18.     Taxes. (a) If any sum payable by the Company under this Agreement is subject to tax in the hands of an Underwriter or taken into account as a receipt in computing the taxable income of that Underwriter (excluding net income taxes on underwriting commissions payable under, or in connection with, this Agreement or the matters contemplated hereunder), the sum payable to the Underwriter under this Agreement shall be increased to such sum as will ensure that the Underwriter shall be left with the sum it would have had in the absence of such tax. (b) Where the Company is obliged to pay any fee, commission or other sum to any Representative or any Underwriter in connection with this Agreement and any amount of value added, sales, turnover or similar tax (“ VAT ”) is properly charged on it, the Company shall (except where the reverse charge procedure applies), in addition to that payment, pay an amount

 

30


equal to the VAT, subject to receipt, where applicable, of a valid VAT invoice. Where, pursuant to this Agreement, a sum is paid by the Company to any Representative or any Underwriter by way of reimbursement of a cost, charge or expense, the Company shall also pay to such payee in respect of VAT, an amount equal to any VAT charged to the payee in respect of that cost, charge or expense and which such payee determines is not recoverable by the payee (or the representative member of its VAT group) by repayment or credit.

[Remainder of page intentionally left blank]

 

31


Very truly yours,
CUSHMAN & WAKEFIELD PLC
By:  

 

  Name:
  Title:

 

 

 

Accepted as of the date hereof

 

Morgan Stanley & Co. LLC

J.P. Morgan Securities LLC

Goldman Sachs & Co. LLC

UBS Securities LLC

Acting severally on behalf of themselves and

the several Underwriters named in Schedule I hereto.

By:   Morgan Stanley & Co. LLC
By:  

 

  Name:
  Title:
By:   J.P. Morgan Securities LLC
By:  

 

  Name:
  Title:


By:   Goldman Sachs & Co. LLC
By:  

 

  Name:
  Title:
By:   UBS Securities LLC
By:  

 

  Name:
  Title:


SCHEDULE I

 

Underwriter

   Number of Firm Shares To
Be Purchased

Morgan Stanley & Co. LLC

  

J.P. Morgan Securities LLC

  

Goldman Sachs & Co. LLC

  

UBS Securities LLC

  

Merrill Lynch, Pierce, Fenner & Smith

                     Incorporated

  

Citigroup Global Markets Inc.

  

Credit Suisse Securities (USA) LLC

  

Barclays Capital Inc.

  

William Blair & Company, L.L.C.

  

TPG Capital BD, LLC

  

Credit Agricole Securities (USA) Inc.

  

JMP Securities LLC

  

Academy Securities, Inc.

  

Siebert Cisneros Shank & Co., L.L.C.

  

The Williams Capital Group, L.P.

  

Samuel A. Ramirez & Company, Inc.

  

HSBC Securities (USA) Inc.

  

Fifth Third Securities, Inc.

  

China Renaissance Securities (Hong Kong) Limited

  

Loop Capital Markets LLC

  
  

 

Total:

  
  

 

 

I-1


SCHEDULE II

Time of Sale Prospectus

 

1. Preliminary prospectus issued [date]

 

2. [Identify all free writing prospectuses filed by the Company under Rule 433(d) of the Securities Act]

 

3. [Free writing prospectus containing a description of terms that does not reflect final terms, if the Time of Sale Prospectus does not include a final term sheet]

 

4. [Orally communicated pricing information such as price per share and size of offering if a Rule 134 pricing term sheet is used at the time of sale instead of a pricing term sheet filed by the Company under Rule 433(d) as a free writing prospectus]

 

II-1


SCHEDULE III

The following persons shall execute a lock-up agreement in the form set forth on Exhibit A hereto:

 

    DTZ Investment Holdings LP;

 

    TPG Drone Investment, L.P.;

 

    TPG Drone Co-Invest, L.P.;

 

    PAGAC Drone Holding I LP;

 

    Ontario Teachers’ Pension Plan Board;

 

    2339532 Ontario Limited;

 

    Jonathan Coslet;

 

    Timothy Dattels;

 

    Lincoln Pan;

 

    Qi Chen;

 

    Rajeev Ruparelia;

 

    Billie Williamson;

 

    Brett White;

 

    Duncan Palmer;

 

    Brett Soloway;

 

    John Forrester;

 

    Michelle Hay; and

 

    Nathaniel Robinson.

 

III-1


Exhibit A

FORM OF LOCK-UP LETTER

                                     , 2018

Morgan Stanley & Co. LLC

J.P. Morgan Securities LLC

Goldman Sachs & Co. LLC

UBS Securities LLC

 

c/o

   Morgan Stanley & Co. LLC
  

1585 Broadway

  

New York, NY 10036

c/o

   J.P. Morgan Securities LLC
  

383 Madison Avenue

  

New York, NY 10179

c/o

   Goldman Sachs & Co. LLC
   200 West Street
   New York, NY 10282

c/o

   UBS Securities LLC
   1285 Avenue of the Americas
   New York, NY 10019

Ladies and Gentlemen:

The undersigned understands that Morgan Stanley & Co. LLC (“ Morgan Stanley ”), J.P. Morgan Securities LLC (“ J.P. Morgan ”), Goldman Sachs & Co. LLC and UBS Securities LLC, as representatives (the “ Representatives ”), propose to enter into an Underwriting Agreement (the “ Underwriting Agreement ”) on behalf of the several underwriters named in Schedule I to such agreement (collectively, the “ Underwriters ”), with Cushman & Wakefield plc, a public limited company organized under the laws of England and Wales (the “ Company ”), providing for the public offering (the “ Public Offering ”) by the several Underwriters, including the Representatives (the “ Underwriters ”), of ordinary shares, nominal value $0.10 per share (the “ Shares ”) pursuant to a Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “ Commission ”).

To induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of each of Morgan Stanley and J.P. Morgan on behalf of the Underwriters, it will not, during the period commencing on the date hereof and continuing until, and including, the date that is 180 days after the date of the final prospectus (the “ Restricted Period ”) relating to the Public Offering (the “ Prospectus ”),

 

1


(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Shares beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Shares, or publicly announce its intention to enter into any such transaction, or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Shares or such other securities, in cash or otherwise. The foregoing sentence shall not apply to:

(a) transactions relating to Shares or other securities acquired in open market transactions after the completion of the Public Offering, provided that no filing under Section 16(a) of the Exchange Act and the rules and regulations of the Commission thereunder shall be required or shall be voluntarily made in connection with subsequent sales of Shares or other securities acquired in such open market transactions,

(b) (i) transfers of Shares or any security convertible into Shares as a bona fide gift, (ii) transfers of Shares as a result of the operation of law through estate, other testamentary document or intestate succession, (iii) transfers of Shares to any immediate family member of the undersigned or any trust for the direct or indirect benefit of the undersigned or any immediate family member of the undersigned (for purposes of this letter, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin) or (iv) the transfer of Shares or any security convertible into or exercisable or exchangeable for Shares pursuant to a qualified domestic order or in connection with a divorce settlement,

(c) if the undersigned is a corporation, partnership or other business entity, distributions or transfers of Shares or any security convertible into Shares to limited partners, general partners, members, nominees or shareholders of the undersigned or its direct or indirect affiliates or other entities controlled or managed by the undersigned not involving a disposition for value,

(d) if permitted by the Company, the establishment of a written trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Shares, provided that such plan does not provide for the transfer of Shares during the Restricted Period and no public disclosure of such plan shall be required or shall be made during the Restricted Period,

(e) the exercise or settlement of stock options, restricted stock units or other equity awards pursuant to any plan or agreement granting such an award to an employee or other service provider of the Company or its affiliates (and any related transfer to the Company of Ordinary Shares necessary to generate such amount of cash needed for the payment of taxes, including estimated taxes, due as a result of such settlement or exercise whether by means of a “net settlement” or otherwise),

 

2


(f) transfers of Shares to the Company in connection with the repurchase by the Company (i) of Shares issued pursuant to the Cassidy Turley deferred payment obligation or (ii) pursuant to a management stockholders agreement or other agreement in effect as of the date hereof and pursuant to which such Shares were issued or are subject[,]/[or]

(g) in connection with the dissolution of DTZ Investment Holdings LP, DTZ Investment Holdings GenPar LLP and/or FTL Nominees 2 Limited, distributions or transfers of Shares to the undersigned’s limited partners, general partners, members, nominees or shareholders or any investment fund controlled or managed by any affiliate of DTZ Investment Holdings LP or DTZ Investment Holdings GenPar LLP or any of their direct or indirect affiliates, not involving a disposition for value[;]/[or

(h) transfers of Shares to Vanke Service (HongKong) Co., Limited or its affiliates in one or more private placement transactions]; 1

provided that in the case of any transfer or distribution pursuant to clauses (b), (c)[,]/[or] (g) [or (h)], each transferee or distributee shall sign and deliver to the Representatives a lock-up letter substantially in the form of this letter if it has not previously done so; and provided, further, that in the case of any transfer or distribution pursuant to clause (b) through (f), no filing under Section 16(a) of the Exchange Act and the rules and regulations of the Commission thereunder, reporting a reduction in beneficial ownership of Shares, shall be required or shall be voluntarily made during the Restricted Period, other than:

 

  i. a filing made on Form 4 solely in connection with transfers described in clause (e) above, which shall specify in such Form 4 that (a) the exercise or settlement of stock options, restricted stock units or other equity awards or (b) the related transfer to the Company of Ordinary Shares, in each case as applicable, that required such filing of a Form 4, was (x) deemed to occur upon the cashless exercise of such securities or (y) for the purpose of paying the exercise price of such securities or for paying taxes (including estimated taxes) due as a result of the exercise of such exercises, as applicable, and in the case of clause (b) above, was a transfer to the Company; or

 

  ii. a filing on Form 5 made after the expiration of the Restricted Period.

In addition, the undersigned agrees that, without the prior written consent of each of Morgan Stanley and J.P. Morgan on behalf of the Underwriters, it will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for Shares. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s Shares except in compliance with the foregoing restrictions.

 

 

1  

Note: Clause (h) to be inserted only for lock-ups signed by the sponsor entities, the consortium vehicle and Brett White.

 

3


If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed Shares the undersigned may purchase in the Public Offering.

If the undersigned is an officer or director of the Company, (i) each of Morgan Stanley and J.P. Morgan agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Shares, Morgan Stanley and J.P. Morgan will notify the Company of the impending release or waiver, and (ii) the Company has agreed or will agree in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted by Morgan Stanley and J.P. Morgan hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of the transfer.

The undersigned understands that the Company and the Underwriters are relying upon this agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns.

This letter shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would result in the application of any law other than the laws of the State of New York. The undersigned agrees that any suit or proceeding arising in respect of this agreement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in the City and County of New York and the undersigned agrees to submit to the jurisdiction of, and to venue in, such courts.

Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.

Notwithstanding anything to the contrary contained herein, this letter will automatically terminate and the undersigned will be released from all of his, her or its obligations hereunder upon the earliest to occur, if any, of (i) prior to the execution of the Underwriting Agreement, either the Company on the one hand, or the Representatives on the other hand, advises the other in writing that it has determined not to proceed with the Public Offering, (ii) the withdrawal of the Registration Statement on Form S-1 related to the Public Offering, (iii) the Underwriting Agreement is executed but is terminated (other than the provisions thereof which survive termination) prior to payment for and delivery of the Shares to be sold thereunder, or (iv) September 30, 2018, in the event that the Underwriting Agreement has not been executed by such date; provided, however, that the Company may, by written notice to the undersigned prior to such date, extend such date for a period of up to three additional months.

 

4


Very truly yours,

 

(Name)

 

(Address)

 

5


EXHIBIT B

FORM OF WAIVER OF LOCK-UP

                         , 2018

[Name and Address of Officer or Director Requesting Waiver]

Dear Mr./Ms. [Name]:

This letter is being delivered to you in connection with the offering by Cushman & Wakefield plc, a public limited company organized under the laws of England and Wales (the “ Company ”) of          ordinary shares, nominal value $0.10 per share (the “ Ordinary Shares ”), of the Company and the lock-up letter dated         , 20         (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated         , 20        , with respect to          Ordinary Shares (the “ Shares ”).

Each of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC hereby agrees to [waive] [release] the transfer restrictions set forth in the Lock-up Letter, but only with respect to the Shares, effective        , 2018; provided, however, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness of such [waiver] [release]. This letter will serve as notice to the Company of the impending [waiver] [release].

Except as expressly [waived] [released] hereby, the Lock-up Letter shall remain in full force and effect.

 

Very truly yours,

Morgan Stanley & Co. LLC

J.P. Morgan Securities LLC

Goldman Sachs & Co. LLC

UBS Securities LLC

Acting severally on behalf of themselves

and the several Underwriters named

in Schedule I to the Underwriting Agreement

 

1


By:   Morgan Stanley & Co. LLC
By:  

 

  Name:
  Title:
By:   J.P. Morgan Securities LLC
By:  

 

  Name:
  Title:
By:   Goldman Sachs & Co. LLC
By:  

 

  Name:
  Title:
By:   UBS Securities LLC
By:  

 

  Name:
  Title:

cc: Company

 

2


FORM OF PRESS RELEASE

Cushman & Wakefield plc

[Date]

Cushman & Wakefield plc (the “ Company ”) announced today that Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and UBS Securities LLC, the lead book-running managers in the Company’s recent public sale of          ordinary shares is [waiving][releasing] a lock-up restriction with respect to          of the Company’s ordinary shares held by [certain officers or directors] [an officer or director] of the Company. The [waiver][release] will take effect on         , 2018         , and the shares may be sold on or after such date.

This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.

 

3

Exhibit 4.2

 

 

 

REGISTRATION RIGHTS AGREEMENT

BY AND AMONG

CUSHMAN & WAKEFIELD PLC,

TPG DRONE INVESTMENT, L.P.,

TPG DRONE CO-INVEST, L.P.,

PAGAC DRONE HOLDING I LP,

2339532 ONTARIO LIMITED,

ONTARIO TEACHERS’ PENSION PLAN BOARD,

AND

DTZ INVESTMENT HOLDINGS LP

DATED AS OF     , 2018

 

 

 


TABLE OF CONTENTS

 

         Page  

ARTICLE I

 

DEFINITIONS

 

Section 1.01.   Defined Terms      1  
Section 1.02.   Other Interpretive Provisions      6  

ARTICLE II

 

REGISTRATION RIGHTS

 

Section 2.01.   Demand Registration      6  
Section 2.02.   Shelf Registration      9  
Section 2.03.   Piggyback Registration      13  
Section 2.04.   Lock-up Periods      15  
Section 2.05.   Registration Procedures      16  
Section 2.06.   Underwritten Offerings      22  
Section 2.07.   No Inconsistent Agreements; Additional Rights      23  
Section 2.08.   Registration Expenses      23  
Section 2.09.   Indemnification      24  
Section 2.10.   Rules 144 and 144A and Regulation S      27  
Section 2.11.   Existing Registration Statements      27  
Section 2.12.   In-Kind Distributions      28  
Section 2.13.   Trading Windows      28  

ARTICLE III

 

MISCELLANEOUS

 

Section 3.01.   Term      28  
Section 3.02.   Injunctive Relief      28  
Section 3.03.   Attorneys’ Fees      28  
Section 3.04.   Notices      29  
Section 3.05.   Amendment      31  

 

i


TABLE OF CONTENTS

(continued)

 

         Page  
Section 3.06.   Successors, Assigns and Transferees      31  
Section 3.07.   Binding Effect      31  
Section 3.08.   Third Parties      31  
Section 3.09.   Governing Law      31  
Section 3.10.   Consent to Jurisdiction      31  
Section 3.11.   Waiver of Jury Trial      32  
Section 3.12.   Merger; Binding Effect, etc.      32  
Section 3.13.   Severability      32  
Section 3.14.   Counterparts      32  
Section 3.15.   No Recourse      32  
Section 3.16.   Headings      33  

 

ii


REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (the “ Agreement ”), dated as of     , 2018, by and among Cushman & Wakefield PLC, an English public limited company (together with its successors, the “ Company ”), TPG Drone Investment, L.P. (“ TPG Drone Investment ”), TPG Drone Co-Invest, L.P. (“ TPG Drone Co-Invest ” and together with TPG Drone Investment, “ TPG ”), PAGAC Drone Holding I LP (“ PAG ”), OTPP (as defined below), DTZ Investment Holdings LP (“ DTZ Investment ”) and such other Persons, if any, from time to time that become party hereto as holders of Registrable Securities (as defined below) pursuant to Section 3.06.

WITNESSETH :

WHEREAS, on     , 2018, the Company priced an initial public offering (the “ IPO ”) of Common Shares (as defined below) pursuant to an Underwriting Agreement dated     , 2018 (the “ Underwriting Agreement ”);

WHEREAS, the parties believe that it is in the best interests of the Company and the other parties hereto to set forth their agreements regarding registration rights applicable to the Registrable Securities of the Company and certain other matters following the closing of the IPO (the “ IPO Closing ”).

NOW, THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements of the parties hereto, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE I

DEFINITIONS

SECTION 1.01.     Defined Terms . As used in this Agreement, the following terms shall have the following meanings:

Adverse Disclosure ” means public disclosure of material non-public information that, in the Board of Directors’ good faith judgment, after consultation with independent outside counsel to the Company, (i) would be required to be made in any Registration Statement or report filed with the SEC by the Company so that such Registration Statement would not be materially misleading; (ii) would not be required to be made at such time but for the filing of such Registration Statement or report; and (iii) the Company has a bona fide business purpose for not disclosing publicly.

Agreement ” has the meaning set forth in the preamble.

Affiliate ” has the meaning specified in Rule 12b-2 under the Exchange Act; provided , that no Holder shall be deemed an Affiliate of the Company or any of its subsidiaries for purposes of this Agreement and provided further that any portfolio companies of any Sponsor shall not be considered “Affiliates” hereunder. The term “ Affiliated ” has a correlative meaning.


Board of Directors ” means the board of directors of the Company.

Business Day ” means any day other than a Saturday, Sunday or a day on which commercial banks located in New York, New York are required or authorized by law or executive order to be closed.

Common Share Equivalents ” means securities (including, without limitation, warrants) exercisable, exchangeable or convertible into Common Shares.

Common Shares ” means the ordinary shares, nominal value $0.10 per share, of the Company and any shares of capital stock of the Company issued or issuable with respect to such common stock by way of a stock dividend or distribution payable thereon or stock split, reverse stock split, recapitalization, reclassification, reorganization, exchange, subdivision or combination thereof.

Company ” has the meaning set forth in the preamble and shall include the Company’s successors by merger, acquisition, reorganization, conversion or otherwise.

Company Public Sale ” has the meaning set forth in Section 2.03(a).

Coordination Agreement ” means the Coordination Agreement, by and among TPG Drone Investment, TPG Drone Co-Invest, PAG and OTPP, dated as of the date hereof, as amended, modified or supplemented from time to time.

Demand Notice ” has the meaning set forth in Section 2.01(d).

Demand Period ” has the meaning set forth in Section 2.01(c).

Demand Registration ” has the meaning set forth in Section 2.01(a).

Demand Registration Statement ” has the meaning set forth in Section 2.01(a).

Demand Request ” has the meaning set forth in Section 2.01(a).

Demand Suspension ” has the meaning set forth in Section 2.01(e).

Demanding Sponsor ” has the meaning set forth in Section 2.01(a).

DTZ Investment ” has the meaning set forth in the preamble.

Effectiveness Date ” means the date immediately following the IPO Closing.

Exchange Act ” means the Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same shall be in effect from time to time.

FINRA ” means the Financial Industry Regulatory Authority, Inc.

 

2


Holder ” means any holder of Registrable Securities who is a party hereto or who succeeds to rights hereunder pursuant to Section 3.06. For the avoidance of doubt, the term “Holder” includes each of the Sponsors for so long as such Sponsor owns or holds of record, directly or indirectly, any Common Shares.

IPO ” has the meaning set forth in the Recitals.

IPO Closing ” has the meaning set forth in the Recitals.

Issuer Free Writing Prospectus ” means an issuer free writing prospectus, as defined in Rule 433 under the Securities Act, relating to an offer of the Registrable Securities.

Long-Form Registration ” has the meaning set forth in Section 2.01(a).

OTPP ” means 2339532 Ontario Limited and Ontario Teachers’ Pension Plan Board and, after 2339532 Ontario Limited has distributed all of its Ordinary Shares in the Company to Ontario Teachers’ Pension Plan Board or its Affiliates, shall mean Ontario Teachers’ Pension Plan Board and any of its Affiliates holding Common Shares.

PAG ” has the meaning set forth in the preamble.

Participating Holder ” means, with respect to any Registration, any Holder of Registrable Securities covered by the applicable Registration Statement.

Participation Conditions ” has the meaning set forth in Section 2.02(f)(ii).

Permitted Assignee ” has the meaning set forth in Section 3.06.

Person ” means any individual, partnership, corporation, limited liability company, unincorporated organization, trust or joint venture, or a governmental agency or political subdivision thereof.

Piggyback Registration ” has the meaning set forth in Section 2.03(a).

Potential Takedown Participant has the meaning set forth in Section 2.02(f)(ii).

Prospectus ” means the prospectus included in any Registration Statement, all amendments and supplements to such prospectus, including pre- and post-effective amendments to such Registration Statement, and all other material incorporated by reference in such prospectus.

Public Offering ” means the offer and sale of Registrable Securities for cash pursuant to an effective Registration Statement under the Securities Act (other than a Registration Statement on Form S-4 or Form S-8 or any successor form).

Registrable Securities ” means (i) any Common Shares (including any issuable or issued upon exercise, exchange or conversion of any Common Share Equivalents) that are owned or held of record, directly or indirectly, by a Holder and (ii) any securities that may be issued or

 

3


distributed or be issuable in respect of any Common Shares by way of conversion, dividend, stock split or other distribution, merger, consolidation, exchange, recapitalization or reclassification or similar transaction that are owned or held of record, directly or indirectly, by a Holder; provided , however , that any such Registrable Securities shall cease to be Registrable Securities to the extent (w) a Registration Statement with respect to the sale of such Registrable Securities has become effective under the Securities Act and such Registrable Securities have been disposed of in accordance with the plan of distribution set forth in such Registration Statement, (x) such Registrable Securities have been sold pursuant to Rule 144 without volume limitations or other restrictions on transfer thereunder, (y) in the case of any Holder, the aggregate number of such securities held by such Holder and its Affiliates is less than the number that would subject the distribution thereof to any volume limitation or other restrictions on transfer under Rule 144 and such Holder is able to immediately distribute such securities publicly without any restrictions on transfer (including without application of paragraphs (c), (d), (e), (f) and (h) of Rule 144), provided , however , that any Common Shares held by DTZ Investment shall continue to be Registrable Securities for so long as DTZ Investment holds any Common Shares, or (z) such securities shall have ceased to be outstanding.

Registration ” means a registration with the SEC of the Company’s securities for offer and sale to the public under a Registration Statement. The term “ Register ” shall have a correlative meaning.

Registration Expenses ” has the meaning set forth in Section 2.08.

Registration Statement ” means any registration statement of the Company filed with, or to be filed with, the SEC under the rules and regulations promulgated under the Securities Act, including the related Prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement.

Representatives ” means, with respect to any Person, any of such Person’s officers, directors, employees, agents, attorneys, accountants, actuaries, consultants, equity financing partners or financial advisors or other Person associated with, or acting on behalf of, such Person.

Rule 144 ” means Rule 144 under the Securities Act, or any similar or analogous rule promulgated under the Securities Act.

SEC ” means the Securities and Exchange Commission.

Vanke Purchase Agreement ” means the Purchase Agreement, dated July 24, 2018, by and among Vanke Service (HongKong) Co., Limited ( 萬科物業服務 ( 香港 ) 有限公司 ), a Hong Kong limited company, DTZ Investment and the Company.

Securities Act ” means the Securities Act of 1933, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same shall be in effect from time to time.

Shelf Notice ” has the meaning set forth in Section 2.02(d).

 

4


Shelf Period ” has the meaning set forth in Section 2.02(c).

Shelf Registration ” means a Registration effected pursuant to Section 2.02.

Shelf Registration Statement ” means a Registration Statement of the Company filed with the SEC on either (i) Form S-3 (or any successor form or other appropriate form under the Securities Act) or (ii) if the Company is not permitted to file a Registration Statement on Form S-3, an Registration Statement on Form S-1 (or any successor form or other appropriate form under the Securities Act), in each case for an offering to be made on a continuous basis pursuant to Rule 415 under the Securities Act (or any similar rule that may be adopted by the SEC) covering the Registrable Securities, as applicable.

Shelf Suspension ” has the meaning set forth in Section 2.02(g).

Shelf Takedown ” means a Public Offering pursuant to an effective Shelf Registration Statement.

Shelf Takedown Notice ” has the meaning set forth in Section 2.02(f)(ii).

Shelf Takedown Request ” has the meaning set forth in Section 2.02(f)(i).

Short-Form Registration ” has the meaning set forth in Section 2.01(a).

Sponsors ” means each of TPG, PAG and OTPP and their respective Affiliates and Permitted Assignees hereunder, and for as long as it holds at least 2% of the Registrable Securities it owned at the IPO Closing, shall include DTZ Investment.

TPG ” has the meaning set forth in the preamble.

TPG Drone Investment ” has the meaning set forth in the preamble.

TPG Drone Co-Invest ” has the meaning set forth in the preamble.

Underwriting Agreement ” has the meaning set forth in the preamble.

Underwritten Offering ” means an underwritten Public Offering, including any bought deal or block sale to a financial institution conducted as an underwritten Public Offering.

Underwritten Shelf Takedown ” means an Underwritten Offering pursuant to an effective Shelf Registration Statement.

WKSI ” means any Securities Act registrant that is a well-known seasoned issuer as defined in Rule 405 under the Securities Act at the most recent eligibility determination date specified in paragraph (2) of that definition.

SECTION 1.02.     Other Interpretive Provisions . .

(a)    The meanings of defined terms are equally applicable to the singular and plural forms thereof.

 

5


(b)    The words “ hereof ”, “ herein ”, “ hereunder ” and similar words refer to this Agreement as a whole and not to any particular provision of this Agreement; and any subsection, Section, Exhibit, Schedule and Annex references are to this Agreement unless otherwise specified.

(c)    The term “ including ” is not limiting and means “ including without limitation .”

(d)    The captions and headings of this Agreement are for convenience of reference only and shall not affect the interpretation of this Agreement.

(e)    Whenever the context requires, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms.

ARTICLE II

REGISTRATION RIGHTS

SECTION 2.01.     Demand Registration .

(a)     Demand by the Sponsors . If, at any time on or after the Effectiveness Date, there is no currently effective Shelf Registration Statement on file with the SEC, a Sponsor may from time to time and at any time make a written request (a “ Demand Request ”) to the Company for Registration of all or part of the Registrable Securities held by any Sponsor (a “ Demanding Sponsor ”) (i) on Form S-1 or any similar long-form registration statement (a “ Long-Form Registration ”) or (ii) on Form S-3 or any similar short-form registration statement (a “ Short-Form Registration ”) if the Company is qualified to use such short form. Any such requested Long-Form Registration or Short-Form Registration shall hereinafter be referred to as a “ Demand Registration .” Each request for a Demand Registration shall specify the kind and aggregate amount of Registrable Securities to be Registered and the intended methods of disposition thereof. Promptly upon receiving any Demand Request, the Company shall use its reasonable best efforts to file a Registration Statement relating to such Demand Registration (a “ Demand Registration Statement ”), and shall use its reasonable best efforts to cause such Demand Registration Statement to promptly become effective under (x) the Securities Act and (y) the “Blue Sky” laws of such jurisdictions as any Participating Holder or any underwriter, if any, reasonably requests.

(b)     Demand Withdrawal . A Demanding Sponsor and any other Holder that has requested its Registrable Securities be included in a Demand Registration pursuant to Section 2.01(d) may withdraw all or any portion of its Registrable Securities from a Demand Registration at any time prior to the effectiveness of the applicable Demand Registration Statement. The Company shall continue all efforts to secure effectiveness of the applicable Demand Registration Statement in respect of the Registrable Securities of any other Holder that has requested inclusion in the Demand Registration pursuant to Section 2.01(d) so long as at least one of the Sponsors has requested and not withdrawn all of its Registrable Securities to be included in such Demand Registration; provided , however , if all Sponsors have requested for all of their Registrable Securities to be withdrawn from such Demand Registration, the Company

 

6


shall immediately cease all efforts to secure effectiveness of the applicable Demand Registration Statement, even if one or more non-Sponsor Holders have requested for Registrable Securities to be included in such applicable Demand Request pursuant to Section 2.01(d). A withdrawn Demand shall not count as the use of a right under Section 2.01(j) unless withdrawn after effectiveness, and in such case, only if the withdrawing Sponsors do not agree to pay the Company’s costs with respect to such Demand Registration.

(c)     Effective Registration . The Company shall, with respect to each Demand Registration, use its reasonable best efforts to cause the Demand Registration Statement to remain effective for not less than one hundred eighty (180) consecutive calendar days (or such shorter period as shall terminate when all Registrable Securities covered by such Demand Registration Statement have been sold or withdrawn), or if such Registration Statement relates to an Underwritten Offering, such longer period as, in the opinion of counsel for the underwriter or underwriters, a Prospectus is required by law to be delivered in connection with sales of Registrable Securities by an underwriter or dealer (the applicable period, the “ Demand Period ”).

(d)     Demand Notice . Promptly upon receipt of any Demand Request pursuant to Section 2.01(a) (but in no event more than two (2) Business Days thereafter), the Company shall deliver a written notice (a “ Demand Notice ”) of any such Registration request to all other Holders, and the Company shall include in such Demand Registration all such Registrable Securities with respect to which the Company has received written requests for inclusion therein within five (5) calendar days after the date that the Demand Notice has been delivered. All requests made pursuant to this Section 2.01(d) shall specify the aggregate amount of Registrable Securities to be registered and the intended method of distribution of such securities. If any Holder does not deliver a notice to the Company within five (5) calendar days after the delivery of the Demand Notice to such Holder, such Holder shall be deemed to have irrevocably waived any and all rights under this Section 2.01 with respect to such Registration (but not with respect to future Registrations in accordance with this Section 2.01).

(e)     Delay in Filing; Suspension of Registration . If the filing, initial effectiveness or continued use of a Demand Registration Statement at any time would require the Company to make an Adverse Disclosure, the Company may, upon giving prompt written notice of such action to the Holders, delay the filing or initial effectiveness of, or suspend use of, the Demand Registration Statement (a “ Demand Suspension ”); provided , however , that the Company shall not be permitted to exercise a Demand Suspension or Shelf Suspension (as defined in Section 2.02(g)) (i) more than once during any twelve (12)-month period, or (ii) for a period exceeding thirty (30) calendar days on any one occasion. Any such determination shall be evidenced by a resolution of the Board of Directors of the Company and delivered at such time to the Sponsors. In the case of a Demand Suspension, the Holders agree to suspend use of the applicable Prospectus in connection with any sale or purchase, or offer to sell or purchase, Registrable Securities, upon receipt of the notice referred to above. The Company shall immediately notify the Holders upon the termination of any Demand Suspension, amend or supplement the Prospectus, if necessary, so it does not contain any untrue statement or omission and furnish to the Holders such numbers of copies of the Prospectus as so amended or supplemented as the Holders may reasonably request. The Company agrees, if necessary, to supplement or make amendments to the Demand Registration Statement, if required by the registration form used by the Company for the Demand Registration or by the instructions

 

7


applicable to such registration form or by the Securities Act or the rules or regulations promulgated thereunder or as may reasonably be requested by a Demanding Sponsor. Notwithstanding any term of Section 2.01(i) or this Section 2.01(e), in no event may the Company exercise the rights under Sections 2.01(i) or 2.01(e) to cause preemption or postponement of the filing of a Demand Registration Statement or the postponement of the effectiveness or suspension of the use thereof for more than thirty (30) calendar days, unless written consent has been provided by the Sponsors.

(f)     Underwritten Offering . If a Demanding Sponsor so requests, an offering of Registrable Securities pursuant to a Demand Registration shall be in the form of an Underwritten Offering, and such Demanding Sponsor shall have the right to select the managing underwriter or underwriters to administer the offering; provided that such managing underwriter or underwriters shall be reasonably acceptable to the Company and to such other Sponsors that are selling in the Underwritten Offering, if any.

(g)     Priority of Securities Registered Pursuant to Demand Registrations . If the managing underwriter or underwriters of a proposed Underwritten Offering of the Registrable Securities included in a Demand Registration (or, in the case of a Demand Registration not being underwritten, the Sponsors), advise the Board of Directors in writing that, in its or their opinion, the number of securities requested to be included in such Demand Registration exceeds the number which can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, the securities to be included in such Demand Registration (i) first, if DTZ Investment holds less than 2% of the Registrable Securities it owned at the IPO Closing, shall be allocated to DTZ Investment if it has requested to participate in such Demand Registration; (ii) next, and only if all the securities referred to in clause (i) have been included, shall be allocated pro rata among the other Sponsors (including any Demanding Sponsor) and any Holder that acquired Registrable Securities pursuant to the Vanke Purchase Agreement that have requested to participate in such Demand Registration based on the relative number of Registrable Securities then held by each such Sponsor or relevant Holder ( provided that any securities thereby allocated to a Sponsor or relevant Holder that exceed such Sponsor’s or relevant Holder’s request shall be reallocated among the remaining requesting Sponsors and relevant Holders in like manner); and (iii) finally, and only if all the securities referred to in clauses (i) and (ii) have been included, the number of securities that any other Holder that has a right to participate in such registration proposes (allocated pro rata among such Holders that have requested to participate in such Demand Registration based on the relative number of Registrable Securities then held by such Holders and provided that any securities thereby allocated to a Holder that exceed such Holder’s request shall be reallocated among the remaining requesting Holders in like manner) to include in such Registration that, in the opinion of the managing underwriter or underwriters (or the Sponsors, as the case may be) can be sold without having such adverse effect.

(h)     Distributions of Registrable Securities to Partners or Members . In the event any Holder requests to participate in a registration pursuant to this Section 2.01 in connection with a distribution of Registrable Securities to its partners or members, the registration shall provide for resale by such partners or members, if requested by the Holder.

 

8


(i)     Preemption . If not more than thirty (30) calendar days prior to receipt of a Demand Registration Request the Company shall have (i) circulated to prospective underwriters and their counsel a draft of a Registration Statement for a primary offering of equity securities on behalf of the Company; (ii) solicited bids for a primary offering of Shares; or (iii) otherwise reached an understanding with an underwriter with respect to a primary offering of Shares, the Company may preempt the Demand Registration with such primary offering by delivering written notice of such intention (the “ Preemption Notice ”) to the Sponsors within two (2) Business Days after the Company has received the Demand Registration Request. The period of preemption may be up to thirty (30) calendar days following the date of the Preemption Notice. Notwithstanding anything to the contrary herein, the Company shall not be entitled to exercise its right to preempt a Demand Registration pursuant to this Section 2.01(i) more than once in any twelve (12)-month period.

(j)     Limitation on Demand Registrations . The Company shall be obligated to take action to effect up to two Demand Registrations from the Effectiveness Date to the one (1) year anniversary of the IPO Closing. If after the one (1) year anniversary of the IPO Closing, the Company does not qualify to file a Shelf Registration Statement under the Securities Act, the Company shall be obligated to take action to effect two Demand Registrations for each year, or partial year period that the Company continues to not so qualify provided , that in such period the Company shall not be obligated to effect any Demand Registration if a Demand Registration was declared effective or an Underwritten Shelf Takedown was consummated within the preceding forty-five (45) calendar days.

SECTION 2.02.     Shelf Registration .

(a)     Filing . On or after the one (1) year anniversary of the IPO Closing, as promptly as practicable following a request as may be made from time to time by one or more Sponsors, the Company shall file with the SEC a Shelf Registration Statement pursuant to Rule 415 of the Securities Act relating to the offer and sale by Holders from time to time of Registrable Securities in accordance with the methods of distribution elected by the participating Sponsor(s) and set forth in the Shelf Registration Statement. If on the date of a request to file a Shelf Registration Statement (i) the Company is a WKSI, then such request for a Shelf Registration shall request Registration of an unspecified amount of Registrable Securities; and (ii) the Company is not a WKSI, then the request for a Shelf Registration Statement shall specify the aggregate amount of Registrable Securities to be registered. As promptly as practicable after receipt of a request to file a Shelf Registration Statement, the Company shall use its reasonable best efforts to cause such Shelf Registration Statement to become effective under the Securities Act. If fewer than all of the Sponsors make a request pursuant to this Section 2.02(a) to file a Shelf Registration Statement, the Company shall promptly (and, in any event, within two (2) Business Days) notify the other Sponsor(s) of such request. No later than five (5) calendar days after the receipt of the foregoing notification regarding the filing of the Shelf Registration Statement pursuant to this Section 2.02(a), the other Sponsor(s) shall notify the Company in writing the number of its Registrable Securities (if any) that such Sponsor is, or such Sponsors are, requesting to be registered on such Shelf Registration Statement. At any time prior to or after the filing of a Shelf Registration Statement, any of the Sponsors may request that the number of its Registrable Securities (if any) previously requested to be registered on such Shelf Registration Statement be increased to a larger number of its Registrable Securities and the

 

9


Company shall thereafter use its reasonable best efforts to effect such increase for such Shelf Registration Statement as promptly as practicable thereafter.

(b)    The aggregate number of Registrable Securities that the Sponsors request to be so registered on such Shelf Registration Statement (as increased from time to time at the election of any of the Sponsors pursuant to the immediately foregoing sentence) shall be referred to in this Section 2.02 as the “ Sponsor Shelf Registration  Amount .” If, on the date of any such request, the Company does not qualify to file a Shelf Registration Statement under the Securities Act, the provisions of this Section 2.02 shall not apply, and the provisions of Section 2.01 shall apply instead.

(c)     Continued Effectiveness . The Company shall use its reasonable best efforts to keep such Shelf Registration Statement continuously effective under the Securities Act in order to permit the Prospectus forming a part thereof to be usable by Holders until the earlier of (i) the date as of which all Registrable Securities have been sold pursuant to the Shelf Registration Statement or another registration statement filed under the Securities Act (but in no event prior to the applicable period referred to in Section 4(a)(3) of the Securities Act and Rule 174 thereunder) or otherwise cease to be Registrable Securities; and (ii) the date as of which each of the Holders is permitted to sell its Registrable Securities without Registration pursuant to Rule 144 without volume limitation or other restrictions on transfer thereunder (such period of effectiveness, the “ Shelf Period ”). Subject to Section 2.02(g), the Company shall not be deemed to have used its reasonable best efforts to keep the Shelf Registration Statement effective during the Shelf Period if the Company voluntarily takes any action or omits to take any action that would result in Holders of Registrable Securities covered thereby not being able to offer and sell any Registrable Securities pursuant to such Shelf Registration Statement during the Shelf Period, unless such action or omission is required by applicable law.

(d)     Shelf Notice . Promptly upon receipt of any request by a Sponsor to file a Shelf Registration Statement or any request by a Sponsor to increase the number of its Registrable Securities registered on such Shelf Registration Statement pursuant to Section 2.02(a) (but in no event more than two (2) Business Days thereafter), the Company shall deliver a written notice (a “ Shelf Notice ”) of any such request to any other Holders specifying the Sponsor Shelf Registration Amount and the Company shall include in such Shelf Registration Statement the number of Registrable Securities with respect to which the Company has received written requests for inclusion therein within five (5) calendar days after the date that the Shelf Notice has been delivered. If any Holder does not deliver a notice to the Company within five (5) calendar days after the date that the Shelf Notice has been delivered to such Holder, such Holder shall be deemed to have irrevocably waived any and all right under this Section 2.02 with respect to such Registration (but not with respect to future Registrations in accordance with this Section 2.02).

(e)     Underwritten Offering .

(i)    If a Sponsor so elects, an offering of Registrable Securities pursuant to the Shelf Registration Statement shall be in the form of an Underwritten Offering, and the Company shall amend or supplement the Shelf Registration Statement for the purpose of such

 

10


Underwritten Shelf Takedown, such Sponsor(s) shall have the right to select the managing underwriter or underwriters to administer such offering.

(ii)    The provisions of Section 2.01(g) shall apply to any Underwritten Offering pursuant to this Section 2.02(e).

(f)     Shelf Takedown .

(i)    At any time during which the Company has an effective Shelf Registration Statement with respect to a Holder’s Registrable Securities, by notice to the Company specifying the intended method or methods of disposition thereof, a Sponsor may make a written request (a “ Shelf Takedown Request ”) to the Company to effect a Public Offering of all or a portion of such Sponsor’s Registrable Securities that are covered or will be covered by such Shelf Registration Statement, and as soon as practicable the Company shall promptly amend or supplement the Shelf Registration Statement for such purpose.

(ii)    Promptly upon receipt of a Shelf Takedown Request (but in no event more than two (2) Business Days thereafter) for any Shelf Takedown, the Company shall deliver a notice (a “ Shelf Takedown Notice ”) to each other Holder with Registrable Securities covered by the applicable Registration Statement, or to all other Holders if such Registration Statement is undesignated (each a “ Potential Takedown Participant ”). The Shelf Takedown Notice shall offer each such Potential Takedown Participant the opportunity to include in any Shelf Takedown that number of Registrable Securities as each such Potential Takedown Participant may request in writing. The Company shall include in the Shelf Takedown all such Registrable Securities with respect to which the Company has received written requests for inclusion therein within three (3) Business Days after the date that the Shelf Takedown Notice has been delivered. If a Holder does not deliver a notice to the Company within three (3) Business Days after the date that the Shelf Takedown Notice has been delivered to such Holder, such Holder shall be deemed to have irrevocably waived any and all rights under this Section 2.02(f) with respect to such Registration (but not with respect to future Registrations in accordance with this Section 2.02(f)). Any Potential Takedown Participant’s request to participate in a Shelf Takedown shall be binding on the Potential Takedown Participant; provided that each such Potential Takedown Participant that elects to participate may condition its participation on the Underwritten Shelf Takedown being completed within ten (10) Business Days of its acceptance at a price per share (after giving effect to any underwriters’ discounts or commissions) to such Potential Takedown Participant of not less than ninety-two percent (92%) of the closing price for the shares on their principal trading market on the Business Day immediately prior to such Potential Takedown Participant’s election to participate (the “ Participation Conditions ”). Notwithstanding the delivery of any Shelf Takedown Notice, but subject to the Participation Conditions (to the extent applicable), all determinations as to whether to complete any Shelf Takedown and as to the timing, manner, price and other terms of any Shelf Takedown contemplated by this Section 2.02(f)(ii) shall be determined by the Sponsors, and the Company shall use its reasonable best efforts to cause any Shelf Takedown to occur as promptly as practicable;  provided that if such Shelf Takedown is to be completed and subject to the Participation Conditions (to the extent applicable), each Potential Takedown Participant’s Pro Rata Portion (as defined below) shall be included in such Shelf Takedown if such Potential Takedown Participant has complied with the requirements set forth in this Section 2.02(f)(ii). “ Pro Rata Portion ” means a number of shares equal to the aggregate

 

11


number of Registrable Securities to be sold in a Public Offering (excluding any shares to be registered or sold for the account of the Company) multiplied by a fraction, the numerator of which is the aggregate number of Registrable Securities held by such Holder at the time of the Public Offering, and the denominator of which is the aggregate number of Registrable Securities held by all Holders at the time of the Public Offering requesting that their Registrable Securities be sold in such Public Offering.

(iii)    If not more than thirty (30) calendar days prior to the Shelf Takedown Request, the Company shall have (i) circulated to prospective underwriters and their counsel a draft of a Registration Statement for a primary offering of equity securities on behalf of the Company; (ii) solicited bids for a primary offering of Shares; or (iii) otherwise reached an understanding with an underwriter with respect to a primary offering of Shares, the Company may preempt the Shelf Takedown Request by a Preemption Notice to the Sponsors within two (2) Business Days after the Company has received the Shelf Takedown Request. The period of preemption may be up to thirty (30) calendar days following the date of the Preemption Notice. Notwithstanding anything to the contrary herein, the Company shall not be entitled to exercise its right to preempt a Shelf Takedown Request pursuant to this Section 2.02(f)(iii) more than once in any twelve (12)-month period. Notwithstanding any term of Section 2.02(g) or this Section 2.02(f)(iii), in no event may the Company exercise the rights under Sections 2.02(f)(iii) or 2.02(g) to cause preemption or postponement of the filing of a Shelf Takedown Request or the postponement related to the Shelf Registration for more than thirty (30) consecutive days, unless written consent has been provided by the Sponsors.

(g)     Suspension of Registration . If the continued use of such Shelf Registration Statement at any time would require the Company to make an Adverse Disclosure, the Company may, upon giving prompt written notice of such action to the Holders, suspend use of the Shelf Registration Statement (a “ Shelf Suspension ”); provided that the Company shall not be permitted to exercise a Shelf Suspension or Demand Suspension (i) more than one time during any twelve (12)-month period, or (ii) for a period exceeding thirty (30) calendar days on any one occasion. Any such determination shall be evidenced by a resolution of the Board of Directors of the Company and delivered at such time to each of the Sponsors. In the case of a Shelf Suspension, the Holders agree to suspend use of the applicable Prospectus in connection with any sale or purchase of, or offer to sell or purchase, Registrable Securities, upon receipt of the notice referred to above. The Company shall immediately notify the Holders upon the termination of any Shelf Suspension, amend or supplement the Prospectus, if necessary, so it does not contain any untrue statement or omission and furnish to the Holders such numbers of copies of the Prospectus as so amended or supplemented as the Holders may reasonably request. The Company agrees, if necessary, to supplement or make amendments to the Shelf Registration Statement, if required by the registration form used by the Company for the Shelf Registration or by the instructions applicable to such registration form or by the Securities Act or the rules or regulations promulgated thereunder or as may reasonably be requested by the Sponsors.

(h)     Priority of Securities Registered Pursuant to Shelf Takedowns . If the managing underwriter or underwriters of a proposed Underwritten Shelf Takedown (or, in the case of a Shelf Takedown not being underwritten, the Sponsors), advise the Board of Directors in writing that, in its or their opinion, the number of securities requested to be included in such Shelf Takedown exceeds the number which can be sold in such offering without being likely to

 

12


have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, the securities to be included in such Shelf Takedown (i) first, if DTZ Investment holds less than 2% of the Registrable Securities it owned at the IPO Closing, shall be allocated to DTZ Investment if it has requested to participate in such Shelf Takedown; (ii) next, and only if all the securities referred to in clause (i) have been included, shall be allocated pro rata among the other Sponsors and any Holder that acquired Registrable Securities pursuant to the Vanke Purchase Agreement that have requested to participate in such Shelf Takedown based on the relative number of Registrable Securities then held by each such Sponsor or relevant Holder ( provided that any securities thereby allocated to a Sponsor or relevant Holder that exceed such Sponsor’s or relevant Holder’s request shall be reallocated among the remaining requesting Sponsors and relevant Holders in like manner); and (iii) finally, and only if all the securities referred to in clauses (i) and (ii) have been included, the number of securities that any other Holder that has a right to participate in such registration (allocated pro rata among such Holders that have requested to participate in such Shelf Takedown based on the relative number of Registrable Securities then held by such Holders and provided that any securities thereby allocated to a Holder that exceed such Holder’s request shall be reallocated among the remaining requesting Holders in like manner) proposes to include in such Registration that, in the opinion of the managing underwriter or underwriters (or the Sponsors, as the case may be) can be sold without having such adverse effect.

(i)     Distributions of Registrable Securities to Partners or Members . In the event any Holder requests to participate in a registration pursuant to this Section 2.02 in connection with a distribution of Registrable Securities to its partners or members, the registration shall provide for resale by such partners or members, if requested by the Holder.

SECTION 2.03.     Piggyback Registration .

(a)     Participation . If the Company at any time proposes to file a Registration Statement under the Securities Act with respect to any offering of its equity securities for its own account or for the account of any other Persons or to conduct a Public Offering (other than (i) a Registration under Section 2.01 or 2.02, (ii) a Registration on Form S-4 or S-8 or any successor form to such Forms or (iii) a Registration of securities solely relating to an offering and sale to employees or directors of the Company pursuant to any employee stock plan or other employee benefit plan arrangement) (a “ Company Public Sale ”), then, as soon as reasonably practicable (but in no event less than ten (10) calendar days prior to the proposed date of filing of such Registration Statement or, in the case of any such Public Offering, the anticipated pricing date), the Company shall give written notice of such proposed filing or Public Offering to the Holders, and such notice shall offer the Holders the opportunity to Register under such Registration Statement, or to sell in such Public Offering, such number of Registrable Securities as each such Holder may request in writing (a “ Piggyback Registration ”). Subject to Section 2.03(b), the Company shall include in such Registration Statement or in such Public Offering, as applicable, all such Registrable Securities that are requested to be included therein within five (5) calendar days after the receipt by such Holders of any such notice; provided that if at any time after giving written notice of its intention to Register or sell any securities and prior to the effective date of the Registration Statement filed in connection with such Registration, or the pricing or trade date of such Public Offering, the Company shall determine for any reason not to Register or sell or to delay Registration or sale of such securities, the Company shall give written notice of such

 

13


determination to each Holder and, thereupon, (i) in the case of a determination not to Register or sell, shall be relieved of its obligation to Register or sell any Registrable Securities in connection with such Registration or Public Offering (but not from its obligation to pay the Registration Expenses in connection therewith), without prejudice, however, to the rights of the Sponsors to request that such Registration be effected as a Demand Registration under Section 2.01 or an Underwritten Shelf Takedown, as the case may be, and (ii) in the case of a determination to delay Registering or selling, in the absence of a request for a Demand Registration or an Underwritten Shelf Takedown, shall be permitted to delay Registering or selling any Registrable Securities, for the same period as the delay in Registering or selling such other securities. If the offering pursuant to such Registration Statement or Public Offering is to be underwritten, then each Holder making a request for a Piggyback Registration pursuant to this Section 2.03(a) must, and the Company shall make such arrangements with the managing underwriter or underwriters so that each such Holder may, participate in such Underwritten Offering. If the offering pursuant to such Registration Statement is to be on any other basis, then each Holder making a request for a Piggyback Registration pursuant to this Section 2.03(a) must, and the Company shall make such arrangements so that each such Holder may, participate in such offering on such basis. Each Holder shall be permitted to withdraw all or part of its Registrable Securities from a Piggyback Registration at any time prior to the effectiveness of such Registration Statement.

(b)     Priority of Piggyback Registration . If the managing underwriter or underwriters of any proposed Underwritten Offering of Registrable Securities included in a Piggyback Registration informs the Company and the Holders of Registrable Securities in writing that, in its or their opinion, the number of securities which such Holders and any other Persons intend to include in such offering exceeds the number which can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, then the securities to be included in such Registration shall be (i) first, 100% of the securities proposed to be sold in such Registration by the Company or (subject to Section 2.07) any Person (other than a Holder) exercising a contractual right to demand Registration, as the case may be, proposes to sell, (ii) second, and only if all the securities referred to in clause (i) have been included, the number of Registrable Securities that, in the opinion of such managing underwriter or underwriters, can be sold without having such adverse effect, with such number to be allocated pro rata among the Sponsors and any Holder that acquired Registrable Securities pursuant to the Vanke Purchase Agreement that have requested to participate in such Registration based on the relative number of Registrable Securities then held by each such Sponsor or relevant Holder ( provided that any securities thereby allocated to a Sponsor or relevant Holder that exceed such Sponsor’s or relevant Holder’s request shall be reallocated among the remaining requesting Sponsors and relevant Holders in like manner), (iii) third, and only if all the securities referred to in clause (ii) have been included, the number of Registrable Securities that, in the opinion of such managing underwriter or underwriters, can be sold without having such adverse effect, with such number to be allocated pro rata among the other Holders that have requested to participate in such Registration based on the relative number of Registrable Securities then held by each such Holder ( provided that any securities thereby allocated to a Holder that exceed such Holder’s request shall be reallocated among the remaining requesting Holders in like manner) and (iv) fourth, and only if all of the Registrable Securities referred to in clause (iii) have been included in such Registration, any other securities eligible for inclusion in such Registration.

 

14


(c)     No Effect on Demand Registrations . No Registration of Registrable Securities effected pursuant to a request under this Section 2.03 shall be deemed to have been effected pursuant to Sections 2.01 and 2.02 or shall relieve the Company of its obligations under Sections 2.01 or 2.02.

(d)     Withdrawal . Each Holder shall be permitted to withdraw all or part of its Registrable Securities in a Company Public Sale by giving written notice to the Company of its request to withdraw; provided , that (i) such request must be made in writing prior to the effectiveness of such Registration Statement or, in the case of a Public Offering, at least two (2) Business Days prior to the earlier of the anticipated filing of the “red herring” Prospectus, if applicable, and the anticipated pricing or trade date and (ii) such withdrawal shall be irrevocable and, after making such withdrawal, the Holder shall no longer have any right to include Registrable Securities in the Company Public Sale as to which such withdrawal was made.

(e)     Underwritten Offerings . If any Piggyback Registration is an Underwritten Offering, the right of any Holder to include Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.

SECTION 2.04.     Lock-up Periods .

(a)     Lock-up Periods for Holders . In the event of a Company Public Sale of the Company’s equity securities in an Underwritten Offering, the Holders agree, if requested by the managing underwriter or underwriters in such Underwritten Offering and agreed to by all of the Sponsors, not to effect any public sale or distribution of any securities (except, in each case, as part of the applicable Registration, if permitted) that are the same as or similar to those being Registered in connection with such Company Public Sale, or any securities convertible into or exchangeable or exercisable for such securities, during the period beginning seven (7) calendar days before and ending ninety (90) calendar days (or such lesser period as may be permitted by the Sponsors or such managing underwriter or underwriters) after, the effective date of the Registration Statement filed in connection with such Registration, to the extent timely notified in writing by the Company or the managing underwriter or underwriters; provided , however , such restrictions shall not apply to (i) securities acquired in the public market subsequent to the IPO, (ii) distributions-in-kind to a Holder’s partners or members, (iii) transfers to Affiliates, but only if such Affiliates agree to be bound by the restrictions herein, (iv) transfers to Permitted Assignees of each Holder in accordance with the terms of this Agreement and (v) the extent otherwise set forth in the lock-up agreements signed by each Holder.

(b)     Lock-up Period for the Company and Others . In the case of a Registration of Registrable Securities pursuant to Section 2.01 or 2.02 for an Underwritten Offering, the Company and the Holders agree, if requested by the participating Sponsor(s) or the managing underwriter or underwriters with respect to such Registration, not to effect any public sale or distribution of any securities that are the same as or similar to those being Registered, or any securities convertible into or exchangeable or exercisable for such securities, during the period beginning seven (7) calendar days before, and ending ninety (90) calendar days (or such lesser period as may be permitted by the participating Sponsor(s) or such managing underwriter or underwriters) after, the effective date of the Registration Statement filed in connection with such

 

15


Registration (or, in the case of an offering under a Shelf Registration Statement, the date of the closing under the underwriting agreement in connection therewith), to the extent timely notified in writing by the Sponsors or the managing underwriter or underwriters. Notwithstanding the foregoing, the Company may effect a public sale or distribution of securities of the type described above and during the periods described above if such sale or distribution is made as part of any Registration of securities for offering and sale to employees or directors of the Company pursuant to any employee stock plan or other employee benefit plan arrangement. The Company agrees to use its reasonable best efforts to obtain from all directors and executive officers of the Company, an agreement not to effect any public sale or distribution of such securities during any such period referred to in this paragraph, except as part of any such Registration, if permitted. Without limiting the foregoing (but subject to Section 2.07), if after the date hereof the Company grants any Person (other than a Holder) any rights to demand or participate in a Registration, the Company agrees that the agreement with respect thereto shall include such Person’s agreement to comply with any lock-up period required by this Section 2.04 as if it were a Holder hereunder.

SECTION 2.05.     Registration Procedures .

(a)    In connection with the Company’s Registration obligations under Sections 2.01, 2.02 and 2.03, the Company shall use its reasonable best efforts to effect such Registration and to permit the sale of such Registrable Securities in accordance with the intended method or methods of distribution thereof as expeditiously as reasonably practicable, and in connection therewith the Company shall:

(i)    prepare the required Registration Statement including all exhibits and financial statements required under the Securities Act to be filed therewith, and before filing a Registration Statement or Prospectus, or any amendments or supplements thereto, (x) furnish to the underwriters, if any, and to Participating Holders, copies of all documents prepared to be filed, which documents shall be subject to the review of such underwriters and such Holders and their respective counsel and (y) except in the case of a Registration under Section 2.03, not file any Registration Statement or Prospectus or amendments or supplements thereto to which the Sponsors or the underwriters, if any, shall reasonably object and (z) make such changes in such documents concerning the Holders prior to the filing thereof as such Holders, or their counsel, may reasonably request;

(ii)    as soon as reasonably practicable (in the case of a Demand Registration or Shelf Registration, no later than ten (10) calendar days after a request for a Demand Registration or Shelf Registration on Form S-3 or sixty (60) calendar days after a request for a Demand Registration or Shelf Registration on Form S-1) file with the SEC a Registration Statement relating to the Registrable Securities including all exhibits and financial statements required by the SEC to be filed therewith, and use its reasonable best efforts to cause such Registration Statement to become effective under the Securities Act as soon as practicable;

(iii)    prepare and file with the SEC such pre- and post-effective amendments to such Registration Statement and supplements to the Prospectus as may be (x) reasonably

 

16


requested by a Sponsor, (y) reasonably requested by any other Participating Holder (to the extent such request relates to information relating to such Holder), or (z) necessary to keep such Registration effective for the period of time required by this Agreement, and comply with provisions of the applicable securities laws with respect to the sale or other disposition of all securities covered by such Registration Statement during such period in accordance with the intended method or methods of disposition by the sellers thereof set forth in such Registration Statement;

(iv)    notify the Participating Holders and the managing underwriter or underwriters, if any, and (if requested) confirm such advice in writing and provide copies of the relevant documents, as soon as reasonably practicable after notice thereof is received by the Company (a) when the applicable Registration Statement or any amendment thereto has been filed or becomes effective, and when the applicable Prospectus or any amendment or supplement to such Prospectus has been filed, (b) of any written comments by the SEC or any request by the SEC or any other federal or state governmental authority for amendments or supplements to such Registration Statement or such Prospectus or for additional information, (c) of the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or any order by the SEC or any other regulatory authority preventing or suspending the use of any preliminary or final Prospectus or the initiation or threatening of any proceedings for such purposes, (d) if, at any time, the representations and warranties of the Company in any applicable underwriting agreement cease to be true and correct in all material respects, and (e) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose;

(v)    promptly notify the Participating Holders and the managing underwriter or underwriters, if any, when the Company becomes aware of the happening of any event as a result of which the applicable Registration Statement or the Prospectus included in such Registration Statement (as then in effect) contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein (in the case of such Prospectus and any preliminary Prospectus, in light of the circumstances under which they were made) not misleading, when any Issuer Free Writing Prospectus includes information that may conflict with the information contained in the Registration Statement, or, if for any other reason it shall be necessary during such time period to amend or supplement such Registration Statement or Prospectus in order to comply with the Securities Act and, in either case as promptly as reasonably practicable thereafter, prepare and file with the SEC, and furnish without charge to the Participating Holders and the managing underwriter or underwriters, if any, an amendment or supplement to such Registration Statement or Prospectus which shall correct such misstatement or omission or effect such compliance;

(vi)    to the extent the Company is eligible under the relevant provisions of Rule 430B under the Securities Act, if the Company files any Shelf Registration Statement, the Company shall include in such Shelf Registration Statement such disclosures as may be required by Rule 430B under the Securities Act (referring to the unnamed selling security holders in a generic manner by identifying the initial offering of the securities to the

 

17


Holders) in order to ensure that the Holders may be added to such Shelf Registration Statement at a later time through the filing of a Prospectus supplement rather than a post-effective amendment;

(vii)    use its reasonable best efforts to prevent, or obtain the withdrawal of, any stop order or other order suspending the use of any preliminary or final Prospectus;

(viii)    promptly incorporate in a Prospectus supplement, Issuer Free Writing Prospectus or post-effective amendment such information as the managing underwriter or underwriters and the Sponsors agree should be included therein relating to the plan of distribution with respect to such Registrable Securities; and make all required filings of such Prospectus supplement, Issuer Free Writing Prospectus or post-effective amendment as soon as reasonably practicable after being notified of the matters to be incorporated in such Prospectus supplement, Issuer Free Writing Prospectus or post-effective amendment;

(ix)    furnish to each Participating Holder and each underwriter, if any, without charge, as many conformed copies as such Holder or underwriter may reasonably request of the applicable Registration Statement and any amendment or post-effective amendment or supplement thereto, including financial statements and schedules, all documents incorporated therein by reference and all exhibits (including those incorporated by reference);

(x)    deliver to each Participating Holder and each underwriter, if any, without charge, as many copies of the applicable Prospectus (including each preliminary prospectus) and any amendment or supplement thereto as such Holder or underwriter may reasonably request (it being understood that the Company consents to the use of such Prospectus or any amendment or supplement thereto by such Holder and the underwriters, if any, in connection with the offering and sale of the Registrable Securities covered by such Prospectus or any amendment or supplement thereto) and such other documents as such Holder or underwriter may reasonably request in order to facilitate the disposition of the Registrable Securities by such Holder or underwriter;

(xi)    on or prior to the date on which the applicable Registration Statement becomes effective, use its reasonable best efforts to register or qualify, and cooperate with the Participating Holders, the managing underwriter or underwriters, if any, and their respective counsel, in connection with the registration or qualification of such Registrable Securities for offer and sale under the securities or “Blue Sky” laws of each state and other jurisdiction of the United States as any Participating Holder or managing underwriter or underwriters, if any, or their respective counsel reasonably request in writing and do any and all other acts or things reasonably necessary or advisable to keep such registration or qualification in effect for such period as required by Section 2.01(c) or Section 2.02(b), whichever is applicable, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or to take any action which would subject it to taxation or general service of process in any such jurisdiction where it is not then so subject;

 

18


(xii)    cooperate with the Participating Holders and the managing underwriter or underwriters, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends; and enable such Registrable Securities to be in such denominations and registered in such names as the managing underwriters may request at least two (2) Business Days prior to any sale of Registrable Securities to the underwriters;

(xiii)    use its reasonable best efforts to cause the Registrable Securities covered by the applicable Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the seller or sellers thereof or the underwriter or underwriters, if any, to consummate the disposition of such Registrable Securities;

(xiv)    not later than the effective date of the applicable Registration Statement, provide a CUSIP number for all Registrable Securities and, if applicable, provide the applicable transfer agent with printed certificates for the Registrable Securities which are in a form eligible for deposit with The Depository Trust Company;

(xv)    make such representations and warranties to the Participating Holders and the underwriters or agents, if any, in form, substance and scope as are customarily made by issuers in secondary underwritten public offerings;

(xvi)    enter into such customary agreements (including underwriting and indemnification agreements) and take all such other actions as the Sponsors or the managing underwriter or underwriters, if any, reasonably request in order to expedite or facilitate the registration and disposition of such Registrable Securities;

(xvii)    obtain for delivery to the Participating Holders and to the underwriter or underwriters, if any, an opinion or opinions from counsel for the Company dated the effective date of the Registration Statement or, in the event of an Underwritten Offering, the date of the closing under the underwriting agreement, in customary form, scope and substance, which opinions shall be reasonably satisfactory to such Holders or underwriters, as the case may be, and their respective counsel;

(xviii)    in the case of an Underwritten Offering, (a) obtain for delivery to the Company and the managing underwriter or underwriters, with copies to the Participating Holders, a cold comfort letter from the Company’s independent certified public accountants or independent auditors (and, if necessary, any other independent certified public accountants or independent auditors of any subsidiary of the Company or any business acquired by the Company for which financial statements and financial data are, or are required to be, included in the Registration Statement) in customary form and covering such matters of the type customarily covered by cold comfort letters as the managing underwriter or underwriters reasonably request, dated the date of execution of the underwriting agreement and brought down to the closing under the underwriting agreement and (b) obtain the required consents from the Company’s independent certified public accountants and, if applicable, independent auditors to include the accountants’ or auditors’ report, as applicable, relating to the specified financial

 

19


statements in the Registration Statement and to be named as an expert in the Registration Statement;

(xix)    cooperate with each Participating Holder and each underwriter, if any, participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA;

(xx)    use its reasonable best efforts to comply with all applicable securities laws and make available to its security holders, as soon as reasonably practicable, an earnings statement satisfying the provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated thereunder;

(xxi)    provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration Statement from and after a date not later than the effective date of such Registration Statement;

(xxii)    use its best efforts to cause all Registrable Securities covered by the applicable Registration Statement to be listed on each securities exchange on which any of the Company’s securities are then listed or quoted and on each inter-dealer quotation system on which any of the Company’s securities are then quoted;

(xxiii)    make available upon reasonable notice at reasonable times and for reasonable periods for inspection by the Sponsors, by any underwriter participating in any disposition to be effected pursuant to such Registration Statement and by any attorney, accountant or other agent retained by the Sponsors or any such underwriter, all pertinent financial and other records, pertinent corporate documents and properties of the Company, and cause all of the Company’s officers, directors and employees and the independent public accountants who have certified its financial statements to make themselves available to discuss the business of the Company and to supply all information reasonably requested by any such Person in connection with such Registration Statement as shall be necessary to enable them to exercise their due diligence responsibility; provided that any such Person gaining access to information regarding the Company pursuant to this Section 2.05(a)(xxiii) shall agree to hold in strict confidence and shall not make any disclosure or use any information regarding the Company that the Company determines in good faith to be confidential, and of which determination such Person is notified, unless (v) the release of such information is requested or required by deposition, interrogatory, requests for information or documents by a governmental entity, subpoena or similar process), (w) disclosure of such information, in the opinion of counsel to such Person, is otherwise required by law, (x) such information is or becomes publicly known other than through a breach of this or any other agreement of which such Person has knowledge, (y) such information is or becomes available to such Person on a non-confidential basis from a source other than the Company or (z) such information is independently developed by such Person;

(xxiv)    in the case of an Underwritten Offering, cause the senior executive officers of the Company to participate in the customary “road show” presentations that may be reasonably requested by the managing underwriter or underwriters in any such

 

20


Underwritten Offering and otherwise to facilitate, cooperate with, and participate in each proposed offering contemplated herein and customary selling efforts related thereto;

(xxv)    take no direct or indirect action prohibited by Regulation M under the Exchange Act;

(xxvi)    take all reasonable action to ensure that any Issuer Free Writing Prospectus utilized in connection with any Registration complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby and, when taken together with the related Prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading;

(xxvii)    provide and cause to be maintained a depositary and a depositary nominee, if applicable, for any depositary receipts representing all shares covered by a Registration Statement;

(xxviii)    if required by the Company’s transfer agent for the shares and/or The Depository Trust Company, the Company will use reasonable efforts to cause opinions of counsel to be delivered to and maintained with the transfer agent and/or DTC, together with any other agreements, authorizations, certificates and directions required by the transfer agent and/or DTC which authorize and direct the transfer agent to transfer shares without any restrictive legend and which allow DTC to accept such shares for settlement;

(xxix)    use all reasonable efforts to facilitate the settlement of the shares to be sold pursuant to this Agreement, including through the facilities of DTC and by facilitating the issuance or cancellation of depositary receipts underlying such shares; and

(xxx)    take all such other commercially reasonable actions as are necessary or advisable in order to expedite or facilitate the disposition of such Registrable Securities in accordance with the terms of this Agreement.

(b)    The Company may require each Participating Holder to furnish to the Company such information regarding the distribution of such securities and such other information relating to such Holder and its ownership of Registrable Securities as the Company may from time to time reasonably request in writing. Each Participating Holder agrees to furnish such information to the Company and to cooperate with the Company as reasonably necessary to enable the Company to comply with the provisions of this Agreement.

(c)    Each Participating Holder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 2.05(a)(v), such Holder will forthwith discontinue disposition of Registrable Securities pursuant to such Registration Statement until such Holder’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 2.05(a)(v), or until such Holder is advised in writing by the Company that the use of the Prospectus may be resumed, and if so directed by the Company, such Holder shall deliver to the Company (at the Company’s expense) all copies, other than permanent file

 

21


copies then in such Holder’s possession, of the Prospectus covering such Registrable Securities current at the time of receipt of such notice. In the event the Company shall give any such notice, the period during which the applicable Registration Statement is required to be maintained effective shall be extended by the number of days during the period from and including the date of the giving of such notice to and including the date when each seller of Registrable Securities covered by such Registration Statement either receives the copies of the supplemented or amended Prospectus contemplated by Section 2.05(a)(v) or is advised in writing by the Company that the use of the Prospectus may be resumed.

(d)    To the extent that any of the Sponsors or any of their Affiliates is deemed to be an underwriter of Registrable Securities pursuant to any SEC comments or policies or otherwise, the Company agrees that (1) the indemnification and contribution provisions contained in this Agreement shall be applicable to the benefit of such Sponsor or its Affiliates in its role as deemed underwriter in addition to its capacity as Holder and (2) such Sponsor and its Affiliates shall be entitled to conduct such activities which it would normally conduct in connection with satisfying its “due diligence” defense as an underwriter in connection with an offering of securities registered under the Securities Act, including conducting due diligence and the receipt of customary opinions and comfort letters.

SECTION 2.06.     Underwritten Offerings .

(a)     Demand and Shelf Registrations . If requested by the underwriters for any Underwritten Offering requested by the Sponsors pursuant to a Registration under Section 2.01 or Section 2.02, the Company shall enter into an underwriting agreement with such underwriters for such offering, such agreement to be reasonably satisfactory in substance and form to the Company, the Sponsors and the underwriters, and to contain such representations and warranties by the Company and such other terms as are generally prevailing in agreements of that type, including indemnities no less favorable to the recipient thereof than those provided in Section 2.09. The Participating Holders shall cooperate with the Company in the negotiation of such underwriting agreement and shall give consideration to the reasonable suggestions of the Company regarding the form thereof. Such Holders shall be parties to such underwriting agreement, which underwriting agreement shall (i) contain such representations and warranties by, and the other agreements on the part of, the Company to and for the benefit of such Holders as are customarily made by issuers to selling stockholders in secondary underwritten public offerings and (ii) provide that any or all of the conditions precedent to the obligations of such underwriters under such underwriting agreement also shall be conditions precedent to the obligations of such Holders. Such Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters other than representations, warranties or agreements regarding such Holders, such Holder’s title to the Registrable Securities, such Holder’s intended method of distribution and any other representations required to be made by such Holder under applicable law, and the aggregate amount of the liability of such Holder shall not exceed such Holder’s net proceeds from such Underwritten Offering.

(b)     Piggyback Registrations . If the Company proposes to register any of its securities under the Securities Act as contemplated by Section 2.03 and such securities are to be distributed in an Underwritten Offering through one or more underwriters, the Company shall, if requested by any Holder pursuant to Section 2.03 and subject to the provisions of Section

 

22


2.03(b), use its reasonable best efforts to arrange for such underwriters to include on the same terms and conditions that apply to the other sellers in such Registration all the Registrable Securities to be offered and sold by such Holder among the securities of the Company to be distributed by such underwriters in such Registration. The Participating Holders shall be parties to the underwriting agreement between the Company and such underwriters, which underwriting agreement shall (i) contain such representations and warranties by, and the other agreements on the part of, the Company to and for the benefit of such Holders as are customarily made by issuers to selling stockholders in secondary underwritten public offerings and (ii) provide that any or all of the conditions precedent to the obligations of such underwriters under such underwriting agreement also shall be conditions precedent to the obligations of such Holders. Any such Holder shall not be required to make any representations or warranties to, or agreements with the Company or the underwriters other than representations, warranties or agreements regarding such Holder, such Holder’s title to the Registrable Securities and such Holder’s intended method of distribution or any other representations required to be made by such Holder under applicable law, and the aggregate amount of the liability of such Holder shall not exceed such Holder’s net proceeds from such Underwritten Offering.

(c)     Participation in Underwritten Registrations . Subject to the provisions of Sections 2.06(a) and (b) above, no Person may participate in any Underwritten Offering hereunder unless such Person (i) agrees to sell such Person’s securities on the basis provided in any underwriting arrangements approved by the Persons entitled to approve such arrangements and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements.

(d)     Price and Underwriting Discounts . In the case of an Underwritten Offering under Section 2.01 or 2.02, the price, underwriting discount and other financial terms for the Registrable Securities shall be determined by the Sponsor(s) selling Registrable Securities in the offering. In addition, in the case of any Underwritten Offering, and in the case of Shelf Takedowns, subject to the conditions of Section 2.02(f)(ii), each of the Holders may withdraw their request to participate in the registration pursuant to Section 2.01, 2.02 or 2.03 after being advised of such price, discount and other terms and shall not be required to enter into any agreements or documentation that would require otherwise.

SECTION 2.07.     No Inconsistent Agreements; Additional Rights . None of the Company or any of its subsidiaries shall hereafter enter into, and none are currently a party to, any agreement with respect to their respective securities that is inconsistent with the rights granted to the Holders by this Agreement. Without the prior written consent of the Sponsors, none of the Company or any of its subsidiaries shall enter into any agreement granting registration or similar rights to any Person, and the Company hereby represents and warrants that, as of the date hereof, no registration or similar right has been granted to any other Person other than pursuant to this Agreement.

SECTION 2.08.     Registration Expenses . All expenses incident to the Company’s performance of or compliance with this Agreement shall be paid by the Company, including (i) all registration and filing fees, and any other fees and expenses associated with filings required to be made with the SEC or FINRA, (ii) all fees and expenses in connection with compliance with any securities or “Blue Sky” laws (including reasonable fees and disbursement

 

23


of counsel for the underwriters in connection with blue sky qualifications of the Registrable Securities), (iii) all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses (including expenses of printing certificates for the Registrable Securities in a form eligible for deposit with The Depository Trust Company and of printing prospectuses), (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company and any subsidiaries of the Company (including the expenses of any special audit and cold comfort letters required by or incident to such performance), (v) Securities Act liability insurance or similar insurance if the Company so desires or the underwriters so require in accordance with then-customary underwriting practice, (vi) all fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange or quotation of the Registrable Securities on any inter-dealer quotation system, (vii) all reasonable fees and disbursements of legal counsel for each Sponsor participating in such Registration (or, in the case of a Shelf Registration, each Sponsor selling Registrable Securities under the Shelf Registration Statement), (viii) all fees and expenses of accountants selected by the Demanding Sponsor(s) (or, in the case of a Shelf Registration, the Holder selling Registrable Securities under the Shelf Registration Statement), (ix) any reasonable fees and disbursements of underwriters customarily paid by issuers or sellers of securities, (x) all fees and expenses of any special experts or other Persons retained by the Company in connection with any Registration, (xi) all of the Company’s internal expenses (including all salaries and expenses of its officers and employees performing legal or accounting duties), (xii) all expenses related to the “road show” for any underwritten offering (including all reasonable out-of-pocket expenses of the Sponsors), including all travel, meals and lodging and (xiii) all fees and expenses incurred in connection with the distribution or transfer of Registrable Securities to or by a Holder or its Permitted Assignees in connection with a Public Offering. All such expenses are referred to herein as “ Registration Expenses .” The Company shall not be required to pay underwriting discounts and commissions and transfer taxes, if any, attributable to the sale of Registrable Securities.

SECTION 2.09.     Indemnification .

(a)     Indemnification by the Company . The Company agrees to indemnify and hold harmless, to the full extent permitted by law, each Holder, each member, limited or general partner thereof, each member, limited or general partner of each such member, limited or general partner, each of their respective Affiliates, officers, directors, shareholders, employees, advisors, and agents and each Person who controls (within the meaning of the Securities Act or the Exchange Act) such Persons and each of their respective Representatives from and against any and all losses, penalties, judgments, suits, costs, claims, damages, liabilities and expenses, joint or several (including reasonable costs of investigation and legal expenses) (each, a “ Loss ” and collectively “ Losses ”) arising out of or based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement under which such Registrable Securities were Registered under the Securities Act (including any final, preliminary or summary Prospectus contained therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein) or any other disclosure document produced by or on behalf of the Company or any of its subsidiaries including, without limitation, reports and other documents filed under the Exchange Act, (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a Prospectus or preliminary Prospectus, in light of the circumstances under which they were made)

 

24


not misleading or (iii) any actions or inactions or proceedings in respect of the foregoing whether or not such indemnified party is a party thereto; provided , that the Company shall not be liable to any particular indemnified party (A) to the extent that any such Loss arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in any such Registration Statement or other document in reliance upon and in conformity with written information furnished to the Company by such indemnified party expressly for use in the preparation thereof or (B) to the extent that any such Loss arises out of or is based upon an untrue statement or omission in a preliminary Prospectus relating to Registrable Securities, if a Prospectus (as then amended or supplemented) that would have cured the defect was furnished to the indemnified party from whom the Person asserting the claim giving rise to such Loss purchased Registrable Securities at least five (5) calendar days prior to the written confirmation of the sale of the Registrable Securities to such Person and a copy of such Prospectus (as amended and supplemented) was not sent or given by or on behalf of such indemnified party to such Person at or prior to the written confirmation of the sale of the Registrable Securities to such Person. This indemnity shall be in addition to any liability the Company may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Holder or any indemnified party and shall survive the transfer of such securities by such Holder. The Company shall also indemnify underwriters, selling brokers, dealer managers and similar securities industry professionals participating in the distribution, their officers and directors and each Person who controls such Persons (within the meaning of the Securities Act and the Exchange Act) to the same extent as provided above with respect to the indemnification of the indemnified parties.

(b)     Indemnification by the Participating Holders . Each Participating Holder agrees (severally and not jointly) to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors and officers and each Person who controls the Company (within the meaning of the Securities Act or the Exchange Act) from and against any Losses resulting from (i) any untrue statement of a material fact in any Registration Statement under which such Registrable Securities were Registered under the Securities Act (including any final, preliminary or summary Prospectus contained therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein), or (ii) any omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a Prospectus or preliminary Prospectus, in light of the circumstances under which they were made) not misleading, in each case, to the extent, but only to the extent, that such untrue statement or omission is contained in any information furnished in writing by such Holder to the Company specifically for inclusion in such Registration Statement and has not been corrected in a subsequent writing prior to or concurrently with the sale of the Registrable Securities to the Person asserting the claim. In no event shall the liability of such Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder under the sale of Registrable Securities giving rise to such indemnification obligation. The Company shall be entitled to receive indemnities from underwriters, selling brokers, dealer managers and similar securities industry professionals participating in the distribution, to the same extent as provided above (with appropriate modification) with respect to information furnished in writing by such Persons specifically for inclusion in any Prospectus or Registration Statement.

(c)     Conduct of Indemnification Proceedings . Any Person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any

 

25


claim with respect to which it seeks indemnification ( provided that any delay or failure to so notify the indemnifying party shall relieve the indemnifying party of its obligations hereunder only to the extent, if at all, that it is actually and materially prejudiced by reason of such delay or failure) and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any Person entitled to indemnification hereunder shall have the right to select and employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (A) the indemnifying party has agreed in writing to pay such fees or expenses, (B) the indemnifying party shall have failed to assume the defense of such claim within a reasonable time after receipt of notice of such claim from the Person entitled to indemnification hereunder and employ counsel reasonably satisfactory to such Person, (C) the indemnified party has reasonably concluded (based upon advice of its counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, or (D) in the reasonable judgment of any such Person (based upon advice of its counsel) a conflict of interest may exist between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person). If the indemnifying party assumes the defense, the indemnifying party shall not have the right to settle such action without the consent of the indemnified party. No indemnifying party shall consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of an unconditional release from all liability in respect to such claim or litigation without the prior written consent of such indemnified party. If such defense is not assumed by the indemnifying party, the indemnifying party will not be subject to any liability for any settlement made without its prior written consent, but such consent may not be unreasonably withheld. It is understood that the indemnifying party or parties shall not, except as specifically set forth in this Section 2.09(c), in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements or other charges of more than one separate firm admitted to practice in such jurisdiction at any one time unless (x) the employment of more than one counsel has been authorized in writing by the indemnifying party or parties, (y) an indemnified party has reasonably concluded (based on the advice of counsel) that there may be legal defenses available to it that are different from or in addition to those available to the other indemnified parties or (z) a conflict or potential conflict exists or may exist (based upon advice of counsel to an indemnified party) between such indemnified party and the other indemnified parties, in each of which cases the indemnifying party shall be obligated to pay the reasonable fees and expenses of such additional counsel or counsels.

(d)     Contribution . If for any reason the indemnification provided for in paragraphs (a) and (b) of this Section 2.09 is unavailable to an indemnified party or insufficient in respect of any Losses referred to therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Loss in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party or parties on the other hand in connection with the acts, statements or omissions that resulted in such losses, as well as any other relevant equitable considerations. In connection with any Registration Statement filed with the SEC by the Company, the relative

 

26


fault of the indemnifying party on the one hand and the indemnified party on the other hand shall be determined by reference to, among other things, whether any untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just or equitable if contribution pursuant to this Section 2.09(d) were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in this Section 2.09(d). No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The amount paid or payable by an indemnified party as a result of the Losses referred to in Sections 2.09(a) and 2.09(b) shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 2.09(d), in connection with any Registration Statement filed by the Company, a Participating Holder shall not be required to contribute any amount in excess of the dollar amount of the net proceeds received by such Holder under the sale of Registrable Securities giving rise to such contribution obligation less any amounts paid by such Holder pursuant to Section 2.09(b). If indemnification is available under this Section 2.09, the indemnifying parties shall indemnify each indemnified party to the full extent provided in Sections 2.09(a) and 2.09(b) hereof without regard to the provisions of this Section 2.09(d). The remedies provided for in this Section 2.09 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity.

SECTION 2.10.     Rules 144 and 144A and Regulation  S . The Company covenants that it will file the reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the SEC thereunder (or, if the Company is not required to file such reports, it will, upon the reasonable request of the Sponsors, make publicly available such necessary information for so long as necessary to permit sales pursuant to Rules 144, 144A or Regulation S under the Securities Act, as such Rules may be amended from time to time), and it will take such further action as the Sponsors may reasonably request, all to the extent required from time to time to enable the Sponsors to sell Registrable Securities without Registration under the Securities Act within the limitation of the exemptions provided by (i) Rules 144, 144A or Regulation S under the Securities Act, as such Rules may be amended from time to time, or (ii) any similar rule or regulation hereafter adopted by the SEC. Upon the reasonable request of a Holder, the Company will deliver to such Holder a written statement as to whether it has complied with such requirements and, if not, the specifics thereof.

SECTION 2.11.     Existing Registration Statements . Notwithstanding anything herein to the contrary and subject to applicable law and regulation, the Company may satisfy any obligation hereunder to file a Registration Statement or to have a Registration Statement become effective by a specified date by designating, by notice to the Holders, a Registration Statement that previously has been filed with the SEC or become effective, as the case may be, as the relevant Registration Statement for purposes of satisfying such obligation, and all references to any such obligation shall be construed accordingly; provided that such previously filed Registration Statement may be amended or, subject to applicable securities laws, supplemented to add the

 

27


number of Registrable Securities, and, to the extent necessary, to identify as selling stockholders those Holders demanding the filing of a Registration Statement pursuant to the terms of this Agreement. To the extent this Agreement refers to the filing or effectiveness of other Registration Statements, by or at a specified time and the Company has, in lieu of then filing such Registration Statements or having such Registration Statements become effective, designated a previously filed or effective Registration Statement as the relevant Registration Statement for such purposes, in accordance with the preceding sentence, such references shall be construed to refer to such designated Registration Statement, as amended.

SECTION 2.12.     In-Kind Distributions . If any Holder seeks to effectuate an in-kind distribution of all or part of its Common Shares to its direct or indirect equityholders, the Company will, subject to applicable lockups pursuant to Section 2.04, reasonably cooperate with and assist such Holder, such equityholders and the Company’s transfer agent to facilitate such in-kind distribution in the manner reasonably requested by such Holder (including the delivery of instruction letters by the Company or its counsel to the Company’s transfer agent and the delivery of Common Shares without restrictive legends, to the extent no longer applicable).

SECTION 2.13.     Trading Windows . The Company shall (i) use its reasonable best efforts to notify each Sponsor of each “closing” and “opening” date under the trading windows established by the Company’s insider trading policy, in each case, at least two (2) Business Days prior to each such date and (ii), at the request of any Sponsor, confirm to the requesting Sponsor whether a trading window is open at such time.

ARTICLE III

MISCELLANEOUS

SECTION 3.01.     Term . This Agreement shall terminate upon the later of the expiration of the Shelf Period and such time as there are no Registrable Securities, except for the provisions of Sections 2.09 and 2.10 and all of this Article III, which shall survive any such termination.

SECTION 3.02.     Injunctive Relief . It is hereby agreed and acknowledged that it will be impossible to measure in money the damage that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person will be irreparably damaged and will not have an adequate remedy at law. Any such Person shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including specific performance, to enforce such obligations, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

SECTION 3.03.     Attorneys Fees . In any action or proceeding brought to enforce any provision of this Agreement or where any provision hereof is validly asserted as a defense, the successful party shall, to the extent permitted by applicable law, be entitled to recover reasonable attorneys’ fees in addition to any other available remedy.

 

28


SECTION 3.04.     Notices . Unless otherwise specified herein, all notices and other communications authorized or required to be given pursuant to this Agreement shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by personal hand-delivery, by electronic mail, by mailing the same in a sealed envelope, registered first-class mail, postage prepaid, return receipt requested, or by air courier guaranteeing overnight delivery, sent to the Person at the address given for such Person below or such other address as such Person may specify by notice to the Company:

If to the Company:

Cushman & Wakefield plc

225 West Wacker Drive, Suite 3000

Chicago, Illinois 60606

  Attention:

General Counsel

  Telephone:

(312) 470-1800

  Email:

brett.soloway@cushwake.com

If to TPG Drone Investment or TPG Drone Co-Invest:

301 Commerce Street

Suite 3300

Fort Worth, TX 76102

Attention: Office of General Counsel

Telephone: (817) 871-4000

E-mail: officeofgeneralcounsel@tpg.com

with a copy to:

345 California Street

San Francisco, CA 94104

Attention: Adam Fliss

E-mail: afliss@tpg.com

If to PAG:

c/o 32/F, AIA Central

1 Connaught Road Central

Hong Kong

  Attention:

Jon Lewis

Elaine Chen

  Email:

jlewis@pag.com

echen@pag.com

with a copy (which shall not constitute notice) to:

Fenwick & West LLP

Unit 908, 9th Floor, Kerry Parkside Office

No. 1155 Fang Dian Road

Pudong New Area, Shanghai 201204

 

29


People’s Republic of China

  Attention: Niping Wu
  Email: niping.wu@fenwick.com

If to OTPP:

Ontario Teachers’ Pension Plan Board

5650 Yonge Street

Toronto, Ontario M2M 4H5

Canada

  Attention: Raju Ruparelia
  E-mail: raju_ruparelia@otpp.com
     law_investments@otpp.com

with a copy (which shall not constitute notice) to:

Baker McKenzie

Tower One - International Towers Sydney

Level 46 - 100 Barangaroo Avenue

Sydney NSW 2000

Australia

  Attention: Michael Kunstler

Lewis Apostolou

  E-mail: michael.kunstler@bakermckenzie.com

lewis.apostolou@bakermckenzie.com

If to the Company or Sponsors, copies shall be delivered (which shall not constitute notice) to:

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, New York 10006

  Attention: Jeffrey D. Karpf, Esq. and

Helena K. Grannis, Esq.

  Telephone: (212) 225-2000

If to DTZ Investment, to each of the Sponsors at the addresses indicated above.

If to any other Holder who becomes party to this agreement after the date hereof, to the address on the counterpart signature page to this Agreement executed by such holder.

SECTION 3.05.     Amendment . Any provision of this Agreement may be amended, modified, extended or terminated, and the provisions hereof may be waived, if, and only if, such

 

30


amendment, modification, extension, termination or waiver is in writing and signed by the Sponsors; provided that (a) any amendment, modification, extension, termination or waiver that would have a material adverse effect on a Holder relative to the Sponsors shall require the written consent of that Holder and (b) this Section 3.05 may not be amended without the prior written consent of the Holders (other than the Sponsors) holding a majority of the outstanding Registrable Securities of such Holders.

SECTION 3.06.     Successors, Assigns and Transferees . Each party may assign all or a portion of its rights and obligations hereunder to any of its Affiliates to which such party transfers its ownership of all or any of its Registrable Securities (each such Person, a “ Permitted Assignee ”). Such Persons and any other Person that acquires Registrable Securities pursuant to the terms of the Coordination Agreement, the limited partnership agreement of DTZ Investment, or the Vanke Purchase Agreement shall execute a counterpart to this Agreement and become a party hereto and such Person’s Registrable Securities shall be subject to the terms of this Agreement; provided , however , that upon the delivery to the Company of an executed counterpart to this Agreement promptly following the acquisition of such Registrable Securities, such Person shall be deemed a Holder (and, solely in the event that such Person is affiliated with TPG, PAG or OTPP, a Sponsor) for purposes of this Agreement. All other rights and obligations hereunder shall not be assignable without the prior written consent of the Sponsors. Any attempted assignment in violation of this Section 3.06 shall be null and void.

SECTION 3.07.     Binding Effect . Except as otherwise provided in this Agreement, the terms and provisions of this Agreement shall be binding on and inure to the benefit of each of the parties hereto and their respective successors.

SECTION 3.08.     Third Parties . Nothing in this Agreement, express or implied, is intended or shall be construed to confer upon any Person not a party hereto (other than each other Person entitled to indemnity or contribution under Section 2.09) any right, remedy or claim under or by virtue of this Agreement.

SECTION 3.09.     Governing Law . This Agreement shall be governed and construed in accordance with the domestic substantive laws of the State of New York without giving effect to any choice of law or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction.

SECTION 3.10.     Consent to Jurisdiction . Each party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York for the purpose of any action, claim, cause of action or suit (in contract, tort or otherwise), inquiry, proceeding or investigation arising out of or based upon this Agreement or relating to the subject matter hereof, (b) hereby waives to the extent not prohibited by applicable law, and agrees not to assert, and agrees not to allow any of its subsidiaries to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such proceeding brought in one of the above-named courts is improper, or that this Agreement or the subject matter hereof or thereof may not be enforced in or by such court and (c) hereby agrees not to commence or maintain any action, claim, cause of action or suit (in contract, tort or otherwise), inquiry, proceeding or investigation

 

31


arising out of or based upon this Agreement or relating to the subject matter hereof or thereof other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action, claim, cause of action or suit (in contract, tort or otherwise), inquiry, proceeding or investigation to any court other than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. Notwithstanding the foregoing, to the extent that any party hereto is or becomes a party in any litigation in connection with which it may assert indemnification rights set forth in this Agreement, the court in which such litigation is being heard shall be deemed to be included in clause (a) above. Notwithstanding the foregoing, any party to this Agreement may commence and maintain an action to enforce a judgment of any of the above-named courts in any court of competent jurisdiction. Each party hereto hereby consents to service of process in any such proceeding in any manner permitted by New York law, and agrees that service of process by registered or certified mail, return receipt requested, at its address specified pursuant to Section 3.04 hereof is reasonably calculated to give actual notice

SECTION 3.11.     WAIVER OF JURY TRIAL . EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 3.11.

SECTION 3.12.     Merger; Binding Effect, etc. . This Agreement constitutes the entire agreement of the parties with respect to its subject matter, supersedes all prior or contemporaneous oral or written agreements or discussions with respect to such subject matter, and shall be binding upon and inure to the benefit of the parties hereto and thereto and their respective heirs, representatives, successors and Permitted Assignees.

SECTION 3.13.     Severability . If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

SECTION 3.14.     Counterparts . This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same agreement.

SECTION 3.15.     No Recourse . Notwithstanding anything that may be expressed or implied in this Agreement, the Company and each Holder covenant, agree and acknowledge that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, general or

 

32


limited partner or member of any Holder or of any Affiliate or assignee thereof, as such, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future officer, agent or employee of any Holder or any current or future member of any Holder or any current or future director, officer, employee, partner or member of any Holder or of any Affiliate or assignee thereof, as such, for any obligation of any Holder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.

SECTION 3.16.     Headings . The heading references herein and in the table of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

[SIGNATURE PAGES TO FOLLOW]

 

33


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

 

CUSHMAN & WAKEFIELD PLC
By:  

 

Name:  
Title:  
TPG DRONE INVESTMENT, L.P.
By:  

 

Name:  
Title:  
TPG DRONE CO-INVEST, L.P.
By:  

 

Name:  
Title:  
PAGAC DRONE HOLDING I LP
By: PAGAC Drone Holding GP I Limited, its general partner
By:  

 

Name:  
Title:  

[Signature Page to Registration Rights Agreement]


2339532 ONTARIO LIMITED
By:  

 

Name:  
Title:  
ONTARIO TEACHERS’ PENSION PLAN BOARD
By:  

 

Name:  
Title:  
DTZ INVESTMENT HOLDINGS LP
By:  

 

Name:  
Title:  

[Signature Page to Registration Rights Agreement]

Exhibit 4.3

JOINDER AGREEMENT

August     , 2018

Vanke Service (HongKong) Co., Limited ( 萬科物業服務 ( 香港 ) 有限公司 ), a Hong Kong limited company (the “ Shareholder ”), is executing and delivering this Joinder Agreement pursuant to Section 3.06 of the Registration Rights Agreement (the “ Registration Rights Agreement ”), dated as of August     , 2018, by and among Cushman & Wakefield plc, a public limited company organized under the laws of England and Wales (the “ Company ”), and the stockholders of the Company who are party thereto, in connection with the acquisition by the Shareholder of the Secondary Shares as defined in and pursuant to the terms of the Purchase Agreement, dated July 24, 2018, by and among the Shareholder, DTZ Investment Holdings LP, an English limited partnership, and the Company.

By executing and delivering this Joinder Agreement to the Registration Rights Agreement, the Shareholder hereby adopts and approves the Registration Rights Agreement and acknowledges, agrees and confirms, effective commencing on the date hereof, to be bound by and to comply with all of the terms, provisions and conditions of the Registration Rights Agreement, as a Holder (as defined therein) thereunder, and that ordinary shares, nominal value $0.10 per share, of the Company owned or held of record, directly or indirectly, by the Shareholder be subject thereto, in the same manner as if the Shareholder was an original signatory to the Registration Rights Agreement.

This Joinder Agreement shall be governed and construed in accordance with the laws of the State of New York, without regard to the conflicts of law principles thereof. This Joinder Agreement may be executed in two or more counterparts (including counterparts submitted via facsimile or email), each of which shall be deemed to be an original, but each of which together shall constitute one and the same document.

[ Signature Page Follows ]


Accordingly, as of the date first written above, the undersigned has executed and delivered this Joinder Agreement.

 

Vanke Service (HongKong) Co., Limited

萬科物業服務 ( 香港 ) 有限公司

By:  

 

  Name:
  Title:

[Signature Page to Joinder Agreement – Registration Rights Agreement]


Acknowledged and Accepted:
CUSHMAN & WAKEFIELD PLC
By:  

 

  Name:
  Title:

[Signature Page to Joinder Agreement – Registration Rights Agreement]

Exhibit 10.22

 

 

 

SHAREHOLDERS AGREEMENT

BY AND AMONG

CUSHMAN & WAKEFIELD PLC

AND

THE SHAREHOLDERS PARTY HERETO

DATED AS OF     , 2018

 

 

 

 


TABLE OF CONTENTS

 

          Page  

ARTICLE I DEFINITIONS

     2  

Section 1.1

   Definitions      2  

Section 1.2

   Other Interpretive Provisions.      6  

ARTICLE II REPRESENTATIONS AND WARRANTIES

     6  

Section 2.1

   Existence; Authority; Enforceability      6  

Section 2.2

   Absence of Conflicts      6  

Section 2.3

   Consents      6  

ARTICLE III GOVERNANCE

     7  

Section 3.1

   The Board.      7  

ARTICLE IV GENERAL PROVISIONS

     12  

Section 4.1

   Company Articles      12  

Section 4.2

   Trading Windows      12  

Section 4.3

   Corporate Opportunities.      12  

Section 4.4

   Assignment; Benefit.      14  

Section 4.5

   Confidentiality.      14  

Section 4.6

   Termination      16  

Section 4.7

   Severability      16  

Section 4.8

   Entire Agreement; Amendment.      16  

Section 4.9

   Counterparts      16  

Section 4.10

   Notices      16  

Section 4.11

   Governing Law      18  

Section 4.12

   Dispute Resolution.      18  

Section 4.13

   Specific Performance      20  

Section 4.14

   Acquisition of Shares.      20  

 

 

i


This SHAREHOLDERS AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, the “ Agreement ”), dated as of     , 2018, is made by and among:

i.     Cushman & Wakefield plc, a public limited company incorporated in England and Wales with registered number 11414195 (the “ Company ”);

ii.    TPG Drone Investment, L.P. (“ TPG Drone Investment ”) and TPG Drone Co-Invest, L.P. (“ TPG Drone Co -Invest ” and, together with TPG Drone Investment and their Affiliates, “ TPG ”);

iii.   PAGAC Drone Holding I LP (together with its Affiliates, “ PAG ”);

iv.   2339532 Ontario Limited and Ontario Teachers’ Pension Plan Board (together with their respective Affiliates, “ OTPP ”)

v.    DTZ Investment Holdings LP (“ DTZ LP ”); and

vi.   such other Persons who from time to time become party hereto by executing a counterpart signature page hereof and are designated by the Board (as defined below) as “Other Shareholders” (the “ Other Shareholders ” and, together with TPG, PAG and OTPP, the “ Shareholders ”).

RECITALS

WHEREAS, on November 3, 2014, TPG Asia VI SF Pte. Ltd., PAG, OTPP, DTZ Investment Holdings GenPar LLP (the “ LLP ”), DTZ LP, DTZ Jersey Holdings Limited (“ Drone TopCo ”) and Fairway Trust Limited (the “ Designated Partner ”) entered into the First Amended and Restated Limited Liability Partnership Agreement relating to DTZ Investment Holdings GenPar LLP, as amended by an amendment agreement, dated March 22, 2017 between TPG Drone Investment, L.P., PAG, OTPP, the LLP, the DTZ LP, Drone TopCo and the Designated Partner, which contained certain enumerated governance rights;

WHEREAS, on July 6, 2018, FTL Nominees 2 Limited, a Jersey company, on behalf of DTZ LP, exchanged all of the shares it held in Drone TopCo for depositary receipts issued by a nominee of Computershare Trust Company, N.A. in respect of newly issued ordinary shares, with a nominal value of $0.10, of Cushman & Wakefield Limited, a private limited company under the laws of England and Wales (now known as the Company);

WHEREAS, on July 6, 2018, Drone TopCo distributed and transferred its shares in DTZ UK Guarantor Limited to Cushman & Wakefield Limited, after which it intended to commence a summary winding-up procedure under the laws of Jersey;

WHEREAS, on July 19, 2018, Cushman & Wakefield Limited re-registered as a public limited company under the laws of England and Wales;

 


WHEREAS, on August     , 2018, the Company priced an initial public offering (the “ IPO ”) of the Company’s ordinary shares (the “ Ordinary Shares ”), pursuant to an Underwriting Agreement dated August     , 2018 (the “ Underwriting Agreement ”); and

WHEREAS, the parties hereto desire to provide for certain governance rights and other matters, and to set forth the respective rights and obligations of the Shareholders following the IPO.

NOW, THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements of the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

ARTICLE I

DEFINITIONS

Section 1.1     Definitions . As used in this Agreement, the following terms shall have the following meanings:

Affiliate ” means any Person that directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such specified Person; provided that the Company, and each of its subsidiaries shall not be deemed to be Affiliates of TPG, PAG, OTPP or DTZ LP; and provided further that any portfolio companies of any Sponsor shall not be considered “Affiliates” hereunder. As used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through beneficial ownership of voting securities, by contract or otherwise.

Affiliated Person ” has the meaning set forth in Section 4.5(a).

Agreement ” has the meaning set forth in the Preamble.

Acquired Knowledge ” has the meaning set forth in Section 4.3(a).

beneficially own ” has the meaning set forth in Rule 13d-3 promulgated under the Exchange Act; provided that, prior to the distribution by DTZ LP to the Sponsors of all of their respective shares in the Company, a Sponsor will be deemed to beneficially own, in addition to the shares it owns directly, the shares in DTZ LP attributable to such Sponsor; and provided further that, after such a distribution by DTZ LP of all or any portion of their respective shares in the Company, a Sponsor will not be deemed to beneficially own the shares held by the other Sponsors solely as a result of entering into this Agreement.

Board ” means the board of directors of the Company.

Business Day ” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in the City of New York, New York.

 

2


Chief Executive Officer ” means the chief executive officer of the Company then in office.

Closing ” means the closing of the IPO.

Company ” has the meaning set forth in the Preamble.

Company Articles ” means the articles of association of the Company in effect on the date hereof, as may be amended from time to time.

Company Shares ” means (i) all Ordinary Shares outstanding at the time of determination, (ii) all Ordinary Shares issuable upon exercise, conversion or exchange of any option, warrant or convertible security and (iii) all Ordinary Shares directly or indirectly issued or issuable with respect to the securities referred to in clauses (i) or (ii) above by way of unit or stock dividend or unit or stock split, or in connection with a combination of units or shares, recapitalization, merger, consolidation or other reorganization.

Consolidation Order ” has the meaning set forth in Section 4.12(i).

Coordination Agreement ” means the Coordination Agreement, by and among TPG Drone Investment, TPG Drone Co-Invest, PAG and OTPP, dated as of the date hereof, as amended, modified or supplemented from time to time.

Corporate Opportunity ” means (i) an investment or business opportunity or activity, including without limitation those that might be considered the same as or similar to the Company’s business or the business of any Affiliate or any direct or indirect subsidiary of the Company, including those deemed to be competing with the Company or any Affiliate or any direct or indirect subsidiary of the Company, or (ii) a prospective economic or competitive advantage in which the Company or any Affiliate or any direct or indirect subsidiary of the Company could have an interest or expectancy. In addition to and notwithstanding the foregoing, a Corporate Opportunity shall not be deemed to be a potential opportunity for the Company or any Affiliates or any direct or indirect subsidiary if it is a business opportunity that (i) the Company, Affiliate or direct or indirect subsidiary, as applicable, is not financially able or contractually permitted or legally able to undertake, (ii) from its nature, is not in the line of the Company’s, Affiliate’s or direct or indirect subsidiary’s, as applicable, business or is of no practical advantage to it or (iii) is one in which the Company, Affiliate or direct or indirect subsidiary, as applicable, has no interest or reasonable expectancy.

Designated Partner ” has the meaning set forth in the Recitals.

Dispute ” has the meaning set forth in Section 4.12(a).

Drone TopCo ” has the meaning set forth in the Recitals.

DTZ LP ” has the meaning set forth in the Preamble.

 

3


Exchange Act ” means the Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same shall be in effect from time to time.

Fund Indemnitors ” has the meaning set forth in Section 3.1(n).

ICC Court ” has the meaning set forth in Section 4.12(a).

ICC Rules ” has the meaning set forth in Section 4.12(a).

Indemnification Agreement ” has the meaning set forth in Section 3.1(n).

Indemnitee ” has the meaning set forth in Section 3.1(n).

Independent Director ” means a director that satisfies both (a) the requirements to qualify as an “independent director” under the stock exchange rules of the stock exchange on which the Ordinary Shares are then-currently listed and (b) the independence criteria set forth in Rule 10A-3 under the Exchange Act, as amended from time to time.

IPO ” has the meaning set forth in the Recitals.

Majority in Interest ” means, with respect to the Shareholders or any subset thereof, Shareholders who beneficially own a majority of Company Shares held by the Shareholders or such subset of Shareholders, as applicable.

Necessary Action ” means, with respect to a specified result, all actions necessary (subject to Section 4.14(b)), to the fullest extent permitted by applicable law, to cause such result, including, without limitation, (i) voting or providing a written consent or proxy with respect to the Company Shares, (ii) causing the adoption of shareholders’ resolutions and amendments to the organizational documents of the Company, (iii) in the case of each Sponsor, exercising its rights as limited partners of DTZ LP and as limited liability partners of the LLP to cause DTZ LP and the LLP, respectively, to take all actions necessary to achieve such result; (iv) in the case of each Sponsor, causing its Sponsor Directors (subject to any fiduciary duties that such Sponsor Directors may have as directors of the Company) to act in a certain manner or causing them to be removed in the event they do not act in such a manner; (v) executing agreements and instruments, and (vi) making, or causing to be made, with governmental, administrative or regulatory authorities, all filings, registrations or similar actions that are required to achieve such result.

Ordinary Shares ” has the meaning set forth in the Recitals.

Other Shareholders ” has the meaning set forth in the Preamble.

OTPP ” has the meaning set forth in the Preamble, it being understood that prior to the distribution, directly or indirectly, by 2339532 Ontario Limited of all of its Company Shares to Ontario Teachers’ Pension Plan Board, including through one or more of its Affiliates, “OTPP” shall refer to 2339532 Ontario Limited and Ontario Teachers’ Pension Plan Board and after such

 

4


distribution “OTPP” shall refer to Ontario Teachers’ Pension Plan Board and any such Affiliates holding Company Shares.

OTPP Designee ” has the meaning set forth in Section 3.1(d).

OTPP Director ” has the meaning set forth in Section 3.1(a).

PAG ” has the meaning set forth in the Preamble.

PAG Designee ” has the meaning set forth in Section 3.1(c).

PAG Director ” has the meaning set forth in Section 3.1(a).

Person ” means any individual, partnership, limited liability company, corporation, trust, association, estate, unincorporated organization or government or any agency or political subdivision thereof.

Representatives ” means, with respect to any Person, any of such Person’s officers, directors, employees, agents, attorneys, accountants, actuaries, consultants or financial advisors or other Person associated with, or acting on behalf of, such Person.

Shareholders ” has the meaning set forth in the Preamble.

Sponsor Affiliated Person ” means each of TPG, PAG, OTPP and DTZ LP and all of their respective partners, principals, directors, officers, members, managers, managing directors, advisors, consultants and employees, Affiliates, the Sponsor Directors, or any officer of the Company that is an Affiliate of the Sponsors.

Sponsor Confidential Information ” has the meaning set forth in Section 4.5(a).

Sponsor Designee ” has the meaning set forth in Section 3.1(d).

Sponsor Director ” has the meaning set forth in Section 3.1(a).

Sponsors ” mean each of TPG, PAG and OTPP.

TPG ” has the meaning set forth in the Preamble.

TPG Designee ” has the meaning set forth in Section 3.1(b).

TPG Director ” has the meaning set forth in Section 3.1(a).

TPG Drone Co -Invest ” has the meaning set forth in the Preamble.

TPG Drone Investment ” has the meaning set forth in the Preamble.

Unaffiliated Director ” has the meaning set forth in Section 3.1(a).

Underwriting Agreement ” has the meaning set forth in the Recitals.

 

5


Section 1.2     Other Interpretive Provisions.

(a) The meanings of defined terms are equally applicable to the singular and plural forms of the defined terms.

The words “ hereof ,” “ herein ,” “ hereunder ” and similar words refer to this Agreement as a whole and not to any particular provision of this Agreement; and any subsection and section references are to this Agreement unless otherwise specified.

The term “ including ” is not limiting and means “ including without limitation .”

The captions and headings of this Agreement are for convenience of reference only and shall not affect the interpretation of this Agreement.

Whenever the context requires, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms.

ARTICLE II

REPRESENTATIONS AND WARRANTIES

Each of the parties to this Agreement hereby represents and warrants to each other party to this Agreement that as of the date such party executes this Agreement:

Section 2.1     Existence; Authority; Enforceability . Such party has the power and authority to enter into this Agreement and to carry out its obligations hereunder. Such party is duly organized and validly existing under the laws of its jurisdiction of organization, and the execution of this Agreement, and the consummation of the transactions contemplated herein, have been authorized by all necessary action on the part of its board of directors (or equivalent) and shareholders (or other holders of equity interests), if required, and no other act or proceeding on its part is necessary to authorize the execution of this Agreement or the consummation of any of the transactions contemplated hereby. This Agreement has been duly executed by such party and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights generally or by equitable principles relating to enforceability.

Section 2.2     Absence of Conflicts . The execution and delivery by such party of this Agreement and the performance of its obligations hereunder does not and will not (a) conflict with, or result in the breach of any provision of the constitutive documents of such party, (b) result in any violation, breach, conflict, default or an event of default (or an event which with notice, lapse of time, or both, would constitute a default or an event of default), or give rise to any right of acceleration or termination or any additional payment obligation, under the terms of any material contract, agreement or permit to which such party is a party or by which such party’s assets or operations are bound or affected, or (c) violate, in any material respect, any law applicable to such party.

Section 2.3     Consents . Other than as expressly required herein or any consents which have already been obtained, no consent, waiver, approval, authorization, exemption, registration,

 

6


license or declaration is required to be made or obtained by such party in connection with (a) the execution, delivery or performance of this Agreement or (b) the consummation of any of the transactions contemplated herein.

ARTICLE III

GOVERNANCE

Section 3.1     The Board .

(a) Composition of the Board . Prior to Closing, the Company, DTZ LP and the Shareholders shall take all Necessary Action to cause the Board to be comprised of seven (7) directors, (i) two (2) of whom shall be designated by TPG (including any other directors designated by TPG and elected to the Board pursuant to Section 3.1(b) or (f) below, each, a “ TPG Director ”), (ii) two (2) of whom shall be designated by PAG (including any other directors designated by PAG and elected to the Board pursuant to Section 3.1(c) or (f) below, each, a “ PAG Director ”), (iii) one (1) of whom shall be designated by OTPP (including any other director designated by OTPP and elected to the Board pursuant to Section 3.1(d) or (f) below, an “ OTPP Director ” and, together with each TPG Director and PAG Director, the “ Sponsor Directors ”), (iv) one (1) of whom shall be the Chief Executive Officer, and (v) one (1) of whom shall satisfy the requirements to qualify as an Independent Director and whom shall be jointly designated for nomination by the Sponsors.

The foregoing directors shall be divided into three classes of directors, each of whose members shall serve for staggered three-year terms as follows:

 

  (1) the class I directors shall include Jonathan Coslet (designated by TPG) and Elaine Chen (designated by PAG);

 

  (2) the class II directors shall include Brett White and Billie Williamson; and

 

  (3) the class III directors shall include Timothy Dattels (designated by TPG), Lincoln Pan (designated by PAG) and Raju Ruparelia (designated by OTPP).

The initial term of the class I directors shall expire at the Company’s 2019 annual general meeting of shareholders; the initial term of the class II directors shall expire at the Company’s 2020 annual general meeting of shareholders; and the initial term of the class III directors shall expire at the Company’s 2021 annual general meeting of shareholders, in each case subject to the applicable thresholds described in Section 3.1(b), (c) and (d) below.

Subject to the Company Articles, a director shall remain a member of the class of directors to which he or she was assigned in accordance with this Section 3.1(a). The initial terms of each class of directors shall expire as set forth in this Section 3.1(a), subject to such director’s earlier death, resignation, disqualification or removal. Subject to any fiduciary duties that any Sponsor Director may have as a director of the Company and the provisions of Section 3.1(f) below, the Sponsors agree to procure that their respective Sponsor Directors do not vote to remove another Sponsor Director from the Board.

 

7


After Closing, if determined by the Sponsors or to comply with stock exchange independence requirements, up to two (2) additional directors satisfying the requirements to qualify as an Independent Director may be appointed by a majority of the Board (each, an “ Unaffiliated Director ”).

The Board shall consist of seven (7) directors until the earlier of (i) such time as a majority of directors vote to expand the board, including at such times as necessary to add one or more Independent Directors to satisfy requirements under applicable stock exchange rules for independent audit committee members, and including in accordance with the foregoing paragraph, and (ii) the Sponsors’ beneficial ownership percentage collectively falls below 50% of the total Ordinary Shares outstanding at Closing, at which time the Company and the Shareholders shall take all Necessary Action to cause the Board to act to increase the number of directors to nine (9), including action to fill vacancies, if any, created by such increase.

(b) TPG Representation . At each applicable annual or special meeting of shareholders at which directors are to be elected, there shall be included in the slate of nominees recommended by the Board for election as directors that number of individuals designated by TPG (each, a “ TPG Designee ”) that, if elected, will result in TPG having two (2) TPG Directors; provided , however , that (A) if TPG, in the aggregate, beneficially owns, as of the date that is 120 days before the date of such annual or special meeting of shareholders, less than 7.5% of the Ordinary Shares outstanding as of Closing, then one (1) TPG Director must offer to tender his or her resignation in connection with such meeting and, with respect to such meeting and subsequent meetings, the number of TPG Designees shall be reduced to one (1) TPG Designee; and (B) if TPG, in the aggregate, beneficially owns, as of the date that is 120 days before the date of such annual or special meeting of shareholders, less than 2.5% of the Ordinary Shares outstanding as of Closing, then the remaining TPG Director must offer to tender his or her resignation in connection with such meeting and, with respect to such meeting and subsequent meetings, TPG shall have no right to designate a TPG Designee. In the event that any TPG Director offers to tender his or her resignation, the Board shall use its discretion as to whether to accept such resignation and, if the Board chooses to accept such resignation, such TPG Director shall resign.

(c) PAG Representation . At each applicable annual or special meeting of shareholders at which directors are to be elected, there shall be included in the slate of nominees recommended by the Board for election as directors that number of individuals designated by PAG (each, a “ PAG Designee ”) that, if elected, will result in PAG having two (2) PAG Directors; provided , however , that (A) if PAG, in the aggregate, beneficially owns, as of the date that is 120 days before the date of such annual or special meeting of shareholders, less than 7.5% of the Ordinary Shares outstanding as of Closing, then one (1) PAG Director must offer to tender his or her resignation in connection with such meeting and, with respect to such meeting and subsequent meetings, the number of PAG Designees shall be reduced to one (1) PAG Designee; and (B) if PAG, in the aggregate, beneficially owns, as of the date that is 120 days before the date of such annual or special meeting of shareholders, less than 2.5% of the Ordinary Shares outstanding as of Closing, then the remaining PAG Director must offer to tender his or her resignation in connection with such meeting and, with respect to such meeting and subsequent meetings, PAG shall have no right to designate a PAG Designee. In the event that any PAG Director offers to tender his or her resignation, the Board shall use its discretion as to whether to

 

8


accept such resignation and, if the Board chooses to accept such resignation, such PAG Director shall resign.

(d) OTPP Representation. At each applicable annual or special meeting of shareholders at which directors are to be elected, there shall be included in the slate of nominees recommended by the Board for election as directors that number of individuals designated by OTPP (each, an “ OTPP Designee ” and, together with each TPG Designee and PAG Designee, the “ Sponsor Designees ”) that, if elected, will result in OTPP having one (1) OTPP Director; provided , however , that if OTPP, in the aggregate, beneficially owns, as of the date that is 120 days before the date of such annual or special meeting of shareholders, less than 2.5% of the Ordinary Shares outstanding as of Closing, then the OTPP Director must offer to tender his or her resignation in connection with such meeting and, with respect to such meeting and subsequent meetings, OTPP shall have no right to designate a OTPP Designee. In the event that the OTPP Director offers to tender his or her resignation, the Board shall use its discretion as to whether to accept such resignation and, if the Board chooses to accept such resignation, the OTPP Director shall resign.

(e) CEO Representation . Subject to the penultimate sentence of Section 3.1(f), if the term of the Chief Executive Officer as a director on the Board is to expire in conjunction with any annual or special meeting of shareholders at which directors are to be elected, the Chief Executive Officer shall be included in the slate of nominees recommended by the Board for election.

(f) Vacancies . Except as provided for in Sections 3.1(b), (c) and (d) and to the extent not inconsistent with the Company Articles, (i) each Sponsor shall have the exclusive right to remove its Sponsor Directors from the Board, and the Board and the other Sponsors shall, at the request of such Sponsor, take all Necessary Action to cause the removal of any Sponsor Director nominated by such Sponsor and (ii) each Sponsor shall have the exclusive right to designate for election to the Board directors to fill vacancies created by reason of death, removal or resignation of its Sponsor Directors, and the Board and the other Sponsors shall, at the request of such Sponsor, take all Necessary Action to cause any such vacancies to be filled by replacement directors designated by such Sponsor as promptly as reasonably practicable; provided , that, for the avoidance of doubt and notwithstanding anything to the contrary in this paragraph, a Sponsor shall not have the right to designate a replacement director, and the Board and the Sponsors shall not be required to take any action to cause any vacancy to be filled with any Sponsor Designee, to the extent that election or appointment of such Sponsor Designee to the Board would result in a number of directors designated by a Sponsor in excess of the number of directors that such Sponsor is then entitled to designate for membership on the Board pursuant to Section 3.1(b), (c) or (d), as applicable. If the Chief Executive Officer resigns or is terminated for any reason, the Board and the Sponsors shall take all Necessary Action to remove the Chief Executive Officer from the Board and fill such vacancy with the next Chief Executive Officer in office. If any Independent Director resigns or is terminated for any reason, the Sponsors shall take all Necessary Action to fill such vacancy with another Independent Director who shall be appointed by a majority of the Board.

(g) Additional Unaffiliated Directors . For so long as the Sponsors each have the right to designate at least one (1) director for nomination under this Agreement, the Company and the

 

9


Sponsors will take all Necessary Action to ensure that the number of directors serving on the Board shall not exceed nine (9) (or, after a majority of the directors vote to further expand the Board, eleven (11)) and shall be no fewer than five (5).

(h) Approval Rights . Any amendment to the organizational documents of the Company that would have a disproportionally adverse and material effect on TPG, PAG or OTPP (other than as a result of disparate share ownership) shall require approval by the Board, including the affirmative vote of a majority of the Sponsor Directors for so long as at least one (1) Sponsor Director is on the Board and the affirmative vote of at least one (1) of the Sponsor Directors representing each of the Sponsor(s) so adversely affected for so long as at least one (1) Sponsor Director of such adversely affected Sponsor is on the Board. The parties hereto agree not to vote in favor of any amendment that does not have the requisite Board approval.

(i) Committees . Subject in each case to applicable laws and stock exchange regulations, (i) TPG shall have the right to have a representative appointed to serve on each committee of the Board for so long as TPG has the right to designate at least one (1) director for election to the Board, (ii) PAG shall have the right to have a representative appointed to serve on each committee of the Board for so long as PAG has the right to designate at least one (1) director for election to the Board and (iii) OTPP shall have the right to have a representative appointed to serve on each of the Nominating and Governance Committee and the Compensation Committee of the Board for so long as OTPP has the right to designate at least one (1) director for election to the Board. Subject in each case to applicable laws and stock exchange regulations, each Sponsor shall have the right to have a representative appointed as an observer to any committee of the Board to which such Sponsor (i) has not appointed a representative or (ii) is prohibited by applicable laws or stock exchange regulations from having a representative appointed, in each case for so long as such Sponsor has the right to designate at least one (1) director for nomination under this Agreement.

(j) Reimbursement of Expenses . The Company shall reimburse each Sponsor Director and Sponsor Designee for all reasonable and documented out-of-pocket expenses incurred in connection with such director’s or designee’s participation in the meetings of the Board or any committee of the Board, including all reasonable and documented travel, lodging and meal expenses.

(k) Nomination . With respect to any Sponsor Designee, the Company and the Sponsors shall take all Necessary Action to cause the Board and Nominating and Governance Committee to, if applicable, (i) include such Sponsor Designee in the slate of nominees recommended by the Board for the applicable class of directors for election by the shareholders of the Company or (ii) appoint such Sponsor Designee to fill a vacancy on the Board created by the departure of a Sponsor Director. The Company agrees to take all Necessary Action to include such Sponsor Designee in the applicable proxy statement for such shareholder meeting.

(l) Loss of Controlled Company Exemption . Within one (1) year (or any shorter period that may be required by applicable law or by the applicable rules and regulations of the Securities and Exchange Commission or the applicable stock exchange on which the Company Shares are listed) after the Company ceases to qualify as a “controlled company” as defined by the applicable stock exchange rules on which the Company Shares are then-currently listed, the

 

10


Sponsors shall take all Necessary Action to ensure that a sufficient number of the Sponsor Directors qualify as “independent directors” as defined by the applicable stock exchange rules to ensure that the Board complies with stock exchange independence requirements.

(m) D&O Insurance . The Company shall obtain customary director and officer indemnity insurance on commercially reasonable terms for each of its directors, and the Sponsor Directors shall also be provided the benefit of customary director indemnity agreements.

(n) Indemnification Priority . The Company hereby acknowledges that, in addition to the rights provided to each Sponsor Director or other indemnified person covered by any such indemnity insurance policy (any such Person, an “ Indemnitee ”) or any indemnification agreement that such Indemnitee may enter into with the Company from time to time (the “ Indemnification Agreements ”), the Indemnitees may have certain rights to indemnification, advancement of expenses and/or insurance provided by the Sponsors or one or more of their respective Affiliates (collectively, the “ Fund Indemnitors ”). Notwithstanding anything to the contrary in any of the Indemnification Agreements or this Agreement, the Company hereby agrees that, to the fullest extent permitted by law, with respect to its indemnification and advancement obligations to the Indemnitees under the Indemnification Agreements, this Agreement or otherwise, the Company (i) is the indemnitor of first resort (i.e., its and its insurers’ obligations to advance expenses and to indemnify the Indemnitees are primary and any obligation of the Fund Indemnitors or their insurers to advance expenses or to provide indemnification for the same expenses or liabilities incurred by any of the Indemnitees is secondary and excess), (ii) shall be required to advance the full amount of expenses incurred by each Indemnitee and shall be liable for the full amount of all losses of each Indemnitee or on his, her or its behalf to the extent legally permitted and as required by this Agreement and the Indemnification Agreements, without regard to any rights such Indemnitees may have against the Fund Indemnitors or their insurers, and (iii) irrevocably waives and relinquishes, and releases the Fund Indemnitors and such insurers from, any and all claims against the Fund Indemnitors or such insurers for contribution, subrogation or any other recovery of any kind in respect thereof. In furtherance and not in limitation of the foregoing, the Company agrees that in the event that any Fund Indemnitor or its insurer should advance any expenses or make any payment to any Indemnitee for matters subject to advancement or indemnification by the Company pursuant to this Agreement or otherwise, the Company shall promptly reimburse such Fund Indemnitor or insurer and that such Fund Indemnitor or insurer shall be subrogated to all of the claims or rights of such Indemnitee under the Indemnification Agreements, this Agreement or otherwise, including to the payment of expenses in an action to collect. The Company agrees that any Fund Indemnitor or insurer thereof not a party hereto shall be an express third party beneficiary of this Section 3.1(n), able to enforce such clause according to its terms as if it were a party hereto. Nothing contained in the Indemnification Agreements is intended to limit the scope of this Section 3.1(n) or the other terms set forth in this Agreement or the rights of the Fund Indemnitors or their insurers hereunder.

(o) Voting Agreement . Subject to Section 4.14(b), the Sponsors each hereby agree to vote all Company Shares beneficially owned by such Sponsor at each annual or other meeting of the Company at which directors of the Company are to be elected, in favor of, or to take other Necessary Action and the Company agrees to take all Necessary Action to cause the election as members of the Board of Directors of those individuals described in Section 3.1(b), (c) and (d) in

 

11


accordance with, and otherwise to achieve the composition of the Board of Directors and effect the intent of, the provisions of this Section 3.1;  provided however , the requirements of this Section 3.1(o) shall cease (i) with respect to each Sponsor, upon the earlier to occur of the date on which (A) such Sponsor ceases to have the right, in accordance with this Section 3.1, to designate a director for nomination to the Board of Directors and (B) the Sponsors mutually agree to terminate the requirement to effect the requirements set forth in this Section 3.1(o).

(p) Subsidiaries . The composition of the boards of directors and committees of all other subsidiaries of the Company shall be as determined by the Board.

ARTICLE IV

GENERAL PROVISIONS

Section 4.1     Company Articles . In the event of any conflict between the terms of this Agreement and the Company Articles then, as between the parties hereto, the terms of this Agreement shall prevail.

Section 4.2     Trading Windows . The Company shall (i) use its reasonable best efforts to notify each Sponsor of each “closing” and “opening” date under the trading windows established by the Company’s insider trading policy, in each case, at least three (3) Business Days prior to each such date and (ii), at the request of any Sponsor, confirm to the requesting Sponsor whether a trading window is open at such time.

Section 4.3     Corporate Opportunities .

(a) In recognition and anticipation that the Sponsor Affiliated Persons (i) currently or may in the future serve as directors, officers or agents of the Company or its direct or indirect subsidiaries, (ii) currently or may in the future have access to information about the Company and its direct or indirect subsidiaries that may, to the fullest extent permitted by applicable law, enhance each such Sponsor Affiliated Person’s knowledge and understanding of (A) the industries in which the Company and its direct and indirect subsidiaries operate, (B) the activities in which the Company and its direct or indirect subsidiaries now engage, may continue to engage or may in the future engage (which shall include, without limitation, other business activities that overlap with or compete with those in which the Company and its Affiliates and its direct or indirect subsidiaries may engage directly or indirectly) or (C) related lines of business in which the Company or its direct or indirect subsidiaries may engage directly or indirectly (collectively, “ Acquired Knowledge ”) and (iii) currently or may in the future have an interest in the same or similar areas of corporate opportunity as the Company or its direct or indirect subsidiaries may have an interest directly or indirectly, the provisions of this Section 4.3 are set forth to regulate and define, to the fullest extent permitted by applicable law, the conduct of certain affairs of the Company and its direct or indirect subsidiaries with respect to certain classes or categories of business opportunities as they may involve a Sponsor Affiliated Person, and the powers, rights, duties and liabilities of the Company and its direct or indirect subsidiaries and their respective direct or indirect partners, members, and shareholders in connection therewith.

 

12


(b) Notwithstanding any provision of this Agreement to the contrary, to the fullest extent permitted by applicable law, if any Sponsor Affiliated Person acquires knowledge of a potential Corporate Opportunity or otherwise is then exploiting any Corporate Opportunity, the Company and its Affiliates and its direct or indirect subsidiaries shall have no interest or expectancy in such Corporate Opportunity, or in being offered an opportunity to participate in such Corporate Opportunity, and any interest or expectancy in any Corporate Opportunity or any expectation in being offered the opportunity to participate in any Corporate Opportunity is hereby renounced and waived so that, such Sponsor Affiliated Person, to the fullest extent permitted by applicable law, (i) shall have no duty (fiduciary, statutory, contractual or otherwise) to communicate or present such Corporate Opportunity to the Company or any of its Affiliates or any of its direct or indirect subsidiaries or any shareholder of the Company; (ii) shall have the right to hold or pursue, directly or indirectly, any such Corporate Opportunity for the Sponsor’s own account and benefit or the Sponsor may direct such Corporate Opportunity to another person (including any Sponsor Affiliated Persons); and (iii) shall not be liable to the Company, any of its Affiliates or any of its direct or indirect subsidiaries, their respective Affiliates or their respective direct or indirect partners, members, or shareholder, for breach of any duty (fiduciary, statutory, contractual or otherwise) as a shareholder, director or officer of the Company or otherwise by reason of the fact that it pursues or acquires such Corporate Opportunity, directs such Corporate Opportunity to another person or does not communicate information regarding such Corporate Opportunity to the Company or any of its Affiliates or any of its direct or indirect subsidiaries.

(c) The Company hereby expressly acknowledges and agrees that each of the Sponsors, their Affiliates and affiliated investment funds and any Sponsor Affiliated Person, has the right to, and shall have no duty (fiduciary, statutory, contractual or otherwise) not to, (i) directly or indirectly engage in the same or similar business activities or lines of business as the Company or any of its direct or indirect subsidiaries engages or proposes to engage, on such Person’s own behalf, or in partnership with, or as an employee, officer, director, member or shareholder of any other Person, including those lines of business deemed to be competing with the Company or any of its direct or indirect subsidiaries; (ii) do business with any potential or actual customer or supplier of the Company or any of its Affiliates or its direct or indirect subsidiaries; and (iii) employ or otherwise engage any officer or employee of the Company or any of its Affiliates or direct or indirect subsidiaries. The Company hereby expressly acknowledges and agrees that neither the Company nor any of its Affiliates or any of its direct or indirect subsidiaries nor any shareholder of the Company shall have any rights in and to the business ventures of the Sponsors, their Affiliates and affiliated investment funds, or the income or profits derived therefrom. To the fullest extent permitted by law, none of the Sponsor Affiliated Persons shall be liable to the Company, any of its Affiliates or its direct or indirect subsidiaries, their respective Affiliates or their respective direct or indirect partners, members, or shareholders, for breach of any duty (fiduciary, statutory, contractual or otherwise) as a shareholder, director or officer of the Company or otherwise by reason that such Sponsor Affiliated Person is engaging in any activities or lines of business or competing with the Company or its direct or indirect subsidiaries.

(d) The Company hereby acknowledges and agrees that, to the fullest extent permitted by applicable law, (i) in the event of any conflict of interest between the Company or any of its direct or indirect subsidiaries, on the one hand, and any Sponsor Affiliated Person, on

 

13


the other hand, such Sponsor Affiliated Person (including each Sponsor Director, acting in its capacity as a director and/or any Sponsor Affiliated Person serving as an officer of the Company or any of its direct or indirect subsidiaries, acting in its capacity as an officer) may act in the best interest of the Sponsor and its Affiliates and (ii) no Sponsor Affiliated Person (including any Sponsor Director acting in its capacity as a director, or any other Sponsor Affiliated Person serving as an officer of the Company or any of its direct or indirect subsidiaries acting in its capacity as an officer), shall be obligated to (A) reveal to the Company or any of its direct or indirect subsidiaries confidential information belonging to or relating to the business of the Sponsor or its Affiliates or (B) recommend or take any action in its capacity as shareholder, director or officer of the Company, as the case may be, that prefers the interest of the Company or any of its subsidiaries over the interest of the Sponsor and its Affiliates, or such Sponsor Affiliated Person, as the case may be.

(e) The Company hereby acknowledges and agrees that, to the fullest extent permitted by applicable law, the Sponsor Affiliated Persons (including each Sponsor Director, acting in its capacity as a director and/or any Sponsor Affiliated Person serving as an officer of the Company or any of its direct or indirect subsidiaries, acting in its capacity as an officer) are not restricted from using Acquired Knowledge in making investment, voting, monitoring, governance or other decisions relating to other entities or securities.

(f) For the avoidance of doubt, nothing shall prevent any portfolio company of any Sponsor from pursuing any Corporate Opportunities, and no portfolio company of any Sponsor shall have any obligation to the Company pursuant to this Section 4.3.

Section 4.4     Assignment; Benefit .

(a) All Company Shares held by 2339532 Ontario Limited will, upon the dissolution of DTZ LP, be distributed, directly or indirectly, to Ontario Teachers’ Pension Plan Board, including through one or more of its Affiliates, and in connection with such distribution, Ontario Teachers’ Pension Plan Board or any of such Affiliates holding Company Shares shall, without further action, be deemed to be a Sponsor hereunder and have all of the rights and obligations thereof as a Sponsor as if it were 2339532 Ontario Limited. Notwithstanding the foregoing, and for the avoidance of doubt, after such distribution 2339532 Ontario Limited will continue to be subject to any obligations and restrictions hereunder. All other rights and obligations hereunder shall not be assignable without the prior written consent of the other parties hereto, provided that each Sponsor may assign its rights and obligations hereunder to its Affiliates holding Company Shares, without the prior written consent of the other parties hereto. Any attempted assignment of rights or obligations in violation of this Section 4.4 shall be null and void.

(b) This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, and their respective successors and permitted assigns, and other than the Indemnitees, the Fund Indemnitors and any insurer of a Fund Indemnitor under Section 3.1(n), and the Sponsors, their Representatives and the Sponsor Affiliated Persons under Section 4.3, a person who is not a party to this Agreement may not enforce any of its terms under the Contracts (Rights of Third Parties) Act 1999.

Section 4.5     Confidentiality .

 

14


(a) The Company, hereby agrees that it, and any direct or indirect partner, manager, member, shareholder, employee, director, officer or agent thereof, with the exception of the Sponsor Affiliated Persons (each, an “ Affiliated Person ”), shall keep confidential, and shall not disclose to any third Person or use for its own benefit, without prior written approval of the Sponsors, any non-public information with respect to the Sponsors or any of their respective subsidiaries or Affiliates (including any Person in which a Sponsor holds, or contemplates acquiring, an investment) (“ Sponsor Confidential Information ”) that is in the Company’s or such Affiliated Persons’ possession on the date hereof or disclosed after the date of this Agreement to the Company or such Affiliated Persons by or on behalf of the Sponsors or their respective subsidiaries or Affiliates, provided , that the Company and the Affiliated Persons may disclose any such Sponsor Confidential Information (i) as has become generally available to the public, was or has come into the Company’s or the Affiliated Persons’ possession on a non-confidential basis, without a breach of any confidentiality obligations by the Person disclosing such Sponsor Confidential Information, or has been independently developed by such Person, without use of the Sponsor Confidential Information, (ii) to the Company’s Affiliates, directors, officers, representatives, agents and employees and professional advisers who need to know such Sponsor Confidential Information and agree to keep it confidential on terms consistent with this Section 4.5(a), (iii) to the extent necessary in order to comply with any law, order, regulation or ruling applicable to the Company or its Affiliates, or to a regulatory agency with applicable jurisdiction, and (iv) as may be required in response to any summons or subpoena or in connection with any litigation or arbitration, it being agreed that, unless such Sponsor Confidential Information has been generally available to the public, if such Sponsor Confidential Information is being requested pursuant to a summons or subpoena or a discovery request in connection with a litigation, then (x) the Company shall give the Sponsors notice of such request and shall cooperate with the Sponsors at the Sponsors’ request so that the Sponsors may, in their discretion, seek a protective order or other appropriate remedy, if available, and (y) in the event that such protective order is not obtained (or sought by the Sponsors after notice), the Company (a) shall furnish only that portion of the Sponsor Confidential Information which, in the written opinion of counsel, is legally required to be furnished and (b) will exercise its reasonable efforts to obtain adequate assurances that confidential treatment will be accorded such Sponsor Confidential Information by its recipients.

(b) The Company grants permission to the Sponsors to use the name and logo of the Company in marketing materials used by the Sponsors and their Affiliates. The Sponsors and their Affiliates shall include a trademark attribution notice giving notice of the Company’s ownership of their trademarks in any marketing materials in which the Company’s name and logo appear.

(c) Notwithstanding anything to the contrary contained in this Agreement, the provisions of this Section 4.5 shall survive termination of this Agreement (whether with respect to one or all of the Sponsors) with respect to matters arising before or after such termination, and shall remain in full force and effect until such time as such provisions are explicitly waived and revoked by each of the Sponsors. Such waiver and revocation shall be made in writing to the Company and shall take effect at the time specified therein or, if no time is specified therein, at the time of receipt thereof by the Company.

 

15


Section 4.6     Termination . If not otherwise stipulated, this Agreement shall terminate automatically (without any action by any party hereto) as to each Shareholder as of the date when such Shareholder no longer has the right to nominate any directors to the Board pursuant to Article III hereof (without prejudice to accrued rights and obligations).

Section 4.7     Severability . In the event that any provision of this Agreement shall be invalid, illegal or unenforceable such provision shall be construed by limiting it so as to be valid, legal and enforceable to the maximum extent provided by law and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

Section 4.8     Entire Agreement; Amendment .

(a) This Agreement sets forth the entire understanding and agreement between the parties with respect to the transactions contemplated herein and supersedes and replaces any prior understanding, agreement or statement of intent, in each case written or oral, of any kind and every nature with respect hereto. This Agreement or any provision hereof may only be amended, modified or waived, in whole or in part, at any time by an instrument in writing signed by the Company (whose agreement to such amendment, modification or waiver shall not be unreasonably withheld) and the Sponsors (that remain a party to this Agreement); provided that to the extent that Other Shareholders become party hereto, the prior written consent of the holders of the Majority in Interest of the Company Shares then held by the Other Shareholders shall be required for any amendment, modification or waiver that would have a disproportionate and adverse effect in any material respect on the rights of Other Shareholders under this Agreement relative to the Sponsors.

(b) No waiver of any breach of any of the terms of this Agreement shall be effective unless such waiver is expressly made in writing and executed and delivered by the party against whom such waiver is claimed. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. Except as otherwise expressly provided herein, no failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder, or otherwise available in respect hereof at law or in equity, shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.

Section 4.9     Counterparts . This Agreement may be executed in any number of separate counterparts each of which when so executed shall be deemed to be an original and all of which together shall constitute one and the same agreement. Counterpart signature pages to this Agreement may be delivered by facsimile or electronic delivery ( i.e ., by email of a PDF signature page) and each such counterpart signature page will constitute an original for all purposes.

Section 4.10     Notices . Unless otherwise specified herein, all notices, consents, approvals, reports, designations, requests, waivers, elections and other communications authorized or required to be given pursuant to this Agreement shall be in writing and shall be given, made or delivered by personal hand-delivery, by facsimile transmission, by electronic

 

16


mail, by mailing the same in a sealed envelope, registered first-class mail, postage prepaid, return receipt requested, or by air courier guaranteeing overnight delivery (and such notice shall be deemed to have been duly given, made or delivered (a) on the date received, if delivered by personal hand delivery, (b) on the date received, if delivered by facsimile transmission, by electronic mail or by registered first-class mail prior to 5:00 p.m. prevailing local time on a Business Day, or if delivered after 5:00 p.m. prevailing local time on a Business Day or on other than a Business Day, on the first Business Day thereafter and (c) two (2) Business Days after being sent by air courier guaranteeing overnight delivery), at the following addresses (or at such other address as shall be specified by like notice):

If to the Company to:

Cushman & Wakefield plc

225 West Wacker Drive, Suite 3000

Chicago, Illinois 60606

Attention:         General Counsel

E-mail:             brett.soloway@cushwake.com

with a copy (which shall not constitute notice) to:

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, NY 10006

Attention:         Jeffrey Karpf

                         Helena Grannis

E-mail:             jkarpf@cgsh.com

                          hgrannis@cgsh.com

If to TPG to:

301 Commerce Street

Suite 3300

Fort Worth, TX 76102

Attention: Office of General Counsel

E-mail: officeofgeneralcounsel@tpg.com

with a copy to (which shall not constitute notice) to:

345 California Street

San Francisco, CA 94104

Attention: Adam Fliss

E-mail: afliss@tpg.com

If to PAG to:

c/o 32/F, AIA Central

1 Connaught Road Central

HongKong

Attention:    Jon Lewis

 

17


                    Elaine Chen

E-mail:        jlewis@pag.com

                    echen@pag.com

with a copy (which shall not constitute notice) to:

Fenwick & West LLP

Unit 908, 9th Floor, Kerry Parkside Office

No. 1155 Fang Dian Road

Pudong New Area, Shanghai 201204

People’s Republic of China

Attention:     Niping Wu

Email:           niping.wu@fenwick.com

If to OTPP to:

Ontario Teachers’ Pension Plan Board

5650 Yonge Street

Toronto, Ontario M2M 4H5

Canada

Attention:     Raju Ruparelia

E-mail:         raju_ruparelia@otpp.com

                     law_investments@ottp.com

with a copy (which shall not constitute notice) to:

Baker McKenzie

Tower One—International Towers Sydney

Level 46—100 Barangaroo Avenue

Sydney NSW 2000

Australia

Attention:     Michael Kunstler

                     Lewis Apostolou

E-mail:         michael.kunstler@bakermckenzie.com

                     lewis.apostolou@bakermckenzie.com

Section 4.11     Governing Law . This Agreement, and any disputes arising out of or in connection therewith, shall be governed by and construed in accordance with English law, without reference to its principles of conflicts of law.

Section 4.12     Dispute Resolution .

(a) Any dispute, controversy or claim arising out of, relating to, or in connection with, this Agreement (including its existence, validity, interpretation, breach, termination or enforcement as well as all matters relating to its negotiation, including pre-contractual liability) (each a “ Dispute ”) shall be referred to and finally settled by arbitration administered by the

 

18


International Court of Arbitration of the International Chamber of Commerce (“ ICC Court ”) in accordance with the Rules of Arbitration of the International Chamber of Commerce (the “ ICC Rules ”) then in effect, except as they may be modified in this Agreement or by agreement of the parties.

(b) The arbitration shall be conducted by three arbitrators. To the extent the Dispute involves two parties to this Agreement, each party subject to the Dispute shall nominate an arbitrator within thirty (30) days after delivery of the request for arbitration and the two arbitrators so appointed shall nominate the third arbitrator, who shall be the president of the arbitral tribunal, within thirty (30) days of their appointment. Any arbitrator not nominated within the applicable time limits shall be appointed by the ICC Court.

(c) The seat of arbitration shall be New York, New York, and the language of the arbitration shall be English.

(d) By agreeing to arbitration, the parties do not intend to deprive any court of competent jurisdiction of its ability to issue any form of provisional remedy, including a preliminary injunction or attachment in aid of the arbitration, or order any interim or conservatory measure. A request for such provisional remedy or interim or conservatory measure by a party to a court shall not be deemed a waiver of this agreement to arbitrate. The parties hereby consent to the non-exclusive jurisdiction of the courts of England with respect to applications for provisional remedies or interim or conservatory measures.

(e) The award rendered by the arbitral tribunal, which shall cover which party shall bear the costs of the arbitration, shall be final and binding on the parties. Judgment on the award may be entered in any court of competent jurisdiction.

(f) The validity, construction and interpretation of this arbitration clause shall be governed by English law.

(g) The parties shall maintain strict confidentiality with respect to all aspects of the arbitration and shall not disclose the fact, conduct or outcome of the arbitration to any nonparties or non-participants, except to the extent required by law, court order or to the extent necessary to recognize, confirm or enforce the final award in the arbitration, enforce provisions of this arbitration clause, or seek provision remedies from a court of competent jurisdiction, without the prior written consent of all parties to the arbitration.

(h) The parties agree to opt out of the ICC Rules’ Expedited Procedure provisions.

(i) The parties agree that any arbitral tribunal appointed hereunder may exercise jurisdiction with respect to both this Agreement and the Coordination Agreement. The parties consent to the consolidation of arbitrations commenced hereunder and/or under the Coordination Agreement as follows. If two or more arbitrations are commenced hereunder and/or under the Coordination Agreement, any party named as claimant or respondent in any of these arbitrations may petition any arbitral tribunal appointed in these arbitrations for an order that the several arbitrations be consolidated in a single arbitration before that arbitral tribunal (a “ Consolidation Order ”). In deciding whether to make such a Consolidation Order, that arbitral tribunal shall consider whether the several arbitrations raise common issues of law or fact and whether to

 

19


consolidate the several arbitrations would serve the interests of justice and efficiency. If before a Consolidation Order is made by an arbitral tribunal with respect to another arbitration, arbitrators have already been appointed in that other arbitration, their appointment terminates upon the making of such Consolidation Order and they are deemed to be functus officio . In the event of two or more conflicting Consolidation Orders, the Consolidation Order that was made first in time shall prevail.

Section 4.13     Specific Performance . It is hereby agreed and acknowledged that it may not be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them by this Agreement and that, in the event of any such failure, an aggrieved party may be irreparably damaged and may not have an adequate remedy at law. Any such party shall therefore be entitled (in addition to any other remedy to which such party may be entitled at law or in equity) to injunctive relief, including specific performance, to enforce such obligations, without the posting of any bond, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

Section 4.14     Acquisition of Shares.

(a) Any Company Shares acquired subsequent to the date hereof by a Shareholder shall be subject to the terms and conditions of this Agreement. For the avoidance of doubt, a Shareholder who acquires Company Shares subsequent to the date hereof shall not reacquire any rights previously lost under this Agreement as a result of a decrease in the amount of Company Shares beneficially owned by such Shareholder.

(b) Nothing in this Agreement shall in any way restrict or prohibit any activities of OTPP or its Affiliates, or require OTPP or its Affiliates to take (or not take) any action (including voting or not voting Company Shares), with respect to Company Shares:

(1) where such Company Shares are held in an index fund (or other similar investment) which invests in a broad basket of securities;

(2) where such Company Shares are acquired on behalf of OTPP or an Affiliate of OTPP by third-party investment managers with discretionary authority, or made by investment funds or other pooled investment vehicles in which OTPP or its Affiliates have invested as a passive investor with no power to direct the investments of such passive investments, and such investments are managed by third parties; or

(3) where the decision to acquire or dispose of any interest in such Company Shares on behalf of OTPP or an Affiliate of OTPP is undertaken by a portfolio company of OTPP or an Affiliate of OTTP that, in the ordinary course of business, provides market-maker, broker, trustee or nominee services, and where such decision is made in connection with the provision of such services.

[ Signature pages follow ]

 

 

20


IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the day and year first above written.

 

CUSHMAN & WAKEFIELD PLC
By:  

 

  Name:
  Title:

[Signature Page to Shareholders Agreement]


 

Signed for and on behalf of

TPG Drone Investment, L.P.

  By: TPG Asia Advisors VI, Inc., its general partner
 

 

Name:

  Title:

 

 

Signed for and on behalf of

TPG Drone Co-Invest, L.P.

  By:
 

 

Name:

  Title:

[Signature Page to Shareholders Agreement]


 

Signed for and on behalf of

PAGAC Drone Holding I LP

  By: PAGAC Drone Holding GP I Limited, its general partner
 

 

Name:

  Title:

[Signature Page to Shareholders Agreement]


Signed for and on behalf of

2339532 Ontario Ltd.

 

Name:
Title:

 

Signed for and on behalf of

Ontario Teachers’ Pension Plan Board

 

Name:
Title:

[Signature Page to Shareholders Agreement]


Signed for and on behalf of

DTZ Investment Holdings LP

By: DTZ Investment Holdings GenPar LLP, its general partner

 

Name:
Title:

[Signature Page to Shareholders Agreement]

Exhibit 10.45

PURCHASE AGREEMENT

This PURCHASE AGREEMENT (this “ Agreement ”) is entered into as of July 24, 2018, by and among Vanke Service (HongKong) Co., Limited ( 萬科物業服務 ( 香港 ) 有限公司 ), a Hong Kong limited company (“ Buyer ”), Cushman & Wakefield plc, a public limited company organized under the laws of England and Wales (the “ Company ”), and DTZ Investment Holdings LP, an English limited partnership (the “ Consortium Shareholder ”).

WHEREAS, an initial public offering (the “ IPO ”) of the ordinary shares, nominal value $0.10 per share (the “ Ordinary Shares ”), of the Company is contemplated, pursuant to a registration statement filed with the Securities and Exchange Commission (the “ Registration Statement ”);

WHEREAS, Buyer desires to subscribe for from the Company and the Company desires to issue and sell to Buyer the Primary Shares (as defined below) pursuant to the terms and subject to the conditions set forth in this Agreement;

WHEREAS, the closing of the subscription and sale of the Primary Shares pursuant hereto is conditioned upon the closing of the IPO;

WHEREAS, as of the date hereof, a nominee of Computershare Trust Company, N.A., as depositary (the “ Depositary ”), holds all of the Company’s Ordinary Shares, except for ten Ordinary Shares held by DTZ Investment Holdings GenPar LLP (“ DTZ GP ”), acting in its capacity as general partner of the Consortium Shareholder;

WHEREAS, the Depositary has issued depositary receipts in respect of the Ordinary Shares held by its nominee to FTL Nominees 1 Limited and FTL Nominees 2 Limited (in each of their capacities as nominees on behalf of various Company management holders and DTZ GP, acting in its capacity as general partner of the Consortium Shareholder, respectively) pursuant to the Deposit Agreement, dated as of July 6, 2018 (the “ Deposit Agreement ”), among the Company, the Depositary, FTL Nominees 1 Limited, FTL Nominees 2 Limited and the Holders (as defined therein);

WHEREAS, the Primary Shares will be in the form of depositary receipts issued pursuant to, and in accordance with the terms of, the Deposit Agreement, eligible to be exchanged for Ordinary Shares to be held in “street name” (through banks, brokers and other financial institutions that are record holders) following the end of the applicable holding period in Rule 144 (“ Rule  144 ”) under the Securities Act of 1933, as amended (the “ Securities Act ”); and

WHEREAS, in order to secure the performance of the Company hereunder, on the date hereof, Buyer will be delivering to Company proof of funds issued by Bank of China (Hong Kong) Limited reasonably satisfactory to the Company (the “ Proof of Funds ”).

NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants set forth below, the parties hereto hereby agree as follows:

1. Sale of Primary Shares .

(a) Purchase and Sale . Subject to the terms and conditions set forth in this Agreement, the Company hereby agrees to issue and sell to Buyer, and Buyer hereby agrees to purchase from the Company, an aggregate number of depositary receipts in respect of Ordinary Shares to be held by the nominee of the Depositary (rounded up to the nearest whole share) equal to 4.9% of the total outstanding Ordinary Shares after giving effect to the issuance of the firm shares in the IPO (the “ Firm Primary Shares ”). The purchase price per Firm Primary Share to be paid by Buyer (the “ Price Per Share ”) is equal to the price per Ordinary Share paid by the public in the IPO (before giving effect to any underwriting discounts or commissions). The total purchase price to be paid by Buyer for the Firm Primary Shares is equal to (x) the number of Firm Primary Shares multiplied by (y) the Price Per Share (such product, the “ Firm Purchase Price ”).

 

1


If and to the extent that the Representatives (as defined below) shall have determined to exercise, on behalf of the Underwriters (as defined below), the right to purchase additional shares (the “ Additional Shares ”) granted to the Underwriters (the “ Underwriters’ Option ”) in Section 2 of the Underwriting Agreement (the “ Underwriting Agreement ”) among Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and UBS Securities LLC, as representatives (the “ Representatives ”) of the several underwriters named in Schedule I to such agreement (the “ Underwriters ”), and the Company, subject to the terms and conditions set forth in this Agreement, the Company hereby agrees to issue and sell to Buyer, and Buyer hereby agrees to purchase from the Company, such additional number of depositary receipts in respect of Ordinary Shares to be held by the nominee of the Depositary, in the aggregate, as is necessary for the Buyer to purchase, in the aggregate under this Section 1(a), depositary receipts in respect of Ordinary Shares to be held by a nominee of the Depositary (rounded up to the nearest whole share) equal to 4.9% of the total outstanding Ordinary Shares after giving effect to the issuance of such Additional Shares in the IPO, the purchase of the Firm Primary Shares and any Additional Shares due to the exercise of the Underwriters’ Option (the “ Additional Primary Shares ” and, together with the Firm Primary Shares, the “ Primary Shares ”). The purchase price per Additional Primary Share to be paid by Buyer is the Price Per Share. The total purchase price to be paid by Buyer for the Additional Primary Shares is equal to (x) the number of Additional Primary Shares multiplied by (y) the Price Per Share (such product, the “ Additional Purchase Price ”).

(b) Closing . The closing of the sale and purchase of the Firm Primary Shares (the “ Closing ”) shall take place at the offices of Cleary Gottlieb Steen & Hamilton LLP, One Liberty Plaza, New York, New York 10006, or at such other place as shall be agreed upon by the parties hereto (the “ Closing Location ”), on the date that all of the conditions set forth in Section 4 of this Agreement are either satisfied or waived. At the Closing, Buyer shall deliver the Firm Purchase Price for the Firm Primary Shares, less the First Installment (as defined below) to the extent previously paid, to the Company, and the Company shall issue and deliver to Buyer such Firm Primary Shares to Buyer via depositary receipts registered in the name of Buyer, free and clear of all liens, claims or encumbrances (other than restrictions pursuant to applicable federal, state and foreign securities laws and the Shareholder Agreement (as defined below)).

The closing of the sale and purchase of the Additional Primary Shares (an “ Additional Closing ”) shall take place at the Closing Location upon the Company’s receipt of the applicable Subsequent Installment in accordance with Section 1(c)(i) (an “ Option Closing Date ”), provided that, in each case, all of the conditions set forth in Section 4 of this Agreement are either satisfied or waived. At such Option Closing Date, Buyer shall have delivered the Additional Purchase Price in accordance with Section 1(c)(i) for the Additional Primary Shares to be purchased, and the Company shall issue and deliver to Buyer such Additional Primary Shares to Buyer via depositary receipts registered in the name of Buyer, free and clear of all liens, claims or encumbrances (other than restrictions pursuant to applicable federal, state and foreign securities laws and the Shareholder Agreement).

(c) Installments; Payment of Purchase Price .

(i) The Buyer shall use its reasonable best efforts to initiate the following wire transfers, in each case to the account specified in Schedule I hereto with confirmation thereof reasonably satisfactory to the Company delivered concurrently therewith: (1) a wire transfer of immediately available funds equal to the total Firm Purchase Price as of the pricing of the IPO (the “ First Installment ”), (A) initiated by the Buyer as promptly as reasonably practicable, but no later than 5:00 p.m., Hong Kong time, on the first business day following Buyer’s receipt of written notice from the Company that the Company has entered into the Underwriting Agreement (which notice shall confirm the effectiveness of the Registration Statement and set forth the price per Ordinary Share to be paid by the public in the IPO and the total Firm Purchase Price), provided if such notice is received by Buyer prior to 9:00 a.m., Hong Kong time, on a business day, then initiated prior to 5:00 p.m., Hong Kong time, on the same business day as receipt of such notice, and (B) in any event received by the Company no later than 5:00 p.m., New York City time, on the third business day following Buyer’s receipt of such written notice from the Company, and (2) a wire transfer of immediately available funds equal to the Additional Purchase Price as of any exercise of the Underwriters’ Option (the “ Subsequent Installments ” and, together with the First Installment, the “ Installments ”), initiated by the Buyer as promptly as reasonably practicable, but no later than 5:00 p.m., Hong Kong time, on the business day following receipt by Buyer of written notice from the Company of the related Underwriters’ Option exercise notice (together with a copy of such exercise notice and a calculation setting forth the number of Additional Primary Shares to be purchased by Buyer and the amount of the applicable Additional Purchase

 

2


Price), which the Company shall provide to Buyer as promptly as reasonably practicable following receipt from the Representatives of the related Underwriters’ Option exercise notice pursuant to Section 2 of the Underwriting Agreement, and in any event received by the Company no later than 5:00 p.m., New York City time, on the third business day following receipt by Buyer of such notice from the Company.

(ii) The Company shall keep Buyer reasonably informed of the Company’s IPO process and reasonably informed in advance of the expected timing of each of the events referred to in Section 1(c)(i). The Company agrees to hold the First Installment in accordance with the terms of this Agreement, and not to transfer the First Installment from the account specified in Schedule I hereto, in each case, pending the Closing or earlier release in accordance with Section 5(c).

2. Representations and Warranties .

2.1 Representations and Warranties of the Company . The Company represents and warrants to Buyer as follows:

(a) The Company has been duly organized and is validly existing as a company in good standing under the laws of England and Wales and has the corporate power and authority to own its properties and to conduct its business as described in the Time of Sale Prospectus (as defined in the Underwriting Agreement) and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.

(b) Each of the Company’s Significant Subsidiaries (as defined in Rule 1-02(w) of Regulation S-X under the Securities Act) has been duly incorporated, organized or formed, is validly existing as a corporation or otherwise in good standing under the laws of the jurisdiction of its incorporation or organization (or formation (to the extent the concept of good standing is applicable in such jurisdiction), has the requisite power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification (to the extent the concept of good standing is applicable in such jurisdiction), except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. All of the issued share capital of each subsidiary of the Company has been duly and validly authorized and issued, is fully paid and non-assessable (to the extent such concepts are applicable under relevant law) and is owned directly by the Company or a subsidiary of the Company, free and clear of all liens, encumbrances, equities or claims, except as would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. As used in this Agreement with respect to the Company, “subsidiaries” shall mean direct and indirect subsidiaries of the Company.

(c) This Agreement, the Deposit Agreement, the Registration Rights Agreement (as defined below) and the Shareholder Agreement (as defined below) have been duly and validly authorized by the Company. This Agreement and the Deposit Agreement have been duly executed and delivered by the Company and constitute the valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights generally and to general principles of equity.

(d) The outstanding Ordinary Shares have been duly authorized and are validly issued, fully paid and non-assessable, the Primary Shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement and the Deposit Agreement, will be validly issued and represent valid interests in the Ordinary Shares to be issued by the Company, which such Ordinary Shares underlying the Primary Shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement and the Deposit Agreement, will be validly issued, fully paid and non-assessable, and, upon deposit of such Ordinary Shares underlying the Primary Shares with the Depositary pursuant to the Deposit Agreement and the due execution by the Depositary of the Primary Shares, in accordance with the Deposit Agreement, the persons in whose name the Primary Shares are registered will be entitled to the rights specified in the Deposit Agreement.

 

3


(e) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement, including the issuance and sale of the Primary Shares, will not contravene any provision of applicable law or the memorandum or articles of association of the Company or conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any agreement or other instrument binding upon the Company or any of its Significant Subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any Significant Subsidiary, except in each case, as would not reasonably be expected to have a material adverse effect on the Company’s ability to consummate the transactions contemplated by this Agreement.

(f) No consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may have already been obtained or made or be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Primary Shares, or except where the failure to obtain such consent, approval, authorization or order would not reasonably be expected to have a material adverse effect on the Company’s ability to consummate the transactions contemplated by this Agreement.

(g) Within the six-month period prior to the date of this Agreement, other than in connection with the IPO, the Company has not offered any Primary Shares by means of any general solicitation or general advertising within the meaning of Rule 502(c) under Regulation D under the Securities Act.

(h) Except for actions referred to in Section 2.1(g) above taken in connection with the IPO, the Company has not taken any action which could reasonably be expected to cause the sale of the Primary Shares to be sold by the Company to Buyer to fail to qualify as exempt from the registration requirements of the Securities Act.

(i) There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its Significant Subsidiaries is a party or to which any of the properties of the Company or any of its Significant Subsidiaries is subject that would reasonably be expected to, individually or in the aggregate, have a material adverse effect on the power or ability of the Company to perform its obligations under this Agreement.

2.2 Representations and Warranties of the Consortium Shareholder . The Consortium Shareholder represents and warrants to Buyer as follows:

(a) The Consortium Shareholder has been duly organized and is validly existing as a limited partnership in good standing under the laws of England and Wales.

(b) The execution and delivery of, and the performance by the Consortium Shareholder of its obligations under, this Agreement has been duly and validly authorized by all necessary corporate, limited liability company or similar applicable action on the part of the Consortium Shareholder. This Agreement has been duly executed and delivered by the Consortium Shareholder and constitutes the valid and legally binding obligation of the Consortium Shareholder, enforceable against the Consortium Shareholder in accordance with its terms, subject to bankruptcy, reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights generally and to general principles of equity.

(c) The execution and delivery by the Consortium Shareholder of, and the performance by the Consortium Shareholder of its obligations under this Agreement, the consummation of the transactions contemplated herein and compliance by the Consortium Shareholder with its obligations hereunder does not and will not contravene any provision of applicable law, or the certificate of incorporation or by laws or other organizational documents of the Consortium Shareholder, or any agreement or other instrument binding upon the Consortium Shareholder or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Consortium Shareholder, except, in each case, as would not reasonably be expected to have a material adverse effect on the Consortium Shareholder’s ability to consummate the transactions contemplated hereby.

(d) No consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Consortium Shareholder of its obligations under this Agreement, and except where the failure to obtain any such consent, approval, authorization or order would not reasonably be expected to

 

4


have a material adverse effect on the Consortium Shareholder’s ability to consummate the transactions contemplated hereby.

(e) There are no legal or governmental proceedings pending or, to the knowledge of the Consortium Shareholder, threatened to which the Consortium Shareholder is a party or to which any of its properties is subject that would reasonably be expected to, individually or in the aggregate, have a material adverse effect on the Consortium Shareholder’s ability to consummate the transactions contemplated hereby.

2.3 Buyer Representations . The Buyer represents and warrants to the Company and the Consortium Shareholder as follows:

(a) (i) Buyer has been duly organized and is validly existing as a limited company in good standing under the laws of Hong Kong and has the corporate power and authority to consummate the transactions contemplated hereby; (ii) the execution and delivery of, and the performance by the Buyer of its obligations under, this Agreement has been duly and validly authorized by all necessary corporate, limited liability company or similar applicable action on the part of the Buyer; and (iii) this Agreement has been duly executed and delivered by the Buyer and constitutes the valid and legally binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, subject to bankruptcy, reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights generally and to general principles of equity.

(b) The execution and delivery by the Buyer of, and the performance by the Buyer of its obligations under this Agreement, the sale and delivery of the Primary Shares, the consummation of the transactions contemplated herein and compliance by the Buyer with its obligations hereunder does not and will not contravene any provision of applicable law, or the certificate of incorporation or by laws or other organizational documents of the Buyer, or any agreement or other instrument binding upon the Buyer or the Primary Shares or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Buyer, except, in each case, as would not reasonably be expected to have a material adverse effect on Buyer’s ability to consummate the transactions contemplated hereby.

(c) No consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Buyer of its obligations under this Agreement, except, in each case, such as may have already been obtained or made, and except where the failure to obtain any such consent, approval, authorization or order would not reasonably be expected to have a material adverse effect on the Buyer’s ability to consummate the transactions contemplated hereby.

(d) (i) It is an institutional “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act; (ii) it has sufficient knowledge and experience in investing in companies similar to the Company so as to be able to evaluate the risks and merits of its investment in the Company and it is able financially to bear the risks thereof; (iii) it has had a reasonable opportunity to discuss the Company’s business, management and financial affairs with the Company’s management; (iv) it is not purchasing the Primary Shares as the result of any form of general solicitation or general advertising or as a result of Buyer’s review of public filings by the Company; (v) it has conducted its own investigation of the Company and the Primary Shares, has exercised independent judgment in evaluating its purchase of the Primary Shares and has made its own assessment and has satisfied itself concerning any relevant tax and other economic considerations relevant to its purchase of the Primary Shares; and (vi) Buyer is an institutional account as defined in FINRA Rule 4512(c).

(e) This Agreement is made in reliance upon Buyer’s express representations, which it hereby represents and warrants to the Company, that (i) the Primary Shares being purchased by Buyer are being acquired for Buyer’s own account (and not on behalf of any other person or entity) for the purpose of investment and not with a view to, or for sale in connection with, the distribution thereof, nor with any present intention of distributing or selling the Primary Shares or any portion thereof, (ii) Buyer was not organized for the specific purpose of acquiring the Primary Shares and (iii) the Primary Shares will not be sold by Buyer without registration under the Securities Act or applicable state securities laws, or an exemption therefrom.

(f) Buyer understands that the Primary Shares being purchased by Buyer hereunder have not been registered under the Securities Act, or any state securities laws and are instead being offered and sold in reliance on

 

5


an exemption from such registration requirements. Buyer represents and warrants to the Company that, to Buyer’s knowledge, Buyer has not taken any action which could reasonably be expected to cause the sale of the Primary Shares to be sold by the Company to Buyer to fail to qualify as exempt from the registration requirements of the Securities Act. Buyer further understands that until such time as the Primary Shares shall have been registered under the Securities Act and applicable state securities laws or shall have been transferred in accordance with an opinion of counsel reasonably satisfactory to the Company that such registration is not required, stop transfer instructions shall be issued to the Company’s transfer agent and any certificate or certificates representing such securities shall bear a restrictive legend stating that such securities have not been registered under the Securities Act and applicable state securities laws and referring to restrictions on the transferability and sale thereof.

Buyer further understands that Buyer’s representations and warranties hereunder will not preclude disposition of the Primary Shares without registration thereof, in compliance with Rule 144. Buyer understands and acknowledges, however, that there may not be available when Buyer wishes to sell the Primary Shares, or any portion thereof, the adequate current public information with respect to the Company which would permit offers or sales of such securities pursuant to Rule 144, and, therefore, compliance with the Securities Act or some other exemption from the registration and prospectus delivery requirements of the Securities Act may be required for any such offer or sale.

(g) Buyer is not a party to any contract, agreement or understanding with any person that would give rise to a valid claim for a brokerage commission, finder’s fee or like payment in connection with the purchase of the Primary Shares, whose fees would be payable by the Consortium Shareholder or the Company.

(h) Buyer acknowledges that none of the Company, the Consortium Shareholder or any other person has made any representations, warranties, agreements or undertakings with respect to the transactions contemplated by this Agreement other than those expressly set forth in this Agreement. Buyer acknowledges that none of the Company, the Consortium Shareholder or any other person has made any representation to Buyer about the advisability of the decision to purchase the Primary Shares or the potential future value of the Primary Shares. Buyer further represents and warrants to the Company and the Consortium Shareholder that, in executing and delivering this Agreement, it has not relied on any statement or representation made by any legal counsel or investment advisor to, or other agent of, any of the Company, the Consortium Shareholder or any other person.

(i) Buyer acknowledges that, in connection with the issue and purchase of the Primary Shares, Morgan Stanley & Co. LLC and its affiliates (“ Morgan Stanley ”) has not acted as financial advisor or fiduciary to Buyer. Buyer has conducted its own investigation of the Company and the Primary Shares and has not relied on any statements or other information provided by Morgan Stanley concerning the Company or the Primary Shares.

3. Reasonable Best Efforts; Filings . Subject to the terms and conditions of this Agreement, each of the Company, the Consortium Shareholder and the Buyer shall cooperate with each other and use (and shall cause its subsidiaries to use) its reasonable best efforts to promptly (i) take, or cause to be taken, all actions, and do, or cause to be done, and assist and cooperate with each other in doing, all things necessary, proper or advisable to cause the conditions to Closing to be satisfied as promptly as reasonably practicable and to consummate and make effective, in the most expeditious manner reasonably practicable, the transactions contemplated hereby, including preparing and filing promptly and fully all documentation to effect all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other documents, (ii) obtain all approvals, consents, registrations, waivers, permits, authorizations, orders and other confirmations from any government, court, regulatory or administrative agency, commission, arbitrator or authority or other legislative, executive or judicial governmental entity (in each case including any self-regulatory organization), whether federal, state or local, domestic, foreign or multinational (each, a “ Governmental Authority ”) or third party necessary, proper or advisable to consummate the transactions contemplated hereby, and (iii) execute and deliver any additional instruments necessary to consummate the transactions contemplated hereby. Notwithstanding the foregoing, it is understood and agreed that no party shall be required to litigate with any Governmental Authority or to agree to any governmental conditions (including divestitures, hold separate arrangements, mitigation measures or other conduct relief).

4. Conditions to the Closing . The obligations of the Company, the Consortium Shareholder and Buyer hereunder are subject to the satisfaction or waiver (if permitted by applicable law) of the conditions set forth below on or before the Closing.

 

6


(a) Conditions to Buyer’s Obligations . Buyer’s obligation to purchase the Primary Shares at the Closing or any Option Closing Date, as the case may be, is subject to the satisfaction or waiver by Buyer (if permitted by applicable law) of the following conditions:

(i) Representations and Warranties . The representations and warranties made by the Company and the Consortium Shareholder in this Agreement shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects as of the Closing or the applicable Option Closing Date with the same effect as though such representations and warranties had been made on and as of such date (except to the extent such representations and warranties speak as of a specific date, which shall be true and correct as of such specific date).

(ii) Covenants . Each of the Company and the Consortium Shareholder shall have complied with or performed in all material respects its obligations required to be complied with or performed by them pursuant to this Agreement at or prior to the Closing or the applicable Option Closing Date.

(iii) Initial Public Offering . The Registration Statement shall have been declared effective and the IPO shall have closed.

(iv) IPO Proceeds . Gross proceeds from the issuance and sale of Ordinary Shares by the Company in the IPO shall not be less than $400,000,000.

(v) Registration Rights Agreement . The Company shall have executed and delivered a joinder to the Registration Rights Agreement, dated on or around the date of the closing of the IPO, by and among the Company and the shareholders of the Company who are party thereto, becoming a Holder (as defined therein) thereunder, in accordance therewith, substantially in the form attached as Exhibit  A hereto (the “ Registration Rights Agreement ”).

(vi) Shareholder Agreement . The Company shall have executed and delivered the Shareholder Agreement substantially in the form attached as Exhibit  B hereto (the “ Shareholder Agreement ”).

(vii) No Restraints . No temporary or permanent outstanding order, judgment, injunction, ruling, writ or decree of any Governmental Authority imposed upon any of the parties hereto, in each case, by or before any Governmental Authority shall have been enacted, promulgated, issued, entered, amended or enforced by any Governmental Authority nor shall any proceeding brought by a Governmental Authority seeking any of the foregoing be pending, or any applicable state or federal laws, common law, statutes, ordinances, codes, rules or regulations or other similar requirement enacted, adopted, promulgated, or applied by any Governmental Authority shall be in effect enjoining or otherwise prohibiting consummation of the transactions contemplated hereby (collectively, “ Restraints ”).

(viii) United Kingdom Stamp Duty . Clearance from HM Revenue & Customs, reasonably satisfactory to the Buyer, in response to the revised clearance application submitted by the Company to HM Revenue & Customs on July 23, 2018, shall have been obtained.

(b) Conditions to the Company’s Obligations . The Company’s obligation to issue and sell the Primary Shares at the Closing or any Option Closing Date, as the case may be, is subject to the satisfaction or waiver by the Company (if permitted by applicable law) of the following conditions:

(i) Representations and Warranties . The representations and warranties made by Buyer in this Agreement shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects as of the Closing or the applicable Option Closing Date with the same effect as though such representations and warranties had been made on and as of such date (except to the extent such representations and warranties speak as of a specific date, which shall be true and correct as of such specific date).

(ii) Covenants . The Buyer shall have complied with or performed in all material respects its obligations required to be complied with or performed by it pursuant to this Agreement at or prior to the Closing or the applicable Option Closing Date.

(iii) Initial Public Offering . The Registration Statement shall have been declared effective and the IPO shall have closed.

 

7


(iv) Registration Rights Agreement . The Buyer shall have executed and delivered a joinder to the Registration Rights Agreement.

(v) Shareholder Agreement . Buyer shall have executed and delivered the Shareholder Agreement, and the Buyer’s indirect parent company, China Vanke Co., Ltd., shall have executed in a legally binding manner and delivered a letter agreement in form reasonably satisfactory to the Company agreeing to be bound by the standstill restrictions and certain other provisions in the Shareholder Agreement.

(vi) No Restraints . No Restraints shall be in effect enjoining or otherwise prohibiting consummation of the transactions contemplated hereby.

(vii) United Kingdom Stamp Duty . Clearance from HM Revenue & Customs, reasonably satisfactory to the Company, in response to the revised clearance application submitted by the Company to HM Revenue & Customs on July 23, 2018, shall have been obtained.

(viii) Lock-Up Agreement . The Buyer shall have executed and delivered to the Company the lock-up agreement in the form attached as Exhibit  C hereto as agreed upon by the Buyer and the Underwriters.

(ix) FINRA Questionnaire . The Buyer shall have completed, executed and delivered to the Company the Financial Industry Regulatory Authority questionnaire in the form delivered to Buyer by the Underwriters.

(x) Proof of Funds; Installment . The Buyer shall have (1) delivered to the Company the Proof of Funds reasonably satisfactory to the Company and (2) paid each applicable Installment to the Company in accordance with Section 1(c)(i).

5. Termination . (a) This Agreement may be terminated and the transactions contemplated hereby abandoned at any time prior to the Closing:

(i) By the mutual written consent of the Company and the Buyer;

(ii) By either the Company or the Buyer upon written notice to the other, if (x) the Underwriting Agreement is terminated in accordance with its terms, pursuant to Section 9 thereof, or (y) the Closing should not have occurred on or prior to the later of August 31, 2018 and the date that is five business days after the closing of the IPO (such date, the “ Termination Date ”); provided, that the right to terminate this Agreement under this Section 5(a)(ii)(y) shall not be available to any party if the breach by such party of its representations and warranties set forth in this Agreement or the failure of such party to perform any of its obligations under this Agreement has been a principal cause of or primarily resulted in the failure of the Closing to occur;

(iii) By either the Company or the Buyer if any Restraint enjoining or otherwise prohibiting consummation of the transactions contemplated hereby shall be in effect and shall have become final and nonappealable prior to the Closing; provided that the party seeking to terminate this Agreement pursuant to this Section 5(a)(iii) shall have used the required efforts to cause the conditions to Closing to be satisfied in accordance with Section 3;

(iv) By the Buyer, if the Company or the Consortium Shareholder shall have breached any of their respective representations or warranties or failed to perform any of their respective covenants or agreements set forth in this Agreement, which breach or failure to perform (x) would give rise to the failure of a condition set forth in Section 4(a)(i) or Section 4(a)(ii) and (y) is incapable of being cured prior to the Termination Date, or if capable of being cured, shall not have been cured within the earlier of five (5) calendar days following receipt by the Company or the Consortium Shareholder, as applicable, of written notice of such breach or failure to perform from the Buyer stating the Buyer’s intention to terminate this Agreement pursuant to this Section 5(a)(iv) and the basis for such termination and the Termination Date; provided, that the Buyer shall not have the right to terminate this Agreement pursuant to this Section 5(a)(iv) if the Buyer is then in material breach of any of its representations, warranties, covenants or agreements hereunder which breach would give rise to the failure of a condition set forth in Section 4(b)(i) or Section 4(b)(ii);

 

8


(v) By the Company, if the Buyer shall have breached any of its representations or warranties or failed to perform any of its covenants or agreements set forth in this Agreement, which breach or failure to perform (x) would give rise to the failure of a condition set forth in Section 4(b)(i) or Section 4(b)(ii) and (y) is incapable of being cured prior to the Termination Date, or if capable of being cured, shall not have been cured within the earlier of five (5) calendar days following receipt by the Buyer of written notice of such breach or failure to perform from the Company stating the Company’s intention to terminate this Agreement pursuant to this Section 5(a)(v) and the basis for such termination and the Termination Date; provided, that the Company shall not have the right to terminate this Agreement pursuant to this Section 5(a)(v) if the Company or the Consortium Shareholder is then in material breach of any of its representations, warranties, covenants or agreements hereunder which breach would give rise to the failure of a condition set forth in Section 4(a)(i) or Section 4(a)(ii); or

(vi) By the Company, upon prior written notice to Buyer, if (x) Buyer shall have failed to initiate the wire transfer for the First Installment to the Company or provide confirmation thereof reasonably satisfactory to the Company by 5:00 p.m., Hong Kong time, on the business day following the applicable time specified in Section 1(c)(i); provided that the termination right under this Section 5(a)(vi)(x) may not be exercised after the Company has received evidence reasonably satisfactory to it that the wire transfer for the First Installment has been irrevocably initiated by Buyer, or (y) the Company has not received the First Installment by 5:00 p.m., New York City time, on the business day following the applicable time specified in Section 1(c)(i); provided that the termination right under this Section 5(a)(vi)(y) may not be exercised after the First Installment has been received by the Company.

As to any Additional Closing, the Company may terminate the parties’ respective obligations to purchase and sell the applicable Additional Primary Shares at such Additional Closing, upon prior written notice to Buyer, if (x) Buyer shall have failed to initiate the wire transfer for the applicable Subsequent Installment that was to be paid to the Company in respect of such Additional Closing or provide confirmation thereof reasonably satisfactory to the Company within one business day after the applicable time specified in Section 1(c)(i); provided that the termination right under this Section 5(a)(x) may not be exercised with respect to such Additional Closing after the Company has received evidence reasonably satisfactory to it that the wire transfer for such Subsequent Installment has been irrevocably initiated by Buyer, or (y) the Company has not received such Subsequent Installment within one business day after the applicable time specified in Section 1(c)(i); provided that the termination right under this Section 5(a) may not be exercised with respect to such Additional Closing after such Subsequent Installment has been received by the Company.

(b) Effect of Termination . If this Agreement is terminated by the parties hereto in accordance with Section 5(a) hereof, this Agreement shall become void and of no further force and effect and there shall be no liability on the part of any party hereto to any other party, except that the provisions of this Section 5(b) (Effect of Termination), Section 5(c) (Treatment of the First Installment), and Sections 9 through 23 shall remain in full force and effect and any such termination shall not preclude any party hereto from suing any other party for any willful breach of this Agreement prior to such termination.

(c) Treatment of the First Installment . If, at any time after the First Installment has been paid to the Company, this Agreement is terminated in any circumstance, then the Company shall promptly return the First Installment to the Buyer within three (3) business days following such termination by wire transfer of immediately available funds to an account designated in writing by the Buyer, provided that the Company shall be entitled to retain an amount equal to 15% of the First Installment if this Agreement is terminated:

(i) by the Company in accordance with Section 5(a)(iii) and the imposition of such Restraint has principally arisen or resulted from a breach hereof by Buyer (provided it shall not be deemed to be a breach of this Agreement by Buyer if any Governmental Authority outside the People’s Republic of China imposes a Restraint so long as Buyer’s representations and warranties in Section 2.3 are true and correct in all material respects and Buyer has complied with its obligations under Section 3); or

(ii) by the Company pursuant to Section 5(a)(ii) or Section 5(a)(v) in any circumstance where prior to such termination (1) the Closing shall not have occurred on or before the date required by Section 1(b) (Closing), (2) all of the conditions to Closing set forth in Section 4(a) (Conditions to Buyer’s Obligations) have been satisfied at the

 

9


time of such termination if the Closing were held at the time of such termination (other than conditions that, either (A) by their nature, are to be satisfied at the Closing (and which are, at the time of termination of this Agreement, capable of being satisfied if the Closing were to occur at such time) or (B) the failure of which to be satisfied is attributable to a breach by Buyer of its representations, warranties, covenants or agreements contained in this Agreement), (3) the Company has notified Buyer in writing that the Company is ready, willing and able to effect the Closing on the earlier of the Termination Date and the fifth (5th) business day following the date of delivery of such written notification by the Company (subject to Buyer curing by such time the failure of any condition in Section 4(b) attributable to a breach by Buyer of its representations, warranties, covenants or agreements contained in this Agreement); and (4) Buyer fails to consummate the Closing on the earlier of the Termination Date and the fifth (5th) business day following the date of delivery of such written notification by the Company.

The parties hereto acknowledge and agree that the Company’s retention of the First Installment, if permitted under this Section 5(c), is not a penalty but is liquidated damages in a reasonable amount that will compensate the Company, in part, for the circumstances giving rise to the underlying termination of this Agreement, which amount would otherwise be impossible to calculate with precision; provided that the Company’s retention of the First Installment, if permitted under this Section 5(c), shall not cap or otherwise limit any of the Company’s other remedies that may be available under this Agreement in connection with the circumstances giving rise to such termination.

6. Survival . The representations and warranties contained herein shall survive the latter of the Closing and any Option Closing Date for a period of two years, at which time they shall terminate.

7. Prohibited Transferees . For a period of eighteen months after the date of the Closing, so long as the Buyer owns, directly or indirectly, all of the Ordinary Shares purchased by the Buyer hereunder on the Closing and any Option Closing Date, the Consortium Shareholder agrees not to sell, transfer or convey Ordinary Shares (or securities or receipts exchangeable for, convertible or exercisable into or evidencing Ordinary Shares) in a privately negotiated secondary transaction (a “ Privately Negotiated Secondary Transaction ”), for the avoidance of doubt, not to include underwritten block trades, marketed deals or transfers in connection with a transaction involving the Company, to (i) the persons and their respective subsidiaries named in Schedule II(1) hereto; and (ii) the persons only named in Schedule II(2) hereto.

8. Right of First Offer . (a) For a period of eighteen months after the date of the Closing, so long as the Buyer owns, directly or indirectly, all of the Ordinary Shares purchased by the Buyer hereunder on the Closing and any Option Closing Date, subject to receipt of required regulatory approvals and compliance with the standstill restrictions in the Shareholder Agreement, the Buyer shall have a right of first offer over any Ordinary Shares (or securities or receipts exchangeable for, convertible or exercisable into or evidencing Ordinary Shares) proposed to be transferred by the Consortium Shareholder in a Privately Negotiated Secondary Transaction (other than transfers of Ordinary Shares (or securities or receipts exchangeable for, convertible or exercisable into or evidencing Ordinary Shares) (1) to an affiliate of (x) the Consortium Shareholder or (y) a partner, member or equivalent of the Consortium Shareholder (provided such affiliate agrees to be bound by this Section 8), (2) subject, in the case of an in-kind distribution by the Consortium Shareholder only (and not an in-kind distribution by any other person following any such distribution in-kind by the Consortium Shareholder), to Section 19, as an in-kind distribution to any partner, member or equivalent of the Consortium Shareholder, (3) for the avoidance of doubt, made pursuant to a registered public offering (including any transfer to The Depository Trust Company or its nominee in connection therewith), or (4) for the avoidance of doubt, made pursuant to Rule 144 (including any transfer to The Depository Trust Company or its nominee in connection therewith), which shall be exercised in the following manner:

(i) The Consortium Shareholder shall provide the Buyer with written notice (an “ Offer Notice ”) of its desire to transfer such Ordinary Shares. The Offer Notice shall specify the number of Ordinary Shares Consortium Shareholder wishes to transfer, the proposed purchase price for such Ordinary Shares and any other terms and conditions material to the sale proposed by Consortium Shareholder;

(ii) The Buyer shall have a period of up to five (5) business days following receipt of the Offer Notice to elect to purchase (or to cause one or more of its controlled affiliates that has agreed to be subject to the Shareholder Agreement to purchase) all of such Ordinary Shares on the terms and conditions set forth in the Offer Notice by delivering to the Consortium Shareholder a written notice thereof, provided

 

10


that, in connection with its receipt of the first Offer Notice only (the “ Initial Offer ”) (subject to the following sentence), under this Section 8, Buyer shall have the option to purchase either (x) all such Ordinary Shares or (y) not less than the greatest number of such Ordinary Shares that Buyer and its affiliates could acquire without them then owning (after giving effect to such acquisition) 10% or more of the total Ordinary Shares then outstanding. Each Offer Notice shall be deemed to be an Initial Offer until one of the following occurs: (A) Buyer elects to purchase any Ordinary Shares in response to an Offer Notice and such purchase is consummated or (B) Buyer elects not to purchase Ordinary Shares in response to such Offer Notice, and the Consortium Shareholder sells at least such number of Ordinary Shares subject to such Offer Notice that Buyer would have been permitted to elect to acquire pursuant to this Section 8(a)(ii) to a third party in compliance with clause (iv) below;

(iii) If the Buyer elects to purchase (or to cause one or more of its affiliates to purchase) all (or, only in the case of the Initial Offer, such elected portion) of the Ordinary Shares which are the subject of the proposed transfer within the applicable response period described above, such purchase shall be consummated within the later of (A) ten (10) business days after the date on which the Buyer notifies the Consortium Shareholder of such election or (B) five (5) business days after all required regulatory approvals have been obtained (and all statutory waiting periods have elapsed); and

(iv) If (x) the Buyer fails to elect to purchase all (or, only in the case of the Initial Offer, any portion) of the Ordinary Shares within the applicable response period described above or (y) the purchase has not been consummated on or prior to the date that is ninety (90) days after the date on which the Buyer notifies the Consortium Shareholder of its election, the Consortium Shareholder may transfer such Ordinary Shares (or, only in the case of the Initial Offer, such portion of the Ordinary Shares that Buyer has failed to elect to purchase) at any time within one hundred and eighty (180) days following such event at a price which is not less than the purchase price specified in the Offer Notice and on other terms and conditions no more favorable, in any material respect, to the transferee than those specified in the Offer Notice.

(b) In connection with the transfer of all or any portion of the Consortium Shareholder’s Ordinary Shares pursuant to this Section 8, the Consortium Shareholder shall only be required to represent and warrant as to its authority to sell, the enforceability of such agreement against the Consortium Shareholder, that the Ordinary Shares to be transferred are free and clear of any liens, claims or encumbrances (other than restrictions pursuant to applicable federal, state and foreign securities laws and the Shareholder Agreement), that it is the record and beneficial owner of such Ordinary Shares and that it has obtained or made all necessary consents, approvals, filings and notices from Governmental Authorities or third parties to consummate the transfer and Buyer shall provide customary representations and warranties consistent with Section 2.3.

9. Public Announcements . No party hereto will issue or cause the publication of any press release or other public announcement (including any broad-based employee announcement) with respect to this Agreement, the Registration Rights Agreement, the Shareholder Agreement or the transactions contemplated hereby or thereby or any mutual consideration of potential business opportunities that the parties may undertake following the date hereof, without the prior written consent of the other parties hereto; provided, however, that, nothing herein will prohibit any party hereto from issuing or causing publication of any such press release or public announcement to the extent that such disclosure is, upon advice of counsel, required by applicable law, in which case the party making such determination will, if practicable in the circumstances, use its reasonable best efforts to allow the other parties reasonable time to comment on such release or announcement in advance of its issuance.

10. Waiver and Release . Buyer hereby (a) waives and releases any claim (whether for rescission, damages or otherwise) it may have against the Company, the Consortium Shareholder, any affiliate of any of the foregoing or any director, officer or agent of any of the foregoing (collectively, “ Company Parties ”) arising solely out of or based solely on the sale of the Primary Shares to Buyer being not exempt from registration or qualification under federal or state securities laws, (b) agrees not to, under any circumstances, exercise any right of rescission arising solely out of or based solely on the sale of the Primary Shares to Buyer being not exempt from registration or qualification under federal or state securities laws, and (c) if it is ultimately determined that the agreements and waivers contained in the preceding clauses (a) and (b) are unenforceable, irrevocably agrees to contribute to the Company any proceeds received by Buyer from the Company as a result of any rescission action brought by Buyer based solely on the sale

 

11


of the Primary Shares to Buyer being not exempt from registration or qualification under federal or state securities laws; provided, however, that (a), (b) and (c) shall not apply and Buyer will be free to pursue any claim against the Company Parties and exercise any right of rescission arising out of or based on any aspect of the sale of the Primary Shares to Buyer not being exempt from registration or qualification under federal or state securities laws, in each case without any contribution obligation, if (i) any of the representations and warranties of the Company under Sections 2.1 (g) and (h) are not true and correct in all respects and/or (ii) there is any fraud by any of the Company Parties in connection with the transactions contemplated by this Agreement.

11. Expenses . Except as otherwise expressly provided herein, all costs and expenses, including fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the Transactions shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.

12. Successors and Assigns . This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

13. Notices . Notices given hereunder shall be deemed to have been duly given, only if given in writing, and on (i) the date of personal delivery or by email or facsimile, or (ii) on the date one day after being delivered to a reputable overnight courier with proper delivery instructions, to the party being notified at his, her, or its address specified as follows or such other address as the addressee may subsequently notify the other party of in writing: if to the Buyer, 43/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, China, Attention: Min Huang, Wingkit Chan; Email: huangm05@vanke.com, wingkitchan@vanke.com, with a copy (which copy shall not constitute notice) to Davis Polk & Wardwell, Hong Kong Club Building, 3A Chater Road, Central, Hong Kong, Attention: Paul Chow, paul.chow@davispolk.com; if to the Company, Cushman & Wakefield plc, 225 West Wacker Drive, Suite 3000, Chicago, Illinois 60606, Attention: Brett Soloway, with a copy (which copy shall not constitute notice) to Cleary Gottlieb Steen & Hamilton LLP, One Liberty Plaza, New York, New York 10006, Attention: Jeffrey Karpf, Paul M. Tiger, Email: jkarpf@cgsh.com, ptiger@cgsh.com, Fax: +1 212 225 3999; if to the Consortium Shareholder, (1) 301 Commerce Street, Suite 3300, Fort Worth, TX 76102, Attention: Office of General Counsel, Telephone: (817) 871-4000, E-mail: officeofgeneralcounsel@tpg.com, (2) c/o 32/F, AIA Central, 1 Connaught Road Central, Hong Kong, Attention: Jon Lewis and Elaine Chen, Email: jlewis@pag.com and echen@pag.com, and (3) Ontario Teachers’ Pension Plan Board, 5650 Yonge Street, Toronto, Ontario M2M 4H5, Canada, Attention: Raju Ruparelia, E mail: raju_ruparelia@otpp.com law_investments@otpp.com, with copies (which copies in each case shall not constitute notice) to (1) 345 California Street, San Francisco, CA 94104, Attention: Adam Fliss, E-mail: afliss@tpg.com, (2) Fenwick & West LLP, Unit 908, 9th Floor, Kerry Parkside Office, No. 1155 Fang Dian Road, Pudong New Area, Shanghai 201204, People’s Republic of China, Attention: Niping Wu, Email: niping.wu@fenwick.com, (3) Baker McKenzie, Tower One—International Towers Sydney, Level 46—100 Barangaroo Avenue, Sydney NSW 2000, Australia, Attention: Michael Kunstler and Lewis Apostolou, E mail: michael.kunstler@bakermckenzie.com and lewis.apostolou@bakermckenzie.com, and (4) Cleary Gottlieb Steen & Hamilton LLP, One Liberty Plaza, New York, New York 10006, Attention: Jeffrey Karpf, Paul M. Tiger, Email: jkarpf@cgsh.com, ptiger@cgsh.com, Fax: +1 212 225 3999.

14. Entire Agreement and Amendments . This Agreement, together with the Registration Rights Agreement and the Shareholder Agreement, constitutes the entire agreement of the parties with respect to the subject matter hereof. This Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by each of the parties hereto or, in the case of a waiver, by the party waiving compliance. No waiver shall be deemed a waiver of any subsequent breach or default.

15. Governing Law . This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.

16. Dispute Resolution .

(a) Any dispute, controversy or claim arising out of, relating to, or in connection with, this Agreement (including its existence, validity, interpretation, breach, termination or enforcement as well as all matters relating to its negotiation, including pre contractual liability) (each a “ Dispute ”) shall be referred to and finally settled by arbitration administered by the International Court of Arbitration of the International Chamber of Commerce (“ ICC

 

12


Court ”) in accordance with the Rules of Arbitration of the International Chamber of Commerce (the “ ICC Rules ”) then in effect, except as they may be modified in this Agreement or by agreement of the parties.

(b) The arbitration shall be conducted by three arbitrators. To the extent the Dispute involves two parties to this Agreement, each party subject to the Dispute shall nominate an arbitrator within thirty (30) days after delivery of the Request for Arbitration and the two arbitrators so appointed shall nominate the third arbitrator, who shall be the president of the arbitral tribunal, within thirty (30) days of their appointment. Any arbitrator not nominated within the applicable time limits shall be appointed by the ICC Court.

(c) The seat of arbitration shall be New York, New York, and the language of the arbitration shall be English.

(d) By agreeing to arbitration, the parties do not intend to deprive any court of competent jurisdiction of its ability to issue any form of provisional remedy, including a preliminary injunction or attachment in aid of the arbitration, or order any interim or conservatory measure. A request for such provisional remedy or interim or conservatory measure by a party to a court shall not be deemed a waiver of this agreement to arbitrate. The parties hereby consent to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York with respect to applications for provisional remedies or interim or conservatory measures.

(e) The award rendered by the arbitral tribunal, which shall cover which party shall bear the costs of the arbitration, shall be final and binding on the parties. Judgment on the award may be entered in any court of competent jurisdiction.

(f) The parties shall maintain strict confidentiality with respect to all aspects of the arbitration and shall not disclose the fact, conduct or outcome of the arbitration to any nonparties or non-participants, except to the extent required by law, court order or to the extent necessary to recognize, confirm or enforce the final award in the arbitration, enforce provisions of this arbitration clause, or to seek provisional remedies from a court of competent jurisdiction, without the prior written consent of all parties to the arbitration.

(g) The parties agree to opt out of the ICC Rules’ Expedited Procedure provisions.

(h) The parties agree that any arbitral tribunal appointed hereunder may exercise jurisdiction with respect to both this Agreement and the Registration Rights Agreement and the Shareholder Agreement. The parties consent to the consolidation of arbitrations commenced hereunder and/or under the Registration Rights Agreement and the Shareholder Agreement as follows. If two or more arbitrations are commenced hereunder and/or under the Registration Rights Agreement and the Shareholder Agreement, any party named as claimant or respondent in any of these arbitrations may petition any arbitral tribunal appointed in these arbitrations for an order that the several arbitrations be consolidated in a single arbitration before that arbitral tribunal (a “ Consolidation Order ”). In deciding whether to make such a Consolidation Order, that arbitral tribunal shall consider whether the several arbitrations raise common issues of law or fact and whether to consolidate the several arbitrations would serve the interests of justice and efficiency. If before a Consolidation Order is made by an arbitral tribunal with respect to another arbitration, arbitrators have already been appointed in that other arbitration, their appointment terminates upon the making of such Consolidation Order and they are deemed to be functus officio . In the event of two or more conflicting Consolidation Orders, the Consolidation Order that was made first in time shall prevail.

(i) The parties agree that any damages payable hereunder shall be limited to direct and reasonably foreseeable “benefit of the bargain” damages and that no party shall be liable hereunder for damages that constitute consequential, indirect, special or punitive damages under applicable law or for damages for reputational harm.

17. Specific Performance . It is hereby agreed and acknowledged that it may be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them by this Agreement and that, in the event of any such failure, an aggrieved party may be irreparably damaged and may not have an adequate remedy at law. Any such party shall therefore be entitled (in addition to any other remedy to which such party may be entitled at law or in equity) to injunctive relief, including specific performance, to enforce such obligations, without the posting of any bond, and if any action should be brought in

 

13


equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

18. Severability . The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof.

19. Assignment . This Agreement may not be assigned by the Company, the Consortium Shareholder or the Buyer without the prior written consent of the other parties hereto; provided, that no such consent shall be required for the Consortium Shareholder to assign any or all of its rights and obligations hereunder in connection with it distributing Ordinary Shares in-kind to its limited partners; provided, further, that the Consortium Shareholder agrees not to effect any such distribution in-kind unless such limited partners execute a counterpart to this Agreement and become subject to the terms of this Agreement applicable to the Consortium Shareholder.

20. Captions . Captions are for convenience only and are not deemed to be part of this Agreement. All references herein to numbered Sections are to Sections of this Agreement unless otherwise indicated.

21. Counterparts . This Agreement may be executed by pdf and in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

22. Further Assurances . The parties agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.

23. Third Party Beneficiary . Morgan Stanley is a third-party beneficiary of, and is permitted to rely on, the representations and warranties contained in Section 2.3(d) and Section 2.3(i) in this Agreement.

24. Business Day . For purposes of this Agreement, references to “business day” shall mean any day other than a Saturday, Sunday or other day on which banks in New York or Hong Kong are authorized or required by applicable law to be closed.

25. Subscription of Shares . For purposes of this Agreement, references to the “purchase and sale” of the Primary Shares or any similar formulation shall, unless the context otherwise requires, be references to a subscription for and issue of such Primary Shares.

[ Remainder of Page Intentionally Left Blank ]

 

14


IN WITNESS WHEREOF, this Purchase Agreement has been executed as of the date and year first above written.

 

BUYER:

Vanke Service (HongKong) Co., Limited

萬科物業服務 ( 香港 ) 有限公司

By:  

/s/ Li, Qingping

  Name: Li, Qingping
  Title: Authorized Signatory

[Signature Page to Purchase Agreement]


IN WITNESS WHEREOF, this Purchase Agreement has been executed as of the date and year first above written.

 

COMPANY:
CUSHMAN & WAKEFIELD PLC
By:  

/s/ Brett White

  Name: Brett White
  Title: Director

[Signature Page to Purchase Agreement]


IN WITNESS WHEREOF, this Purchase Agreement has been executed as of the date and year first above written.

 

CONSORTIUM SHAREHOLDER:
DTZ INVESTMENT HOLDINGS L.P.
By: DTZ Investment Holdings GenPar LLP, its general partner
By:  

/s/ Anand Tejani

  Name: Anand Tejani
  Title: Authorized Signatory

[Signature Page to Purchase Agreement]


Schedule I

to

Purchase Agreement

Wire Instructions


Schedule II

to

Purchase Agreement

Prohibited Transferees


Exhibit A

to

Purchase Agreement

Registration Rights Agreement


Exhibit B

to

Purchase Agreement

Shareholder Agreement


Exhibit C

to

Purchase Agreement

Lock-Up Agreement

Exhibit 10.46

 

 

 

SHAREHOLDER AGREEMENT

BY AND BETWEEN

CUSHMAN & WAKEFIELD PLC

AND

VANKE SERVICE (HONGKONG) CO., LIMITED

D ATED AS OF A UGUST     , 2018

 

 

 


TABLE OF CONTENTS

 

            Page  

ARTICLE I DEFINITIONS

     2  

Section 1.1

     Definitions      2  

Section 1.2

     Other Interpretive Provisions      4  

ARTICLE II REPRESENTATIONS AND WARRANTIES

     4  

Section 2.1

     Existence; Authority; Enforceability      4  

Section 2.2

     Absence of Conflicts      5  

Section 2.3

     Consents      5  

ARTICLE III GENERAL PROVISIONS

     5  

Section 3.1

     Standstill      5  

Section 3.2

     Transfer Restrictions      6  

Section 3.3

     Lock-Up Agreement      7  

Section 3.4

     Information Rights      7  

Section 3.5

     Assignment; Benefit      8  

Section 3.6

     Confidentiality      8  

Section 3.7

     Termination      9  

Section 3.8

     Severability      9  

Section 3.9

     Entire Agreement; Amendment      10  

Section 3.10

     Counterparts      10  

Section 3.11

     Notices      10  

Section 3.12

     Governing Law      11  

Section 3.13

     Jurisdiction      11  

Section 3.14

     Specific Performance      13  

Section 3.15

     Subsequent Acquisition of Shares      13  

 

i


This SHAREHOLDER AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, the “ Agreement ”), dated as of August     , 2018, is made by and between Cushman & Wakefield plc, a public limited company incorporated in England and Wales with registered number 11414195 (the “ Company ”), and Vanke Service (HongKong) Co., Limited ( 科物業服務 ( 香港 ) 有限公司 ), a Hong Kong limited company (the “ Shareholder ”).

RECITALS

WHEREAS, pursuant to the terms and subject to the conditions set forth in a Purchase Agreement, dated July 24, 2018 (the “ Purchase Agreement ”), by and among the Shareholder, the Company and DTZ Investment Holdings LP, an English limited partnership (“ DTZ LP ”), the Shareholder agreed to purchase from the Company and the Company agreed to issue and sell to the Shareholder the Primary Shares (as defined in the Purchase Agreement) in the form of depositary receipts issued pursuant to, and in accordance with the terms of, the Deposit Agreement;

WHEREAS, on August     , 2018, the Company priced an initial public offering (the “ IPO ”) of the Company’s ordinary shares, nominal value $0.10 per share (the “ Ordinary Shares ”), pursuant to an Underwriting Agreement, dated August     , 2018;

WHEREAS, as of the date of the Purchase Agreement, a nominee of Computershare Trust Company, N.A., as depositary (the “ Depositary ”), held all of the Company’s Ordinary Shares, except for ten Ordinary Shares held by DTZ Investment Holdings GenPar LLP (the “ LLP ”), acting in its capacity as general partner of DTZ LP.

WHEREAS, prior to the date of the Purchase Agreement, the Depositary issued depositary receipts in respect of the Ordinary Shares held by its nominee to FTL Nominees 1 Limited and FTL Nominees 2 Limited (in each of their capacities as nominees on behalf of various Company management holders and the LLP, acting in its capacity as general partner of DTZ LP, respectively) pursuant to the Deposit Agreement, dated as of July 6, 2018 (the “ Deposit Agreement ”), among the Company, the Depositary, FTL Nominees 1 Limited, FTL Nominees 2 Limited and the Holders (as defined therein).

WHEREAS, in connection with the Shareholder’s acquisition of the Primary Shares and in consideration of the Company’s willingness to enter into the Registration Rights Agreement (as defined in the Purchase Agreement) with the Shareholder, the parties hereto desire to provide for certain information and other rights, and to provide for certain limitations on the conduct of the Shareholder, including with respect to certain transfer restrictions and standstill provisions.

NOW, THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements of the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:


ARTICLE I

DEFINITIONS

Section 1.1     Definitions . As used in this Agreement, the following terms shall have the following meanings:

Action ” means any pending or threatened legal or administrative proceeding, suit, investigation, arbitration or action.

Affiliate ” means, with respect to any specified Person, (a) any Person that directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such specified Person or (b) in the event that the specified Person is a natural Person, a Member of the Immediate Family of such Person. As used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through beneficial ownership of voting securities, by contract or otherwise.

Affiliated Person ” means a Person and all of its respective partners, principals, directors, officers, members, managers, managing directors, advisors, consultants and employees, Affiliates, or any officer of the Company that is an Affiliate of such Person.

Agreement ” has the meaning set forth in the Preamble.

beneficially own ” has the meaning set forth in Rule 13d-3 promulgated under the Exchange Act.

Board ” means the board of directors of the Company.

Business Day ” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in the City of New York, New York.

Closing ” means the closing of the IPO.

Company ” has the meaning set forth in the Preamble.

Company Articles ” means the articles of association of the Company in effect on the date hereof, as may be amended from time to time.

Company Shares ” means (i) all Ordinary Shares outstanding at the time of determination, (ii) all Ordinary Shares issuable upon exercise, conversion or exchange of any option, warrant or convertible security and (iii) all Ordinary Shares directly or indirectly issued or issuable with respect to the securities referred to in clauses (i) or (ii) above by way of unit or stock dividend or unit or stock split, or in connection with a combination of units or shares, recapitalization, merger, consolidation or other reorganization.

Confidential Information ” has the meaning set forth in Section 3.6(b).

 

2


Consolidation Order ” has the meaning set forth in Section 3.13(h).

Depositary ” has the meaning set forth in the Recitals.

Deposit Agreement ” has the meaning set forth in the Recitals.

Dispute ” has the meaning set forth in Section 3.13(a).

DTZ LP ” has the meaning set forth in the Recitals.

Exchange Act ” means the Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same shall be in effect from time to time.

Furnishing Parties ” has the meaning set forth in Section 3.6(b).

ICC Court ” has the meaning set forth in Section 3.13(a).

ICC Rules ” has the meaning set forth in Section 3.13(a).

IPO ” has the meaning set forth in the Recitals.

Member of the Immediate Family ” means, with respect to an individual, (a) each parent, spouse (but not including a former spouse or a spouse from whom such individual is legally separated) or child (including those adopted) of such individual and (b) each trustee, solely in his or her capacity as trustee and so long as such trustee is reasonably satisfactory to the Company, for a trust naming only one or more of the Persons listed in sub-clause (a) as beneficiaries.

Other Investors ” means (i) TPG Drone Investment, L.P. and TPG Drone Co Invest, L.P., together with their respective Affiliates, (ii) PAGAC Drone Holding I LP, together with its Affiliates, (iii) 2339532 Ontario Limited and Ontario Teachers’ Pension Plan Board, together with their respective Affiliates, and (iv) DTZ LP.

Ordinary Shares ” has the meaning set forth in the Recitals.

Permitted Transferee ” means, with respect to any Person, any Affiliate of such Person.

Person ” means any individual, partnership, limited liability company, corporation, trust, association, estate, unincorporated organization or government or any agency or political subdivision thereof.

Purchase Agreement ” has the meaning set forth in the Recitals.

Representatives ” means, with respect to any Person, any of such Person’s officers, directors, employees, agents, attorneys, accountants, actuaries, consultants or financial advisors or other Person associated with, or acting on behalf of, such Person.

Restricted Period ” has the meaning set forth in Section 3.3.

 

3


SEC ” means the U.S. Securities and Exchange Commission or any successor thereof.

Shareholder ” has the meaning set forth in the Preamble.

Shareholder Parties ” means the Shareholder and each Permitted Transferee of the Shareholder to whom Company Shares are transferred pursuant to Section 3.2(b)(i).

Subsidiary ”, when used with respect to any Person, means any corporation, limited liability company, partnership, association, trust or other entity of which (x) securities or other ownership interests representing more than 50% of the ordinary voting power (or, in the case of a partnership, more than 50% of the general partnership interests) or (y) sufficient voting rights to elect at least a majority of the board of directors or other governing body are, as of such date, owned by such Person or one or more Subsidiaries of such Person or by such Person and one or more Subsidiaries of such Person.

Transfer ” by any Person means, directly or indirectly, to sell, transfer, assign, pledge, encumber, hypothecate or otherwise dispose of or transfer (by the operation of law or otherwise), either voluntarily or involuntarily, or to enter into any contract, option or other arrangement, agreement or understanding with respect to the sale, transfer, assignment, pledge, encumbrance, hypothecation or other disposition or transfer (by the operation of law or otherwise), of any interest in any equity securities beneficially owned by such Person.

Section 1.2     Other Interpretive Provisions . (a) The meanings of defined terms are equally applicable to the singular and plural forms of the defined terms.

The words “ hereof ,” “ herein ,” “ hereunder ” and similar words refer to this Agreement as a whole and not to any particular provision of this Agreement; and any subsection and section references are to this Agreement unless otherwise specified.

The term “ including ” is not limiting and means “ including without limitation .”

The captions and headings of this Agreement are for convenience of reference only and shall not affect the interpretation of this Agreement.

Whenever the context requires, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms.

ARTICLE II

REPRESENTATIONS AND WARRANTIES

Each of the parties to this Agreement hereby represents and warrants to the other party to this Agreement that as of the date such party executes this Agreement:

Section 2.1     Existence; Authority; Enforceability . Such party has the power and authority to enter into this Agreement and to carry out its obligations hereunder. Such party is duly organized and validly existing under the laws of its jurisdiction of organization, and the execution of this Agreement, and the consummation of the transactions contemplated herein,

 

4


have been authorized by all necessary action on the part of its board of directors (or equivalent) and shareholders (or other holders of equity interests), if required, and no other act or proceeding on its part is necessary to authorize the execution of this Agreement or the consummation of any of the transactions contemplated hereby. This Agreement has been duly executed by such party and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights generally or by equitable principles relating to enforceability.

Section 2.2     Absence of Conflicts . The execution and delivery by such party of this Agreement and the performance of its obligations hereunder does not and will not (a) conflict with, or result in the breach of any provision of the constitutive documents of such party, (b) result in any violation, breach, conflict, default or an event of default (or an event which with notice, lapse of time, or both, would constitute a default or an event of default), or give rise to any right of acceleration or termination or any additional payment obligation, under the terms of any material contract, agreement or permit to which such party is a party or by which such party’s assets or operations are bound or affected, or (c) violate, in any material respect, any law applicable to such party.

Section 2.3     Consents . Other than as expressly required herein or any consents which have already been obtained, no consent, waiver, approval, authorization, exemption, registration, license or declaration is required to be made or obtained by such party in connection with (a) the execution, delivery or performance of this Agreement or (b) the consummation of any of the transactions contemplated herein.

ARTICLE III

GENERAL PROVISIONS

Section 3.1     Standstill . The Shareholder agrees that for a period of eighteen months from the date of this Agreement, the Shareholder shall not, and shall cause its controlled Affiliates to not, alone or with others, in any manner, directly or indirectly, unless approved in writing by the Company, acting in accordance with the due approval of the Board: (a) effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in, or in any way knowingly assist (including, without limitation, through the provision of financing) any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in, (i) any acquisition of beneficial ownership (as such term is defined under the Exchange Act) of any securities of the Company or securities or rights convertible into or exchangeable for any securities of the Company in excess of the Company Shares that Shareholder is required to acquire under Section 1 of the Purchase Agreement, (ii) any acquisition of all or substantially all of the assets of the Company or any of its businesses, (iii) any tender or exchange offer involving the securities of the Company, (iv) any merger, other business combination, recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Company or (v) any “solicitation” of “proxies” (as such terms are used under the Exchange Act) or consents with respect to any voting securities of the Company; (b) form, join or in any way participate in a “group” (as such term is used under the Exchange Act) with respect to any securities of the Company; (c) otherwise act, alone or in concert with others, to seek to control or influence the management, board of directors or

 

5


policies of the Company; (d) take any action that would reasonably be expected to require the Company to make a public announcement regarding any of the types of matters set forth in clause (a) above; or (e) enter into discussions or arrangements with any third party with respect to any of the matters set forth in clauses (a) through (d) above. Notwithstanding the foregoing, (x) Shareholder shall be permitted to make confidential proposals to the Board or any or all of the Other Investors that, in and of themselves, will not require a public announcement, (y) in the event any person or group (other than the Shareholder and the Other Investors) publicly announces a bona fide tender or exchange offer involving the securities of the Company, publicly makes a bona fide proposal regarding any merger or other business combination or extraordinary transaction with respect to the Company or publicly announces it has acquired beneficial ownership of 15% or more of the outstanding Company Shares, the restrictions set forth in this Section 3.1 shall lapse and terminate unless the Company takes appropriate action in response thereto within ten (10) Business Days following such event (which shall include, but does not necessarily require, adoption of a shareholder rights plan or implementation of other measures), and (z) in the event the Company consummates a primary offering of Company Shares during the term of the standstill contemplated by this Section 3.1, the Shareholder shall be permitted to consummate one or more brokered transactions through any securities exchange on which the Company Shares are then listed to acquire beneficial ownership of additional Company Shares in order to return its total beneficial ownership of Company Shares to the percentage beneficial ownership interest it held immediately prior to such offering.

Section 3.2     Transfer Restrictions . (a) Except as otherwise permitted in Section 3.2(b), the Shareholder Parties shall not (1) Transfer any Company Shares (including, for the avoidance of doubt, but not limited to, the Primary Shares) or (2) make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a short sale of or the purpose of which is to offset the loss which results from a decline in the market price of, any Company Shares, or otherwise establish or increase, directly or indirectly, a put equivalent position, as defined in Rule 16a-1(h) under the Exchange Act, with respect to any of the Company Shares or any other capital stock of the Company.

(b) Notwithstanding Section 3.2(a), but subject to Section 3.3, the Shareholder Parties shall be permitted to Transfer all or any portion of their Company Shares at any time (except as noted in clause (ii) below) under the following circumstances:

(i) Transfers to any Permitted Transferees of the Shareholder or a Shareholder Party, but only if the transferee agrees in writing prior to such Transfer for the express benefit of the Company (in form and substance reasonably satisfactory to the Company and with a copy thereof to be furnished to the Company) to be bound by the terms of this Agreement and if the transferee and the transferor agree for the express benefit of the Company that the transferee shall Transfer the Company Shares so Transferred back to the transferor at or before such time as the transferee ceases to be a Permitted Transferee of the transferor;

(ii) Transfers following the expiration of the Restricted Period, provided that in no event shall the Shareholder and its related Shareholder Parties (as a group) be permitted to Transfer, in any single Transfer or series of related Transfers to any person or group to the extent that, immediately following such Transfer or series of related

 

6


Transfers, such person or group (together with its Affiliated Persons) would beneficially own five percent (5%) or more of the Company Shares outstanding at such time, except in connection with an underwritten offering of Company Shares or a brokered transaction pursuant to Rule 144 under the Exchange Act, in each case in which the counterparty is not identified; and

(iii) Transfers that have been approved in writing by the Company, acting in accordance with the due approval of the Board.

(c) Any attempted Transfer in violation of this Section 3.2 shall be null and void ab initio .

Section 3.3     Lock-Up Agreement . The Shareholder hereby agrees that, unless approved in writing by the Company, acting in accordance with the due approval of the Board, it will not, for (x)12 months, with respect to 50% of Shareholder’s Primary Shares, and (y) 18 months, with respect to the remaining 50% of Shareholder’s Primary Shares, in each case after the date of the Closing (collectively, the “ Restricted Period ”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Company Shares beneficially owned, by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for the Company Shares, or publicly announce its intention to enter into any such transaction, or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Company Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Company Shares or such other securities, in cash or otherwise.

Section 3.4     Information Rights . Following the Closing, solely to the extent the Company is not current in its, or subject to, periodic SEC reporting obligations, the Company agrees to provide the Shareholder with the following:

(a) within 90 days after the end of each fiscal year of the Company, (A) an audited, consolidated balance sheet of the Company and its Subsidiaries as of the end of such fiscal year, (B) an audited, consolidated income statement of the Company and its Subsidiaries for such fiscal year and (C) an audited, consolidated statement of cash flows of the Company and its Subsidiaries for such fiscal year;

(b) within 45 days after the end of each of the first three quarters of each fiscal year of the Company, (A) an unaudited, consolidated balance sheet of the Company and its Subsidiaries as of the end of such fiscal quarter, (B) an unaudited, consolidated income statement of the Company and its Subsidiaries for such fiscal quarter and (C) an unaudited, consolidated statement of cash flows of the Company and its Subsidiaries for such fiscal quarter; and

(c) reasonable access, to the extent reasonably requested by the Shareholder and at the sole expense of the Shareholder, to discuss with the Company’s officers, all upon reasonable notice, no more than quarterly, the consolidated financial statements provided pursuant to this Section 3.4; provided that any discussion pursuant to this Section 3.4 shall be conducted in a

 

7


manner as not to interfere unreasonably with the conduct of the business of the Company and its Subsidiaries;

provided that, solely in the case of clause (c) above, the Company shall not be obligated to provide such access or materials if the Company determines, in its reasonable judgment, that doing so could (1) materially violate applicable law, an applicable order or a contract or obligation of confidentiality owing to a third party, (2) jeopardize the protection of an attorney-client privilege, attorney work product protection or other legal privilege, or (3) be materially adverse to the interests of the Company or any of its Subsidiaries in any pending or threatened Action. In addition, notwithstanding anything to the contrary contained herein, neither the Company nor any of its Subsidiaries will be required to provide any information or material that relates to, contains or reflects any analyses, studies, notes, memoranda and other information related to or prepared in connection with any of this Agreement, the Registration Rights Agreement, the Purchase Agreement, or any matters relating thereto or any transactions with or matters relating to any of the Shareholder or its respective Affiliates.

Section 3.5     Assignment; Benefit .

(a) All rights and obligations hereunder shall not be assignable without the prior written consent of the other parties hereto; provided that the Company shall be permitted to assign its rights and obligations hereunder to any successor entity. Any attempted assignment of rights or obligations in violation of this Section 3.5 shall be null and void.

(b) This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, and their respective successors and permitted assigns; provided that person who is not a party to this Agreement may not enforce any of its terms under the Contracts (Rights of Third Parties) Act 1999.

Section 3.6     Confidentiality .

(a) The Shareholder agrees that it will use the Confidential Information solely for the purpose of monitoring, managing and reporting (as such reporting is required by applicable law and regulations, including stock exchange requirements, or by applicable accounting principles) its investment in the Company and will use reasonable precautions in accordance with its established procedures to keep such information confidential, subject to disclosure permitted by Section 3.6(c)-(d); provided , however , that any such information may be disclosed to the Shareholder’s Affiliated Persons who need to know such information for the purpose of monitoring, managing and reporting the Shareholder’s investment in the Company (it being understood that such Affiliated Persons shall be informed by the Shareholder of the confidential nature of such information and agree to abide by these confidentiality provisions); provided , that the Shareholder shall be responsible for any breach of this Agreement that results from the actions or omissions of the Shareholder’s Affiliated Persons.

(b) The term “ Confidential Information ” means (i) all information related to the Company and its Affiliates provided to the Shareholder hereunder or in connection with its investment in the Company by or on behalf of the Company or its Affiliates (the “ Furnishing Parties ”), and (ii) all analyses developed by the Shareholder using any information specified

 

8


under clause (i) above. The term “Confidential Information” shall not include information that (A) is or becomes generally available to the public other than as a result of a disclosure by the Shareholder or its Affiliated Persons in violation of this Agreement, (B) was within the Shareholder’s possession prior to its being furnished to it by a Furnishing Party or its representatives, provided that the source of such information was not known by the Shareholder to be bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to a Furnishing Party or any other party with respect to such information or (C) is or becomes available to the Shareholder on a non-confidential basis from a source other than a Furnishing Party or their respective representatives, provided that such source is not known by the Shareholder to be bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to a Furnishing Party, or any other party with respect to such information.

(c) The Shareholder and its Affiliated Persons shall be permitted to disclose Confidential Information to the extent required or requested by any governmental authority or pursuant to judicial process or applicable law and regulations, including stock exchange or securities law requirements, provided that the Shareholder, to the extent legally permissible and reasonably practicable, shall have notified the Company of such obligation and, in the case of securities law or stock exchange disclosure requirements, shall have consulted with the Company in good faith with respect to such disclosure giving due regard to the reasonable comments of the Company and, in the case of disclosure required by judicial process, shall have cooperated with any reasonable efforts by the Company to seek an appropriate protective order or similar relief and shall have used its reasonable efforts to minimize the scope of Confidential Information that is disclosed.

(d) The Shareholder and its Affiliated Persons shall be entitled to provide Confidential Information to (i) any potential transferee (provided such Transfer would not be in violation of the terms of this Agreement and such potential transferee agrees to be bound by a confidentiality agreement consistent with the terms hereof) or (ii) any rating agency or any financial institution providing credit to the Shareholder or its Affiliated Persons, so long as the rating agency or financial institution is advised of the confidential nature of such information.

(e) Notwithstanding anything to the contrary contained in this Agreement, the provisions of this Section 3.6 shall survive termination of this Agreement with respect to matters arising before or after such termination, and shall remain in full force and effect until two years following the Closing or such earlier time as such provisions are explicitly waived and revoked by the Company in writing.

Section 3.7     Termination . This Agreement shall terminate automatically upon the date that the Shareholder ceases to beneficially own at least 2.5% of the outstanding Company Shares; provided that the provisions of Sections 3.1 and 3.6 shall survive any such termination in accordance with their respective terms.

Section 3.8     Severability . In the event that any provision of this Agreement shall be invalid, illegal or unenforceable such provision shall be construed by limiting it so as to be valid, legal and enforceable to the maximum extent provided by law and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

9


Section 3.9     Entire Agreement; Amendment .

(a) This Agreement, together with the Purchase Agreement and the Registration Rights Agreement, sets forth the entire understanding and agreement between the parties with respect to the transactions contemplated herein and supersedes and replaces any prior understanding, agreement or statement of intent, in each case written or oral, of any kind and every nature with respect hereto. This Agreement or any provision hereof may only be amended, modified or waived, in whole or in part, at any time by an instrument in writing signed by the Company and the Shareholder.

(b) No waiver of any breach of any of the terms of this Agreement shall be effective unless such waiver is expressly made in writing and executed and delivered by the party against whom such waiver is claimed. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. Except as otherwise expressly provided herein, no failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder, or otherwise available in respect hereof at law or in equity, shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.

Section 3.10     Counterparts . This Agreement may be executed in any number of separate counterparts each of which when so executed shall be deemed to be an original and all of which together shall constitute one and the same agreement. Counterpart signature pages to this Agreement may be delivered by facsimile or electronic delivery ( i.e ., by email of a PDF signature page) and each such counterpart signature page will constitute an original for all purposes.

Section 3.11     Notices . Unless otherwise specified herein, all notices, consents, approvals, reports, designations, requests, waivers, elections and other communications authorized or required to be given pursuant to this Agreement shall be in writing and shall be given, made or delivered by personal hand-delivery, by facsimile transmission, by electronic mail, by mailing the same in a sealed envelope, registered first-class mail, postage prepaid, return receipt requested, or by air courier guaranteeing overnight delivery (and such notice shall be deemed to have been duly given, made or delivered (a) on the date received, if delivered by personal hand delivery, (b) on the date received, if delivered by facsimile transmission, by electronic mail or by registered first-class mail prior to 5:00 p.m. prevailing local time on a Business Day, or if delivered after 5:00 p.m. prevailing local time on a Business Day or on other than a Business Day, on the first Business Day thereafter and (c) two (2) Business Days after being sent by air courier guaranteeing overnight delivery), at the following addresses (or at such other address as shall be specified by like notice):

If to the Company to:

Cushman & Wakefield plc

225 West Wacker Drive, Suite 3000

 

10


Chicago, Illinois 60606

Attention:        General Counsel

E-mail:            brett.soloway@cushwake.com

with a copy (which shall not constitute notice) to:

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, NY 10006

Attention:        Jeffrey Karpf

                         Paul M. Tiger

E-mail:            jkarpf@cgsh.com

                         ptiger@cgsh.com

If to the Shareholder to:

Vanke Service (HongKong) Co., Limited

3/F, Bank of China Tower

1 Garden Road, Central

Hong Kong, China

Attention:        Min Huang, Wingkit Chan

Email:              huangm05@vanke.com, wingkitchan@vanke.com

with a copy (which shall not constitute notice) to:

Davis Polk & Wardwell

Hong Kong Club Building

3A Chater Road, Central

Hong Kong,     China

Attention:        Paul Chow

Email:             paul.chow@davispolk.com

Section 3.12     Governing Law . This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.

Section 3.13     Jurisdiction .

(a) Any dispute, controversy or claim arising out of, relating to, or in connection with, this Agreement (including its existence, validity, interpretation, breach, termination or enforcement as well as all matters relating to its negotiation, including pre contractual liability) (each a “ Dispute ”) shall be referred to and finally settled by arbitration administered by the International Court of Arbitration of the International Chamber of Commerce (“ ICC Court ”) in accordance with the Rules of Arbitration of the International Chamber of Commerce (the “ ICC Rules ”) then in effect, except as they may be modified in this Agreement or by agreement of the parties.

(b) The arbitration shall be conducted by three arbitrators. To the extent the Dispute involves two parties to this Agreement, each party subject to the Dispute shall nominate an

 

11


arbitrator within thirty (30) days after delivery of the Request for Arbitration and the two arbitrators so appointed shall nominate the third arbitrator, who shall be the president of the arbitral tribunal, within thirty (30) days of their appointment. Any arbitrator not nominated within the applicable time limits shall be appointed by the ICC Court.

(c) The seat of arbitration shall be New York, New York, and the language of the arbitration shall be English.

(d) By agreeing to arbitration, the parties do not intend to deprive any court of competent jurisdiction of its ability to issue any form of provisional remedy, including a preliminary injunction or attachment in aid of the arbitration, or order any interim or conservatory measure. A request for such provisional remedy or interim or conservatory measure by a party to a court shall not be deemed a waiver of this agreement to arbitrate. The parties hereby consent to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York with respect to applications for provisional remedies or interim or conservatory measures.

(e) The award rendered by the arbitral tribunal, which shall cover which party shall bear the costs of the arbitration, shall be final and binding on the parties. Judgment on the award may be entered in any court of competent jurisdiction.

(f) The parties shall maintain strict confidentiality with respect to all aspects of the arbitration and shall not disclose the fact, conduct or outcome of the arbitration to any nonparties or non-participants, except to the extent required by law, court order or to the extent necessary to recognize, confirm or enforce the final award in the arbitration, enforce provisions of this arbitration clause, or to seek provisional remedies from a court of competent jurisdiction, without the prior written consent of all parties to the arbitration.

(g) The parties agree to opt out of the ICC Rules’ Expedited Procedure provisions.

(h) The parties agree that any arbitral tribunal appointed hereunder may exercise jurisdiction with respect to both this Agreement and the Registration Rights Agreement and the Purchase Agreement. The parties consent to the consolidation of arbitrations commenced hereunder and/or under the Registration Rights Agreement and the Purchase Agreement as follows. If two or more arbitrations are commenced hereunder and/or under the Registration Rights Agreement and the Purchase Agreement, any party named as claimant or respondent in any of these arbitrations may petition any arbitral tribunal appointed in these arbitrations for an order that the several arbitrations be consolidated in a single arbitration before that arbitral tribunal (a “ Consolidation Order ”). In deciding whether to make such a Consolidation Order, that arbitral tribunal shall consider whether the several arbitrations raise common issues of law or fact and whether to consolidate the several arbitrations would serve the interests of justice and efficiency. If before a Consolidation Order is made by an arbitral tribunal with respect to another arbitration, arbitrators have already been appointed in that other arbitration, their appointment terminates upon the making of such Consolidation Order and they are deemed to be functus officio . In the event of two or more conflicting Consolidation Orders, the Consolidation Order that was made first in time shall prevail.

 

12


Section 3.14     Specific Performance . It is hereby agreed and acknowledged that it may be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them by this Agreement and that, in the event of any such failure, an aggrieved party may be irreparably damaged and may not have an adequate remedy at law. Any such party shall therefore be entitled (in addition to any other remedy to which such party may be entitled at law or in equity) to injunctive relief, including specific performance, to enforce such obligations, without the posting of any bond, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

Section 3.15     Subsequent Acquisition of Shares . Any Company Shares acquired subsequent to the date hereof by the Shareholder shall be subject to the terms and conditions of this Agreement. For the avoidance of doubt, if the Shareholder acquires Company Shares subsequent to the date hereof, the Shareholder shall not reacquire any rights previously lost under this Agreement as a result of a decrease in the amount of Company Shares beneficially owned by the Shareholder.

[ Signature pages follow ]

 

13


IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the day and year first above written.

 

CUSHMAN & WAKEFIELD PLC
By:  

 

  Name:
  Title:

[Signature Page to Shareholder Agreement]


Signed for and on behalf of

VANKE SERVICE (HONGKONG) CO., LIMITED

 

( 科物業服務 ( 香港 ) 有限公司 )

 

Name:
Title:

[Signature Page to Shareholder Agreement]